From 4e32732d8800fa2fbaab3719278f7cbf06ffca71 Mon Sep 17 00:00:00 2001 From: ModelHub XC Date: Wed, 7 Oct 2026 09:13:13 +0800 Subject: [PATCH] =?UTF-8?q?=E5=88=9D=E5=A7=8B=E5=8C=96=E9=A1=B9=E7=9B=AE?= =?UTF-8?q?=EF=BC=8C=E7=94=B1ModelHub=20XC=E7=A4=BE=E5=8C=BA=E6=8F=90?= =?UTF-8?q?=E4=BE=9B=E6=A8=A1=E5=9E=8B?= MIME-Version: 1.0 Content-Type: text/plain; charset=UTF-8 Content-Transfer-Encoding: 8bit Model: google/txgemma-2b-predict Source: Original Platform --- .gitattributes | 49 + README.md | 309 +++++ config.json | 32 + configuration.json | 1 + generation_config.json | 8 + model-00001-of-00003.safetensors | 3 + model-00002-of-00003.safetensors | 3 + model-00003-of-00003.safetensors | 3 + model.safetensors.index.json | 295 +++++ special_tokens_map.json | 34 + tdc_prompts.json | 1 + tokenizer.json | 3 + tokenizer.model | 3 + tokenizer_config.json | 2012 ++++++++++++++++++++++++++++++ 14 files changed, 2756 insertions(+) create mode 100644 .gitattributes create mode 100644 README.md create mode 100644 config.json create mode 100644 configuration.json create mode 100644 generation_config.json create mode 100644 model-00001-of-00003.safetensors create mode 100644 model-00002-of-00003.safetensors create mode 100644 model-00003-of-00003.safetensors create mode 100644 model.safetensors.index.json create mode 100644 special_tokens_map.json create mode 100644 tdc_prompts.json create mode 100644 tokenizer.json create mode 100644 tokenizer.model create mode 100644 tokenizer_config.json diff --git a/.gitattributes b/.gitattributes new file mode 100644 index 0000000..21b3632 --- /dev/null +++ b/.gitattributes @@ -0,0 +1,49 @@ +*.7z filter=lfs diff=lfs merge=lfs -text +*.arrow filter=lfs diff=lfs merge=lfs -text +*.bin filter=lfs diff=lfs merge=lfs -text +*.bin.* filter=lfs diff=lfs merge=lfs -text +*.bz2 filter=lfs diff=lfs merge=lfs -text +*.ftz filter=lfs diff=lfs merge=lfs -text +*.gz filter=lfs diff=lfs merge=lfs -text +*.h5 filter=lfs diff=lfs merge=lfs -text +*.joblib filter=lfs diff=lfs merge=lfs -text +*.lfs.* filter=lfs diff=lfs merge=lfs -text +*.model filter=lfs diff=lfs merge=lfs -text +*.msgpack filter=lfs diff=lfs merge=lfs -text +*.onnx filter=lfs diff=lfs merge=lfs -text +*.ot filter=lfs diff=lfs merge=lfs -text +*.parquet filter=lfs diff=lfs merge=lfs -text +*.pb filter=lfs diff=lfs merge=lfs -text +*.pt filter=lfs diff=lfs merge=lfs -text +*.pth filter=lfs diff=lfs merge=lfs -text +*.rar filter=lfs diff=lfs merge=lfs -text +saved_model/**/* filter=lfs diff=lfs merge=lfs -text +*.tar.* filter=lfs diff=lfs merge=lfs -text +*.tflite filter=lfs diff=lfs merge=lfs -text +*.tgz filter=lfs diff=lfs merge=lfs -text +*.xz filter=lfs diff=lfs merge=lfs -text +*.zip filter=lfs diff=lfs merge=lfs -text +*.zstandard filter=lfs diff=lfs merge=lfs -text +*.tfevents* filter=lfs diff=lfs merge=lfs -text +*.db* filter=lfs diff=lfs merge=lfs -text +*.ark* filter=lfs diff=lfs merge=lfs -text +**/*ckpt*data* filter=lfs diff=lfs merge=lfs -text +**/*ckpt*.meta filter=lfs diff=lfs merge=lfs -text +**/*ckpt*.index filter=lfs diff=lfs merge=lfs -text +*.safetensors filter=lfs diff=lfs merge=lfs -text +*.ckpt filter=lfs diff=lfs merge=lfs -text +*.gguf* filter=lfs diff=lfs merge=lfs -text +*.ggml filter=lfs diff=lfs merge=lfs -text +*.llamafile* filter=lfs diff=lfs merge=lfs -text +*.pt2 filter=lfs diff=lfs merge=lfs -text +*.mlmodel filter=lfs diff=lfs merge=lfs -text +*.npy filter=lfs diff=lfs merge=lfs -text +*.npz filter=lfs diff=lfs merge=lfs -text +*.pickle filter=lfs diff=lfs merge=lfs -text +*.pkl filter=lfs diff=lfs merge=lfs -text +*.tar filter=lfs diff=lfs merge=lfs -text +*.wasm filter=lfs diff=lfs merge=lfs -text +*.zst filter=lfs diff=lfs merge=lfs -text +*tfevents* filter=lfs diff=lfs merge=lfs -text + +tokenizer.json filter=lfs diff=lfs merge=lfs -text \ No newline at end of file diff --git a/README.md b/README.md new file mode 100644 index 0000000..99895fe --- /dev/null +++ b/README.md @@ -0,0 +1,309 @@ +--- +license: other +license_name: health-ai-developer-foundations +license_link: https://developers.google.com/health-ai-developer-foundations/terms +language: + - en +pipeline_tag: text-generation +library_name: transformers +tags: + - therapeutics + - drug-development +extra_gated_heading: Access TxGemma on Hugging Face +extra_gated_prompt: >- + To access TxGemma on Hugging Face, you're required to review and + agree to [Health AI Developer Foundation's terms of use](https://developers.google.com/health-ai-developer-foundations/terms). + To do this, please ensure you're logged in to Hugging Face and click below. + Requests are processed immediately. +extra_gated_button_content: Acknowledge license +--- + +# TxGemma model card + +**Model documentation:** [TxGemma](https://developers.google.com/health-ai-developer-foundations/txgemma) + +**Resources:** + +* Model on Google Cloud Model Garden: [TxGemma](https://console.cloud.google.com/vertex-ai/publishers/google/model-garden/txgemma) +* Model on Hugging Face: [TxGemma](https://huggingface.co/collections/google/txgemma-release-67dd92e931c857d15e4d1e87) +* GitHub repository (supporting code, Colab notebooks, discussions, and + issues): + [TxGemma](https://github.com/google-gemini/gemma-cookbook/tree/main/TxGemma) +* Quick start notebook: [notebooks/quick\_start](https://github.com/google-gemini/gemma-cookbook/blob/main/TxGemma/%5BTxGemma%5DQuickstart_with_Hugging_Face.ipynb) +* Support: See + [Contact](https://developers.google.com/health-ai-developer-foundations/txgemma/get-started.md#contact). + +Terms of use: [Health AI Developer Foundations terms of +use](https://developers.google.com/health-ai-developer-foundations/terms) + +**Author:** Google + +## Model information + +This section describes the TxGemma model and how to use it. + +### Description + +TxGemma is a collection of lightweight, state-of-the-art, open language models +built upon Gemma 2, fine-tuned for therapeutic development. It comes in 3 sizes, +2B, 9B, and 27B. + +TxGemma models are designed to process and understand information related to +various therapeutic modalities and targets, including small molecules, proteins, +nucleic acids, diseases, and cell lines. TxGemma excels at tasks such as +property prediction, and can serve as a foundation for further fine-tuning or as +an interactive, conversational agent for drug discovery. The model is fine-tuned +from Gemma 2 using a diverse set of instruction-tuning datasets, curated from +the [Therapeutics Data Commons (TDC)](https://tdcommons.ai/). + +TxGemma is offered as both a prediction model that expects a narrow form of +prompting and for the 9B and 27B version, conversational models that are more +flexible and can be used in multi-turn interactions, including to explain its +rationale behind a prediction. This conversational model comes at the expense of +some raw prediction performance. See our [manuscript](https://arxiv.org/abs/2504.06196) +for more information. + +**Key Features** + +* Versatility: Exhibits strong performance across a wide range of therapeutic + tasks, outperforming or matching best-in-class performance on a significant + number of benchmarks. +* Data Efficiency: Shows competitive performance even with limited data + compared to larger models, offering improvements over its predecessors. +* Conversational Capability (TxGemma-Chat): Includes conversational variants + that can engage in natural language dialogue and explain the reasoning + behind their predictions. +* Foundation for Fine-tuning: Can be used as a pre-trained foundation for + specialized use cases. + +**Potential Applications** + +TxGemma can be a valuable tool for researchers in the +following areas: + +* Accelerated Drug Discovery: Streamline the therapeutic development process + by predicting properties of therapeutics and targets for a wide variety of + tasks including target identification, drug-target interaction prediction, + and clinical trial approval prediction. + +### How to use + +Below are some example code snippets to help you quickly get started running the +model locally on GPU. If you want to use the model to run inference on a large +number of inputs, we recommend that you create a production version using [Model +Garden](https://console.cloud.google.com/vertex-ai/publishers/google/model-garden/txgemma). + +#### Formatting prompts for therapeutic tasks + +```python +import json +from huggingface_hub import hf_hub_download + +# Load prompt template for tasks from TDC +tdc_prompts_filepath = hf_hub_download( + repo_id="google/txgemma-2b-predict", + filename="tdc_prompts.json", +) +with open(tdc_prompts_filepath, "r") as f: + tdc_prompts_json = json.load(f) + +# Set example TDC task and input +task_name = "BBB_Martins" +input_type = "{Drug SMILES}" +drug_smiles = "CN1C(=O)CN=C(C2=CCCCC2)c2cc(Cl)ccc21" + +# Construct prompt using template and input drug SMILES string +TDC_PROMPT = tdc_prompts_json[task_name].replace(input_type, drug_smiles) +print(TDC_PROMPT) +``` + +The resulting prompt is in the format expected by the model: + +```none +Instructions: Answer the following question about drug properties. +Context: As a membrane separating circulating blood and brain extracellular fluid, the blood-brain barrier (BBB) is the protection layer that blocks most foreign drugs. Thus the ability of a drug to penetrate the barrier to deliver to the site of action forms a crucial challenge in development of drugs for central nervous system. +Question: Given a drug SMILES string, predict whether it +(A) does not cross the BBB (B) crosses the BBB +Drug SMILES: CN1C(=O)CN=C(C2=CCCCC2)c2cc(Cl)ccc21 +Answer: +``` + +#### Running the model on predictive tasks + +```python +# pip install accelerate transformers +from transformers import AutoTokenizer, AutoModelForCausalLM + +# Load model directly from Hugging Face Hub +tokenizer = AutoTokenizer.from_pretrained("google/txgemma-2b-predict") +model = AutoModelForCausalLM.from_pretrained( + "google/txgemma-2b-predict", + device_map="auto", +) + +# Formatted TDC prompt (see "Formatting prompts for therapeutic tasks" section above) +prompt = TDC_PROMPT + +# Prepare tokenized inputs +input_ids = tokenizer(prompt, return_tensors="pt").to("cuda") + +# Generate response +outputs = model.generate(**input_ids, max_new_tokens=8) +print(tokenizer.decode(outputs[0], skip_special_tokens=True)) +``` + +Alternatively, you can use the `pipeline` API, which provides a simple way to +run inference while abstracting away complex details of loading and using the +model and tokenizer: + +```python +# pip install transformers +from transformers import pipeline + +# Instantiate a text generation pipeline using the model +pipe = pipeline( + "text-generation", + model="google/txgemma-2b-predict", + device="cuda", +) + +# Formatted TDC prompt (see "Formatting prompts for therapeutic tasks" section above) +prompt = TDC_PROMPT + +# Generate response +outputs = pipe(prompt, max_new_tokens=8) +response = outputs[0]["generated_text"] +print(response) +``` + +### Examples + +See the following Colab notebooks for examples of how to use TxGemma: + +* To give the model a quick try, running it locally with weights from Hugging + Face, see [Quick start notebook in + Colab](https://colab.research.google.com/github/google-gemini/gemma-cookbook/blob/main/TxGemma/%5BTxGemma%5DQuickstart_with_Hugging_Face.ipynb), + which includes some example eval tasks from TDC. +* For a demo of how to fine-tune TxGemma in Hugging Face, see our [Fine-tuning notebook in Colab](https://colab.research.google.com/github/google-gemini/gemma-cookbook/blob/main/TxGemma/%5BTxGemma%5DFinetune_with_Hugging_Face.ipynb). +* For a demo of how TxGemma can be used as a tool as part of a larger agentic + workflow powered by Gemini 2 see the [Agentic workflow notebook in Colab](https://colab.research.google.com/github/google-gemini/gemma-cookbook/blob/main/TxGemma/%5BTxGemma%5DAgentic_Demo_with_Hugging_Face.ipynb). + +### Model architecture overview + +* TxGemma is based on the Gemma 2 family of lightweight, state-of-the-art open + LLMs. It utilizes a decoder-only transformer architecture. +* Base Model: Gemma 2 (2B, 9B, and 27B parameter versions). +* Fine-tuning Data: Therapeutics Data Commons, a collection of + instruction-tuning datasets covering diverse therapeutic modalities and + targets. +* Training Approach: Instruction fine-tuning using a mixture of therapeutic + data (TxT) and, for conversational variants, general instruction-tuning + data. +* Conversational Variants: TxGemma-Chat models (9B and 27B) are trained with a + mixture of therapeutic and general instruction-tuning data to maintain + conversational abilities. + +### Technical Specifications + +* Model type: Decoder-only Transformer (based on Gemma 2) +* Key publication: [TxGemma: Efficient and Agentic LLMs for Therapeutics](https://arxiv.org/abs/2504.06196) +* Model created: 2025-03-18 (From the TxGemma Variant Proposal) +* Model Version: 1.0.0 + +### Performance & Validation + +TxGemma's performance has been validated on a comprehensive +[benchmark](https://tdcommons.ai/) of 66 therapeutic tasks derived from TDC. + +### Key performance metrics + +* Aggregated Improvement: Improves over the original [Tx-LLM + paper](https://arxiv.org/abs/2406.06316) on 45 out of 66 therapeutic tasks. + +* Best-in-Class Performance: Surpasses or matches best-in-class performance on + 50 out of 66 tasks, exceeding specialist models on 26 tasks. See [Table A.11](https://arxiv.org/abs/2504.06196) + of the TxGemma paper for the full breakdown. + +### Inputs and outputs + +* **Input:** Text. For best performance, text prompts should be formatted + according to the TDC structure, including + instructions, context, question, and, optionally, few-shot examples. Inputs + can include SMILES strings, amino acid sequences, nucleotide sequences, and + natural language text. + +* **Output:** Text. + +## Dataset details + +### Training dataset + +**Therapeutics Data Commons**: A curated collection of instruction-tuning +datasets covering 66 tasks spanning the discovery and development of safe and +effective medicine. This includes over 15 million data points across different +biomedical entities. Released TxGemma models are only trained on datasets with +commercial licenses, whereas models in our publication are also trained on +datasets with non-commercial licenses. + +**General Instruction-Tuning Data**: Used for TxGemma-Chat in combination with +TDC. + +### Evaluation dataset + +**Therapeutics Data Commons**: The same 66 tasks used for training are used +for evaluation, following TDC's recommended methodologies for data splits +(random, scaffold, cold-start, combination, and temporal). + +## License + +The use of TxGemma is governed by the [Health AI Developer Foundations terms of +use](https://developers.google.com/health-ai-developer-foundations/terms). + +## Implementation information + +This section contains details about the model internals. + +### Software + +Training was done using [JAX](https://github.com/jax-ml/jax). + +JAX allows researchers to take advantage of the latest generation of hardware, +including TPUs, for faster and more efficient training of large models. + +## Use and limitations + +### Intended use + +* Research and development of therapeutics. + +### Benefits + +TxGemma provides a versatile and powerful tool for accelerating therapeutic +development. It offers: + +* Strong performance across a wide range of tasks. +* Data efficiency compared to larger models. +* A foundation for further fine-tuning from private data. +* Integration into agentic workflows. + +### Limitations + +* Trained on public data from TDC. +* Task-specific validation remains an important aspect of downstream model + development by the end user. +* As with any research, developers should ensure that any downstream + application is validated to understand performance using data that is + appropriately representative of the intended use setting for the specific + application (e.g., age, sex, gender, condition, scanner, etc.). + +## Citation + +```bibtex +@article{wang2025txgemma, + title={TxGemma: Efficient and Agentic LLMs for Therapeutics}, + author={Wang, Eric and Schmidgall, Samuel and Jaeger, Paul F. and Zhang, Fan and Pilgrim, Rory and Matias, Yossi and Barral, Joelle and Fleet, David and Azizi, Shekoofeh}, + year={2025}, +} +``` + +Find the paper [here](https://arxiv.org/abs/2504.06196). \ No newline at end of file diff --git a/config.json b/config.json new file mode 100644 index 0000000..2693147 --- /dev/null +++ b/config.json @@ -0,0 +1,32 @@ +{ + "architectures": [ + "Gemma2ForCausalLM" + ], + "attention_bias": false, + "attention_dropout": 0.0, + "attn_logit_softcapping": 50.0, + "bos_token_id": 2, + "cache_implementation": "hybrid", + "eos_token_id": 1, + "final_logit_softcapping": 30.0, + "head_dim": 256, + "hidden_act": "gelu_pytorch_tanh", + "hidden_activation": "gelu_pytorch_tanh", + "hidden_size": 2304, + "initializer_range": 0.02, + "intermediate_size": 9216, + "max_position_embeddings": 8192, + "model_type": "gemma2", + "num_attention_heads": 8, + "num_hidden_layers": 26, + "num_key_value_heads": 4, + "pad_token_id": 0, + "query_pre_attn_scalar": 256, + "rms_norm_eps": 1e-06, + "rope_theta": 10000.0, + "sliding_window": 4096, + "torch_dtype": "float32", + "transformers_version": "4.47.1", + "use_cache": true, + "vocab_size": 256000 +} diff --git a/configuration.json b/configuration.json new file mode 100644 index 0000000..bbeeda1 --- /dev/null +++ b/configuration.json @@ -0,0 +1 @@ +{"framework": "pytorch", "task": "text-generation", "allow_remote": true} \ No newline at end of file diff --git a/generation_config.json b/generation_config.json new file mode 100644 index 0000000..f4d8698 --- /dev/null +++ b/generation_config.json @@ -0,0 +1,8 @@ +{ + "_from_model_config": true, + "bos_token_id": 2, + "cache_implementation": "hybrid", + "eos_token_id": 1, + "pad_token_id": 0, + "transformers_version": "4.47.1" +} diff --git a/model-00001-of-00003.safetensors b/model-00001-of-00003.safetensors new file mode 100644 index 0000000..5207c6e --- /dev/null +++ b/model-00001-of-00003.safetensors @@ -0,0 +1,3 @@ +version https://git-lfs.github.com/spec/v1 +oid sha256:445c75b48013d59b7ee078ce7d0805fa022139e6001c39285e8a3a4b132ae44d +size 4992576136 diff --git a/model-00002-of-00003.safetensors b/model-00002-of-00003.safetensors new file mode 100644 index 0000000..1a85cd8 --- /dev/null +++ b/model-00002-of-00003.safetensors @@ -0,0 +1,3 @@ +version https://git-lfs.github.com/spec/v1 +oid sha256:176ebd39cccab8feb64613a7a5f4c095a42e79b5bb7992d5fb0d87f0e7a10a65 +size 4983443424 diff --git a/model-00003-of-00003.safetensors b/model-00003-of-00003.safetensors new file mode 100644 index 0000000..f0a3990 --- /dev/null +++ b/model-00003-of-00003.safetensors @@ -0,0 +1,3 @@ +version https://git-lfs.github.com/spec/v1 +oid sha256:68921f0c0041a5b7ee6420642d3d38d944ea730afe7239fcd1b6f83e206a4b3b +size 481381384 diff --git a/model.safetensors.index.json b/model.safetensors.index.json new file mode 100644 index 0000000..05c7984 --- /dev/null +++ b/model.safetensors.index.json @@ -0,0 +1,295 @@ +{ + "metadata": { + "total_size": 10457367552 + }, + "weight_map": { + "model.embed_tokens.weight": "model-00001-of-00003.safetensors", + "model.layers.0.input_layernorm.weight": "model-00001-of-00003.safetensors", + "model.layers.0.mlp.down_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.0.mlp.gate_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.0.mlp.up_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.0.post_attention_layernorm.weight": "model-00001-of-00003.safetensors", + "model.layers.0.post_feedforward_layernorm.weight": "model-00001-of-00003.safetensors", + "model.layers.0.pre_feedforward_layernorm.weight": "model-00001-of-00003.safetensors", + "model.layers.0.self_attn.k_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.0.self_attn.o_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.0.self_attn.q_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.0.self_attn.v_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.1.input_layernorm.weight": "model-00001-of-00003.safetensors", + "model.layers.1.mlp.down_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.1.mlp.gate_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.1.mlp.up_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.1.post_attention_layernorm.weight": "model-00001-of-00003.safetensors", + "model.layers.1.post_feedforward_layernorm.weight": "model-00001-of-00003.safetensors", + "model.layers.1.pre_feedforward_layernorm.weight": "model-00001-of-00003.safetensors", + "model.layers.1.self_attn.k_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.1.self_attn.o_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.1.self_attn.q_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.1.self_attn.v_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.10.input_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.10.mlp.down_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.10.mlp.gate_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.10.mlp.up_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.10.post_attention_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.10.post_feedforward_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.10.pre_feedforward_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.10.self_attn.k_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.10.self_attn.o_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.10.self_attn.q_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.10.self_attn.v_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.11.input_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.11.mlp.down_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.11.mlp.gate_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.11.mlp.up_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.11.post_attention_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.11.post_feedforward_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.11.pre_feedforward_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.11.self_attn.k_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.11.self_attn.o_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.11.self_attn.q_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.11.self_attn.v_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.12.input_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.12.mlp.down_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.12.mlp.gate_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.12.mlp.up_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.12.post_attention_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.12.post_feedforward_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.12.pre_feedforward_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.12.self_attn.k_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.12.self_attn.o_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.12.self_attn.q_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.12.self_attn.v_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.13.input_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.13.mlp.down_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.13.mlp.gate_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.13.mlp.up_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.13.post_attention_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.13.post_feedforward_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.13.pre_feedforward_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.13.self_attn.k_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.13.self_attn.o_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.13.self_attn.q_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.13.self_attn.v_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.14.input_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.14.mlp.down_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.14.mlp.gate_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.14.mlp.up_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.14.post_attention_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.14.post_feedforward_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.14.pre_feedforward_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.14.self_attn.k_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.14.self_attn.o_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.14.self_attn.q_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.14.self_attn.v_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.15.input_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.15.mlp.down_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.15.mlp.gate_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.15.mlp.up_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.15.post_attention_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.15.post_feedforward_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.15.pre_feedforward_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.15.self_attn.k_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.15.self_attn.o_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.15.self_attn.q_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.15.self_attn.v_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.16.input_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.16.mlp.down_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.16.mlp.gate_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.16.mlp.up_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.16.post_attention_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.16.post_feedforward_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.16.pre_feedforward_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.16.self_attn.k_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.16.self_attn.o_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.16.self_attn.q_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.16.self_attn.v_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.17.input_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.17.mlp.down_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.17.mlp.gate_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.17.mlp.up_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.17.post_attention_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.17.post_feedforward_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.17.pre_feedforward_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.17.self_attn.k_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.17.self_attn.o_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.17.self_attn.q_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.17.self_attn.v_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.18.input_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.18.mlp.down_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.18.mlp.gate_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.18.mlp.up_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.18.post_attention_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.18.post_feedforward_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.18.pre_feedforward_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.18.self_attn.k_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.18.self_attn.o_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.18.self_attn.q_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.18.self_attn.v_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.19.input_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.19.mlp.down_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.19.mlp.gate_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.19.mlp.up_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.19.post_attention_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.19.post_feedforward_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.19.pre_feedforward_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.19.self_attn.k_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.19.self_attn.o_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.19.self_attn.q_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.19.self_attn.v_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.2.input_layernorm.weight": "model-00001-of-00003.safetensors", + "model.layers.2.mlp.down_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.2.mlp.gate_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.2.mlp.up_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.2.post_attention_layernorm.weight": "model-00001-of-00003.safetensors", + "model.layers.2.post_feedforward_layernorm.weight": "model-00001-of-00003.safetensors", + "model.layers.2.pre_feedforward_layernorm.weight": "model-00001-of-00003.safetensors", + "model.layers.2.self_attn.k_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.2.self_attn.o_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.2.self_attn.q_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.2.self_attn.v_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.20.input_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.20.mlp.down_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.20.mlp.gate_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.20.mlp.up_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.20.post_attention_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.20.post_feedforward_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.20.pre_feedforward_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.20.self_attn.k_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.20.self_attn.o_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.20.self_attn.q_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.20.self_attn.v_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.21.input_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.21.mlp.down_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.21.mlp.gate_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.21.mlp.up_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.21.post_attention_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.21.post_feedforward_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.21.pre_feedforward_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.21.self_attn.k_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.21.self_attn.o_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.21.self_attn.q_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.21.self_attn.v_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.22.input_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.22.mlp.down_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.22.mlp.gate_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.22.mlp.up_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.22.post_attention_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.22.post_feedforward_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.22.pre_feedforward_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.22.self_attn.k_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.22.self_attn.o_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.22.self_attn.q_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.22.self_attn.v_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.23.input_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.23.mlp.down_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.23.mlp.gate_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.23.mlp.up_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.23.post_attention_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.23.post_feedforward_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.23.pre_feedforward_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.23.self_attn.k_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.23.self_attn.o_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.23.self_attn.q_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.23.self_attn.v_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.24.input_layernorm.weight": "model-00003-of-00003.safetensors", + "model.layers.24.mlp.down_proj.weight": "model-00003-of-00003.safetensors", + "model.layers.24.mlp.gate_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.24.mlp.up_proj.weight": "model-00003-of-00003.safetensors", + "model.layers.24.post_attention_layernorm.weight": "model-00003-of-00003.safetensors", + "model.layers.24.post_feedforward_layernorm.weight": "model-00003-of-00003.safetensors", + "model.layers.24.pre_feedforward_layernorm.weight": "model-00003-of-00003.safetensors", + "model.layers.24.self_attn.k_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.24.self_attn.o_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.24.self_attn.q_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.24.self_attn.v_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.25.input_layernorm.weight": "model-00003-of-00003.safetensors", + "model.layers.25.mlp.down_proj.weight": "model-00003-of-00003.safetensors", + "model.layers.25.mlp.gate_proj.weight": "model-00003-of-00003.safetensors", + "model.layers.25.mlp.up_proj.weight": "model-00003-of-00003.safetensors", + "model.layers.25.post_attention_layernorm.weight": "model-00003-of-00003.safetensors", + "model.layers.25.post_feedforward_layernorm.weight": "model-00003-of-00003.safetensors", + "model.layers.25.pre_feedforward_layernorm.weight": "model-00003-of-00003.safetensors", + "model.layers.25.self_attn.k_proj.weight": "model-00003-of-00003.safetensors", + "model.layers.25.self_attn.o_proj.weight": "model-00003-of-00003.safetensors", + "model.layers.25.self_attn.q_proj.weight": "model-00003-of-00003.safetensors", + "model.layers.25.self_attn.v_proj.weight": "model-00003-of-00003.safetensors", + "model.layers.3.input_layernorm.weight": "model-00001-of-00003.safetensors", + "model.layers.3.mlp.down_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.3.mlp.gate_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.3.mlp.up_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.3.post_attention_layernorm.weight": "model-00001-of-00003.safetensors", + "model.layers.3.post_feedforward_layernorm.weight": "model-00001-of-00003.safetensors", + "model.layers.3.pre_feedforward_layernorm.weight": "model-00001-of-00003.safetensors", + "model.layers.3.self_attn.k_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.3.self_attn.o_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.3.self_attn.q_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.3.self_attn.v_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.4.input_layernorm.weight": "model-00001-of-00003.safetensors", + "model.layers.4.mlp.down_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.4.mlp.gate_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.4.mlp.up_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.4.post_attention_layernorm.weight": "model-00001-of-00003.safetensors", + "model.layers.4.post_feedforward_layernorm.weight": "model-00001-of-00003.safetensors", + "model.layers.4.pre_feedforward_layernorm.weight": "model-00001-of-00003.safetensors", + "model.layers.4.self_attn.k_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.4.self_attn.o_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.4.self_attn.q_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.4.self_attn.v_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.5.input_layernorm.weight": "model-00001-of-00003.safetensors", + "model.layers.5.mlp.down_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.5.mlp.gate_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.5.mlp.up_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.5.post_attention_layernorm.weight": "model-00001-of-00003.safetensors", + "model.layers.5.post_feedforward_layernorm.weight": "model-00001-of-00003.safetensors", + "model.layers.5.pre_feedforward_layernorm.weight": "model-00001-of-00003.safetensors", + "model.layers.5.self_attn.k_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.5.self_attn.o_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.5.self_attn.q_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.5.self_attn.v_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.6.input_layernorm.weight": "model-00001-of-00003.safetensors", + "model.layers.6.mlp.down_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.6.mlp.gate_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.6.mlp.up_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.6.post_attention_layernorm.weight": "model-00001-of-00003.safetensors", + "model.layers.6.post_feedforward_layernorm.weight": "model-00001-of-00003.safetensors", + "model.layers.6.pre_feedforward_layernorm.weight": "model-00001-of-00003.safetensors", + "model.layers.6.self_attn.k_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.6.self_attn.o_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.6.self_attn.q_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.6.self_attn.v_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.7.input_layernorm.weight": "model-00001-of-00003.safetensors", + "model.layers.7.mlp.down_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.7.mlp.gate_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.7.mlp.up_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.7.post_attention_layernorm.weight": "model-00001-of-00003.safetensors", + "model.layers.7.post_feedforward_layernorm.weight": "model-00001-of-00003.safetensors", + "model.layers.7.pre_feedforward_layernorm.weight": "model-00001-of-00003.safetensors", + "model.layers.7.self_attn.k_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.7.self_attn.o_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.7.self_attn.q_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.7.self_attn.v_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.8.input_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.8.mlp.down_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.8.mlp.gate_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.8.mlp.up_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.8.post_attention_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.8.post_feedforward_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.8.pre_feedforward_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.8.self_attn.k_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.8.self_attn.o_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.8.self_attn.q_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.8.self_attn.v_proj.weight": "model-00001-of-00003.safetensors", + "model.layers.9.input_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.9.mlp.down_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.9.mlp.gate_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.9.mlp.up_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.9.post_attention_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.9.post_feedforward_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.9.pre_feedforward_layernorm.weight": "model-00002-of-00003.safetensors", + "model.layers.9.self_attn.k_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.9.self_attn.o_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.9.self_attn.q_proj.weight": "model-00002-of-00003.safetensors", + "model.layers.9.self_attn.v_proj.weight": "model-00002-of-00003.safetensors", + "model.norm.weight": "model-00003-of-00003.safetensors" + } +} diff --git a/special_tokens_map.json b/special_tokens_map.json new file mode 100644 index 0000000..8d6368f --- /dev/null +++ b/special_tokens_map.json @@ -0,0 +1,34 @@ +{ + "additional_special_tokens": [ + "", + "" + ], + "bos_token": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false + }, + "eos_token": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false + }, + "pad_token": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false + }, + "unk_token": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false + } +} diff --git a/tdc_prompts.json b/tdc_prompts.json new file mode 100644 index 0000000..a87e41f --- /dev/null +++ b/tdc_prompts.json @@ -0,0 +1 @@ +{"Pgp_Broccatelli": "Instructions: Answer the following question about drug properties.\nContext: P-glycoprotein (Pgp) is an ABC transporter protein involved in intestinal absorption, drug metabolism, and brain penetration, and its inhibition can seriously alter a drug's bioavailability and safety. In addition, inhibitors of Pgp can be used to overcome multidrug resistance.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not a PgP inhibitor (B) is a PgP inhibitor\nDrug SMILES: {Drug SMILES}\nAnswer:", "Bioavailability_Ma": "Instructions: Answer the following question about drug properties.\nContext: Oral bioavailability is defined as \u201cthe rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of action\u201d.\n\n\nQuestion: Given a drug SMILES string, predict whether it\n(A) has oral bioavailability < 20% (B) has oral bioavailability \u2265 20%\nDrug SMILES: {Drug SMILES}\nAnswer:", "BBB_Martins": "Instructions: Answer the following question about drug properties.\nContext: As a membrane separating circulating blood and brain extracellular fluid, the blood-brain barrier (BBB) is the protection layer that blocks most foreign drugs. Thus the ability of a drug to penetrate the barrier to deliver to the site of action forms a crucial challenge in development of drugs for central nervous system.\nQuestion: Given a drug SMILES string, predict whether it\n(A) does not cross the BBB (B) crosses the BBB\nDrug SMILES: {Drug SMILES}\nAnswer:", "CYP2D6_Veith": "Instructions: Answer the following question about drug properties.\nContext: The CYP P450 genes are involved in the formation and breakdown (metabolism) of various molecules and chemicals within cells. Specifically, CYP2D6 is primarily expressed in the liver. It is also highly expressed in areas of the central nervous system, including the substantia nigra.\nQuestion: Given a drug SMILES string, predict whether it\n(A) does not inhibit CYP2D6 (B) inhibits CYP2D6\nDrug SMILES: {Drug SMILES}\nAnswer:", "CYP3A4_Veith": "Instructions: Answer the following question about drug properties.\nContext: The CYP P450 genes are involved in the formation and breakdown (metabolism) of various molecules and chemicals within cells. Specifically, CYP3A4 is an important enzyme in the body, mainly found in the liver and in the intestine. It oxidizes small foreign organic molecules (xenobiotics), such as toxins or drugs, so that they can be removed from the body.\nQuestion: Given a drug SMILES string, predict whether it\n(A) does not inhibit CYP3A4 (B) inhibits CYP3A4\nDrug SMILES: {Drug SMILES}\nAnswer:", "CYP2C9_Veith": "Instructions: Answer the following question about drug properties.\nContext: The CYP P450 genes are involved in the formation and breakdown (metabolism) of various molecules and chemicals within cells. Specifically, the CYP P450 2C9 plays a major role in the oxidation of both xenobiotic and endogenous compounds.\nQuestion: Given a drug SMILES string, predict whether it\n(A) does not inhibit CYP2C9 (B) inhibits CYP2C9\nDrug SMILES: {Drug SMILES}\nAnswer:", "CYP2D6_Substrate_CarbonMangels": "Instructions: Answer the following question about drug properties.\nContext: CYP2D6 is primarily expressed in the liver. It is also highly expressed in areas of the central nervous system, including the substantia nigra. Substrates are drugs that are metabolized by the enzyme. \nQuestion: Given a drug SMILES string, predict whether it\n(A) is not a substrate to the enzyme CYP2D6 (B) is a substrate to the enzyme CYP2D6\nDrug SMILES: {Drug SMILES}\nAnswer:", "CYP3A4_Substrate_CarbonMangels": "Instructions: Answer the following question about drug properties.\nContext: CYP3A4 is an important enzyme in the body, mainly found in the liver and in the intestine. It oxidizes small foreign organic molecules (xenobiotics), such as toxins or drugs, so that they can be removed from the body. Substrates are drugs that are metabolized by the enzyme. \nQuestion: Given a drug SMILES string, predict whether it\n(A) is not a substrate to the enzyme CYP3A4 (B) is a substrate to the enzyme CYP3A4\nDrug SMILES: {Drug SMILES}\nAnswer:", "CYP2C9_Substrate_CarbonMangels": "Instructions: Answer the following question about drug properties.\nContext: CYP P450 2C9 plays a major role in the oxidation of both xenobiotic and endogenous compounds. Substrates are drugs that are metabolized by the enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not a substrate to the enzyme CYP2C9 (B) is a substrate to the enzyme CYP2C9\nDrug SMILES: {Drug SMILES}\nAnswer:", "hERG": "Instructions: Answer the following question about drug properties.\nContext: Human ether-\u00e0-go-go related gene (hERG) is crucial for the coordination of the heart's beating. Thus, if a drug blocks the hERG, it could lead to severe adverse effects. Therefore, reliable prediction of hERG liability in the early stages of drug design is quite important to reduce the risk of cardiotoxicity-related attritions in the later development stages.\nQuestion: Given a drug SMILES string, predict whether it\n(A) does not block hERG (B) blocks hERG\nDrug SMILES: {Drug SMILES}\nAnswer:", "AMES": "Instructions: Answer the following question about drug properties.\nContext: Mutagenicity means the ability of a drug to induce genetic alterations. Drugs that can cause damage to the DNA can result in cell death or other severe adverse effects. Nowadays, the most widely used assay for testing the mutagenicity of compounds is the Ames experiment which was invented by a professor named Ames. The Ames test is a short-term bacterial reverse mutation assay detecting a large number of compounds which can induce genetic damage and frameshift mutations.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not mutagenic (B) is mutagenic\nDrug SMILES: {Drug SMILES}\nAnswer:", "DILI": "Instructions: Answer the following question about drug properties.\nContext: Drug-induced liver injury (DILI) is fatal liver disease caused by drugs and it has been the single most frequent cause of safety-related drug marketing withdrawals for the past 50 years (e.g. iproniazid, ticrynafen, benoxaprofen). \nQuestion: Given a drug SMILES string, predict whether it\n(A) cannot cause DILI (B) can cause DILI\nDrug SMILES: {Drug SMILES}\nAnswer:", "HIA_Hou": "Instructions: Answer the following question about drug properties.\nContext: When a drug is orally administered, it needs to be absorbed from the human gastrointestinal system into the bloodstream of the human body. This ability of absorption is called human intestinal absorption (HIA) and it is crucial for a drug to be delivered to the target.\nQuestion: Given a drug SMILES string, predict whether it\n(A) cannot be absorbed (B) can be absorbed\nDrug SMILES: {Drug SMILES}\nAnswer:", "Tox21_NR_AhR": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products, and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. The Aryl hydrocarbon Receptor (AhR), a nuclear receptor member of the family of basic helix-loop-helix transcription factors, is crucial to adaptive responses to environmental changes. AhR mediates cellular responses to environmental pollutants such as aromatic hydrocarbons through induction of phase I and II enzymes but also interacts with other nuclear receptor signaling pathways.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in a NR aryl hydrocarbon receptor assay (B) is toxic in a NR aryl hydrocarbon receptor assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "Tox21_NR_Aromatase": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products, and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Endocrine disrupting chemicals (EDCs) interfere with the biosynthesis and normal functions of steroid hormones including estrogen and androgen in the body. Aromatase is an enzyme that catalyzes the conversion of androgen to estrogen and plays a key role in maintaining the androgen and estrogen balance in many of the EDC-sensitive organs.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in an Aromatase assay (B) is toxic in an Aromatase assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "Tox21_NR_AR": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products, and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Androgen receptor (AR), a nuclear hormone receptor, plays a critical role in AR-dependent prostate cancer and other androgen related diseases. Endocrine disrupting chemicals (EDCs) and their interactions with steroid hormone receptors like AR may cause disruption of normal endocrine function as well as interfere with metabolic homeostasis, reproduction, developmental and behavioral functions.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in an AR full length assay (B) is toxic in an AR full length assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "Tox21_NR_AR_LBD": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products, and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Androgen receptor (AR), a nuclear hormone receptor, plays a critical role in AR-dependent prostate cancer and other androgen related diseases. The ligand-binding domain (LBD) is a specific region of the androgen receptor where hormones attach. Endocrine disrupting chemicals (EDCs) and their interactions with steroid hormone receptors like AR may cause disruption of normal endocrine function as well as interfere with metabolic homeostasis, reproduction, developmental and behavioral functions. \nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in an AR LBD assay (B) is toxic in an AR LBD assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "Tox21_NR_ER": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products, and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Estrogen receptor (ER), a nuclear hormone receptor, plays an important role in development, metabolic homeostasis and reproduction. Endocrine disrupting chemicals (EDCs) and their interactions with steroid hormone receptors like ER causes disruption of normal endocrine function.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in an ER alpha full length assay (B) is toxic in an ER alpha full length assay \nDrug SMILES: {Drug SMILES}\nAnswer:", "Tox21_NR_ER_LBD": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products, and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Estrogen receptor (ER), a nuclear hormone receptor, plays an important role in development, metabolic homeostasis and reproduction. The ligand-binding domain (LBD) is a specific region of the androgen receptor where hormones attach. Endocrine disrupting chemicals (EDCs) and their interactions with steroid hormone receptors like ER causes disruption of normal endocrine function. \nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in an ER alpha LBD assay (B) is toxic in an ER alpha LBD assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "Tox21_NR_PPAR_gamma": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products, and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. The peroxisome proliferator-activated receptors (PPARs) are lipid-activated transcription factors of the nuclear receptor superfamily with three distinct subtypes namely PPAR alpha, PPAR delta (also called PPAR beta) and PPAR gamma (PPARg). All these subtypes heterodimerize with Retinoid X receptor (RXR) and these heterodimers regulate transcription of various genes. PPAR-gamma receptor (glitazone receptor) is involved in the regulation of glucose and lipid metabolism.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in a PPARg assay (B) is toxic in a PPARg assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "Tox21_SR_ARE": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products, and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Oxidative stress has been implicated in the pathogenesis of a variety of diseases ranging from cancer to neurodegeneration. The antioxidant response element (ARE) signaling pathway plays an important role in the amelioration of oxidative stress. Nrf2 (NF-E2-related factor 2) and Nrf1 are transcription factors that bind to AREs and activate these genes.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in a Nrf2/antioxidant responsive element assay (B) is toxic in a Nrf2/antioxidant responsive element assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "Tox21_SR_ATAD5": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products, and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. As cancer cells divide rapidly and during every cell division they need to duplicate their genome by DNA replication. The failure to do so results in the cancer cell death. Based on this concept, many chemotherapeutic agents were developed but have limitations such as low efficacy and severe side effects etc. A new cell based assay was developed to find the compounds that effectively block DNA replication either by directly damaging DNA or by inhibiting other cellular mechanisms. Enhanced Level of Genome Instability Gene 1 (ELG1; human ATAD5) protein levels increase in response to various types of DNA damage.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in an ATAD5 assay (B) is toxic in an ATAD5 assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "Tox21_SR_HSE": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products, and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. The Heat Shock Factor (HSF) response element, often referred to as the Heat Shock Element (HSE), is a specific DNA sequence that is recognized and bound by Heat Shock Factors (HSFs) during the heat shock response or unfolded protein response (HSR/UPR). Various chemicals, environmental and physiological stress conditions may lead to the activation of heat shock response/ unfolded protein response (HSR/UPR). There are three heat shock transcription factors (HSFs) (HSF-1, -2, and -4) mediating transcriptional regulation of the human HSR.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in a HSE assay (B) is toxic in a HSE assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "Tox21_SR_MMP": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products, and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Mitochondrial membrane potential (MMP), one of the parameters for mitochondrial function, is generated by mitochondrial electron transport chain that creates an electrochemical gradient by a series of redox reactions. This gradient drives the synthesis of ATP, a crucial molecule for various cellular processes. Measuring MMP in living cells is commonly used to assess the effect of chemicals on mitochondrial function.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in a MMP assay (B) is toxic in a MMP assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "Tox21_SR_p53": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products, and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. p53, a tumor suppressor protein, is activated following cellular insult, including DNA damage and other cellular stresses. The activation of p53 regulates cell fate by inducing DNA repair, cell cycle arrest, apoptosis, or cellular senescence. The activation of p53, therefore, is a good indicator of DNA damage and other cellular stresses. \nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in a p53 assay (B) is toxic in a p53 assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "PAMPA_NCATS": "Instructions: Answer the following question about drug properties.\nContext: Membrane permeability is a measure of the ability of a drug to pass through a cellular membrane through passive diffusion, which is necessary for the drug to affect a cell. In general, small hydrophobic drugs can easily pass through membranes whereas large polar/charged drugs do not easily pass through. PAMPA (parallel artificial membrane permeability assay) is a commonly employed non-cell-based assay to evaluate drug permeability across the cellular membrane.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not permeable to cell membranes in a PAMPA assay (B) is permeable to cell membranes in a PAMPA assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "CYP2C19_Veith": "Instructions: Answer the following question about drug properties.\nContext: The CYP P450 genes are essential in the breakdown (metabolism) of various molecules and chemicals within cells. A drug that can inhibit these enzymes would mean poor metabolism to this drug and other drugs, which could lead to drug-drug interactions and adverse effects. Specifically, the CYP2C19 gene provides instructions for making an enzyme called the endoplasmic reticulum, which is involved in protein processing and transport.\nQuestion: Given a drug SMILES string, predict whether it\n(A) does not inhibit CYP2C19 (B) inhibits CYP2C19 \nDrug SMILES: {Drug SMILES}\nAnswer:", "CYP1A2_Veith": "Instructions: Answer the following question about drug properties.\nContext: The CYP P450 genes are involved in the formation and breakdown (metabolism) of various molecules and chemicals within cells. Specifically, CYP1A2 localizes to the endoplasmic reticulum and its expression is induced by some polycyclic aromatic hydrocarbons (PAHs), some of which are found in cigarette smoke. It is able to metabolize some PAHs to carcinogenic intermediates. Other xenobiotic substrates for this enzyme include caffeine, aflatoxin B1, and acetaminophen.\nQuestion: Given a drug SMILES string, predict whether it\n(A) does not inhibit CYP1A2 (B) inhibits CYP1A2\nDrug SMILES: {Drug SMILES}\nAnswer:", "Skin_Reaction": "Instructions: Answer the following question about drug properties.\nContext: Repetitive exposure to a chemical agent can induce an immune reaction in inherently susceptible individuals that leads to skin sensitization.\nQuestion: Given a drug SMILES string, predict whether it\n(A) does not cause a skin reaction (B) causes a skin reaction\nDrug SMILES: {Drug SMILES}\nAnswer:", "Carcinogens_Lagunin": "Instructions: Answer the following question about drug properties.\nContext: A carcinogen is any substance, radionuclide, or radiation that promotes carcinogenesis, the formation of cancer. This may be due to the ability to damage the genome or to the disruption of cellular metabolic processes.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not a carcinogen (B) is a carcinogen\nDrug SMILES: {Drug SMILES}\nAnswer:", "SARSCoV2_Vitro_Touret": "Instructions: Answer the following question about drug properties.\nContext: SARS-CoV-2 is a coronavirus that causes the COVID-19 disease and has led to millions of deaths worldwide within a few years. Discovering new drugs that can inhibit viral replication would be useful for combatting the virus. One method is to screen a library of small molecule drugs for inhibition in an infected cell-based assay.\nQuestion: Given a drug SMILES string, predict whether it\n(A) does not inhibit SARS-CoV-2 replication (B) inhibits SARS-CoV-2 replication\nDrug SMILES: {Drug SMILES}\nAnswer:", "SARSCOV2_3CLPro_Diamond": "Instructions: Answer the following question about drug properties.\nContext: SARS-CoV-2 is a coronavirus that causes the COVID-19 disease and has led to millions of deaths worldwide within a few years. Discovering new drugs that can inhibit viral replication would be useful for combatting the virus. One method is to screen a library of small molecule drugs for binding to the SARS-CoV-2 3CL protease using X-ray crystallography.\nQuestion: Given a drug SMILES string, predict whether it\n(A) does not bind SARS-CoV-2 3CL protease (B) binds SARS-CoV-2 3CL protease\nDrug SMILES: {Drug SMILES}\nAnswer:", "HIV": "Instructions: Answer the following question about drug properties.\nContext: HIV is a virus that causes AIDS by infecting T cells and increasing susceptibility to opportunistic infections. HIV has killed 40 million people worldwide, making it a major concern for public health. Discovering drugs that can inhibit HIV replication is useful for reducing the HIV mortality. One method is to screen a library of small molecule drugs for anti-HIV activity.\nQuestion: Given a drug SMILES string, predict whether it\n(A) does not have anti-HIV activity (B) has anti-HIV activity\nDrug SMILES: {Drug SMILES}\nAnswer:", "ClinTox": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products, and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxic drugs can be identified from clinical trials that failed due to toxicity, while non-toxic drugs can be identified from FDA approval status or from clinical trials that report no toxicity.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic (B) is toxic\nDrug SMILES: {Drug SMILES}\nAnswer:", "orexin1_receptor_butkiewicz": "Instructions: Answer the following question about drug properties.\nContext: Orexin1 receptor is a G-protein coupled receptor that binds the neuropeptide orexin and is involved in the regulation of sleep, emotion, and feeding behavior. It is heavily expressed in projections from the lateral hypothalamus.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not active against Orexin1 (B) is active against Orexin1\nDrug SMILES: {Drug SMILES}\nAnswer:", "m1_muscarinic_receptor_agonists_butkiewicz": "Instructions: Answer the following question about drug properties.\nContext: M1 muscarinic receptor is a G-protein coupled receptor that is common in exocrine glands and in the central nervous system. It plays a role in cognitive processing, prostate growth, and glandular secretion. An agonist initiates the response of a receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not an agonist for M1 muscarinic receptor (B) is an agonist for M1 muscarinic receptor\nDrug SMILES: {Drug SMILES}\nAnswer:", "m1_muscarinic_receptor_antagonists_butkiewicz": "Instructions: Answer the following question about drug properties.\nContext: M1 muscarinic receptor is a G-protein coupled receptor that is common in exocrine glands and in the central nervous system. It plays a role in cognitive processing, prostate growth, and glandular secretion. An antagonist inhibits the response of a receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not an antagonist for M1 muscarinic receptor (B) is an antagonist for M1 muscarinic receptor\nDrug SMILES: {Drug SMILES}\nAnswer:", "potassium_ion_channel_kir2.1_butkiewicz": "Instructions: Answer the following question about drug properties.\nContext: Kir2.1 is a lipid-gated potassium ion channel, which is involved in potassium homeostasis. Kir2.1 affects many cellular processes such as heart rhythm, muscle contraction, and bone development.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not active against Kir2.1 (B) is active against Kir2.1\nDrug SMILES: {Drug SMILES}\nAnswer:", "kcnq2_potassium_channel_butkiewicz": "Instructions: Answer the following question about drug properties.\nContext: KCNQ2 encodes the voltage-gated potassium ion channel Kv7.2, which is expressed in the brain. This channel is a critical molecular component of the M-current, a subthreshold voltage-gated potassium current controlling neuronal excitability by dampening repetitive action potential firing. Mutations in KCNQ2 are associated with seizures.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not active against KCNQ2 (B) is active against KCNQ2\nDrug SMILES: {Drug SMILES}\nAnswer:", "cav3_t_type_calcium_channels_butkiewicz": "Instructions: Answer the following question about drug properties.\nContext: Cav3 T-type calcium channels are voltage-gated calcium channels that have low activation voltage, rapid inactivation, and small single channel conductance. They are found in neurons, cardiac tissue, and various other cell types. They are involved in cardiac pacemaker activity, neuron firing, sleep, hormone secretion, and fertilization.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not active against Cav3 T-type calcium channels (B) is active against Cav3 T-type calcium channels\nDrug SMILES: {Drug SMILES}\nAnswer:", "choline_transporter_butkiewicz": "Instructions: Answer the following question about drug properties.\nContext: Choline transporter is a protein encoded by the SLC5A7 gene. It is a membrane transporter that carries choline into acetylcholine-synthesizing neurons. Choline is a precursor of acetylcholine, a neurotransmitter of the nervous system that regulates a variety of autonomic, cognitive, and motor functions. Choline transporter is dependent on sodium and calcium, and mutations have been associated with muscular atrophy and vocal cord paralysis.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not active against choline transporter (B) is active against choline transporter\nDrug SMILES: {Drug SMILES}\nAnswer:", "serine_threonine_kinase_33_butkiewicz": "Instructions: Answer the following question about drug properties.\nContext: Serine/threonine kinase 33 is a protein kinase that phosphorylates the OH group of amino acids serine and threonine, which plays a role in many cellular processes such as proliferation, apoptosis, differentiation, and embryonic development. Mutations have been observed in some types of cancers.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not active against serine/threonine kinase 3 (B) is active against serine/threonine kinase 3\nDrug SMILES: {Drug SMILES}\nAnswer:", "tyrosyl_dna_phosphodiesterase_butkiewicz": "Instructions: Answer the following question about drug properties.\nContext: Tyrosyl-DNA phosphodiesterase is an enzyme involved in repairing stalled topoisomerase I-DNA complexes by catalyzing the hydrolysis of the phophodiester bond between the tyrosine residue of type 1 topoisomerase and the 3-prime phosphate of DNA. Mutations have been associated with axonal neuropathy.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not active against tyrosyl-DNA phosphodiesterase (B) is active against tyrosyl-DNA phosphodiesterase\nDrug SMILES: {Drug SMILES}\nAnswer:", "herg_central": "Instructions: Answer the following question about drug properties.\nContext: Human ether-\u00e0-go-go related gene (hERG) is crucial for the coordination of the heart's beating. Thus, if a drug blocks the hERG, it could lead to severe adverse effects. Therefore, reliable prediction of hERG liability in the early stages of drug design is quite important to reduce the risk of cardiotoxicity-related attritions in the later development stages.\nQuestion: Given a drug SMILES string, predict whether it\n(A) does not inhibit hERG (B) inhibits hERG\nDrug SMILES: {Drug SMILES}\nAnswer:", "hERG_Karim": "Instructions: Answer the following question about drug properties.\nContext: Human ether-\u00e0-go-go related gene (hERG) is crucial for the coordination of the heart's beating. Thus, if a drug blocks the hERG, it could lead to severe adverse effects. Therefore, reliable prediction of hERG liability in the early stages of drug design is quite important to reduce the risk of cardiotoxicity-related attritions in the later development stages.\nQuestion: Given a drug SMILES string, predict whether it\n(A) does not inhibit hERG (B) inhibits hERG\nDrug SMILES: {Drug SMILES}\nAnswer:", "MHC1_IEDB_IMGT_Nielsen": "Instructions: Answer the following question about peptide-MHC binding.\nContext: In the human body, T cells monitor the existing peptides and trigger an immune response if the peptide is foreign. To decide whether or not if the peptide is not foreign, the peptide must bind to a major histocompatibility complex (MHC) molecule. Therefore, predicting peptide-MHC binding affinity is pivotal for determining immunogenicity. In some experiments, the peptide binding is measured against cells that express multiple MHCs, so the peptide could be binding any one of the possible MHCs. Class 1 MHC molecules bind to peptides that are usually 8-14 amino acids long and activate CD8 T cells.\nQuestion: Given the amino acid sequence of the peptide and possible pseudo amino acid sequences of MHC 1, predict whether the peptide\n(A) does not bind to any of the MHCs (B) binds to any of the MHCs\nPeptide amino acid sequence: {Peptide amino acid sequence}\nPossible MHC pseudosequences: {Possible MHC pseudosequences}\nAnswer:", "MHC2_IEDB_Jensen": "Instructions: Answer the following question about peptide-MHC binding.\nContext: In the human body, T cells monitor the existing peptides and trigger an immune response if the peptide is foreign. To decide whether or not if the peptide is not foreign, the peptide must bind to a major histocompatibility complex (MHC) molecule. Therefore, predicting peptide-MHC binding affinity is pivotal for determining immunogenicity. In some experiments, the peptide binding is measured against cells that express multiple MHCs, so the peptide could be binding any one of the possible MHCs. Class 2 MHC molecules bind to peptides that are usually 12-25 amino acids long and activate CD4 T cells.\nQuestion: Given the amino acid sequence of the peptide and possible pseudo amino acid sequences of MHC 2, predict whether the peptide\n(A) does not bind to any of the MHCs (B) binds to any of the MHCs\nPeptide amino acid sequence: {Peptide amino acid sequence}\nPossible MHC pseudosequences: {Possible MHC pseudosequences}\nAnswer:", "weber": "Instructions: Answer the following question about peptide-TCR binding.\nContext: T-cells are an integral part of the adaptive immune system, whose survival, proliferation, activation and function are all governed by the interaction of their T-cell receptor (TCR) with immunogenic peptides (epitopes). A large repertoire of T-cell receptors with different specificity is needed to provide protection against a wide range of pathogens.\nQuestion: Given the amino acid sequences of the peptide and a T-cell receptor (amino acid sequence of the hypervariable CDR3 loop), predict whether the peptide\n(A) does not bind to the TCR (B) binds to the TCR\nEpitope amino acid sequence: {Epitope amino acid sequence}\nTCR amino acid sequence: {TCR amino acid sequence}\nAnswer:", "HuRI": "Instructions: Answer the following question about protein properties.\nContext: Protein-protein interactions (PPIs) are crucial for nearly all biological processes, forming the backbone of cellular processes, signal transduction, metabolic pathways, and cell-to-cell interactions. These interactions can be short-lived (transient) or long-lasting (stable), and understanding them is key for drug discovery, systems biology, evolutionary biology, and biotechnology.\nQuestion: Given the amino acid sequences of one protein and another protein, predict whether the proteins\n(A) do not interact (B) interact\nProtein1 amino acid sequence: {Protein1 amino acid sequence}\nProtein2 amino acid sequence: {Protein2 amino acid sequence}\nAnswer:", "SAbDab_Chen": "Instructions: Answer the following question about antibody developability.\nContext: To be clinically effective, monoclonal antibodies (mAbs) must be present in high concentrations. Therefore, candidates for therapeutic use must retain specificity and safety throughout development, while maintaining high stability and low aggregation to be fit for industrial production. A strategy to minimize failure is to exclude candidates early in the development cycle based on their aggregation propensity. One such metric, Developability Index (DI), relies on an antibody\u2019s hydrophobic and electrostatic interactions as inferred from its three-dimensional structure. \nQuestion: Given an antibody heavy chain and light chain sequence, whether it\n(A) is non-developable (high DI) (B) is developable (low DI)\nAntibody heavy chain sequence: {Antibody heavy chain sequence}\nAntibody light chain sequence: {Antibody light chain sequence}\nAnswer:", "miRTarBase": "Instructions: Answer the following question about miRNA protein interactions.\nContext: MicroRNAs (miRNAs) are, small non-coding RNAs with 18\u201325 nucleotides, which are central regulators at the post-transcriptional level in both animals and plants. Perfect or near-perfect complementary binding of miRNAs and their target mRNA negatively regulates gene expression by accelerating mRNA degradation or suppressing mRNA translation.\nQuestion: Given the miRNA mature sequence and target amino acid sequence, predict whether\n(A) the miRNA and target do not interact (B) the miRNA and target interact\nmiRNA sequence: {miRNA sequence}\nTarget amino acid sequence: {Target amino acid sequence}\nAnswer:", "ToxCast_ACEA_T47D_80hr_Negative": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ACEA_T47D_80hr_Negative assay is as follows: Measures loss of estrogen-dependent cellular growth kinetics, indicating cytotoxicity.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ACEA_T47D_80hr_Positive": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ACEA_T47D_80hr_Positive assay is as follows: Measures gain of estrogen-dependent cellular growth kinetics.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_HepG2_CellCycleArrest_24h_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_HepG2_CellCycleArrest_24h_dn assay is as follows: Hoechst-33342 dye is used as a stain for DNA to understand morphology in the system. The biological focus is gain/loss of cell cycle and the technological target is dna-unspecified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_HepG2_CellCycleArrest_24h_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_HepG2_CellCycleArrest_24h_up assay is as follows: Hoechst-33342 dye is used as a stain for DNA to understand morphology in the system. The biological focus is gain/loss of cell cycle and the technological target is dna-unspecified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_HepG2_CellCycleArrest_72h_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_HepG2_CellCycleArrest_72h_dn assay is as follows: Hoechst-33342 dye is used as a stain for DNA to understand morphology in the system. The biological focus is gain/loss of cell cycle and the technological target is dna-unspecified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_HepG2_CellLoss_24h_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_HepG2_CellLoss_24h_dn assay is as follows: Hoechst-33342 dye is used as a stain for DNA to understand viability in the system. The biological focus is gain/loss of cell death and the technological target is dna-unspecified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_HepG2_CellLoss_72h_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_HepG2_CellLoss_72h_dn assay is as follows: Hoechst-33342 dye is used as a stain for DNA to understand viability in the system. The biological focus is gain/loss of cell death and the technological target is dna-unspecified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_HepG2_MicrotubuleCSK_24h_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_HepG2_MicrotubuleCSK_24h_dn assay is as follows: anti-a-tubulin antibody is used to tag and quantify the level of tubulin, alpha 1a protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:TUBA1A | GeneID:7846 | Uniprot_SwissProt_Accession:Q71U36]. The biological focus is gain/loss of protein stabilization and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_HepG2_MicrotubuleCSK_24h_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_HepG2_MicrotubuleCSK_24h_up assay is as follows: anti-a-tubulin antibody is used to tag and quantify the level of tubulin, alpha 1a protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:TUBA1A | GeneID:7846 | Uniprot_SwissProt_Accession:Q71U36]. The biological focus is gain/loss of protein stabilization and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_HepG2_MicrotubuleCSK_72h_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_HepG2_MicrotubuleCSK_72h_dn assay is as follows: anti-a-tubulin antibody is used to tag and quantify the level of tubulin, alpha 1a protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:TUBA1A | GeneID:7846 | Uniprot_SwissProt_Accession:Q71U36]. The biological focus is gain/loss of protein stabilization and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_HepG2_MicrotubuleCSK_72h_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_HepG2_MicrotubuleCSK_72h_up assay is as follows: anti-a-tubulin antibody is used to tag and quantify the level of tubulin, alpha 1a protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:TUBA1A | GeneID:7846 | Uniprot_SwissProt_Accession:Q71U36]. The biological focus is gain/loss of protein stabilization and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_HepG2_MitoMass_24h_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_HepG2_MitoMass_24h_dn assay is as follows: MitoTracker Red is used as a stain for the morphology of the mitochondria. The biological focus is gain/loss of cell cycle and the technological target is mitochondria.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_HepG2_MitoMass_24h_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_HepG2_MitoMass_24h_up assay is as follows: MitoTracker Red is used as a stain for the morphology of the mitochondria. The biological focus is gain/loss of cell cycle and the technological target is mitochondria.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_HepG2_MitoMass_72h_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_HepG2_MitoMass_72h_dn assay is as follows: MitoTracker Red is used as a stain for the morphology of the mitochondria. The biological focus is gain/loss of cell cycle and the technological target is mitochondria.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_HepG2_MitoMass_72h_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_HepG2_MitoMass_72h_up assay is as follows: MitoTracker Red is used as a stain for the morphology of the mitochondria. The biological focus is gain/loss of cell cycle and the technological target is mitochondria.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_HepG2_MitoMembPot_1h_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_HepG2_MitoMembPot_1h_dn assay is as follows: MitoTracker Red is used as a stain for the membrane potential of the mitochondria. The biological focus is gain/loss of mitochondrial depolarization and the technological target is mitochondria.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_HepG2_MitoMembPot_24h_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_HepG2_MitoMembPot_24h_dn assay is as follows: MitoTracker Red is used as a stain for the membrane potential of the mitochondria. The biological focus is gain/loss of mitochondrial depolarization and the technological target is mitochondria.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_HepG2_MitoMembPot_72h_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_HepG2_MitoMembPot_72h_dn assay is as follows: MitoTracker Red is used as a stain for the membrane potential of the mitochondria. The biological focus is gain/loss of mitochondrial depolarization and the technological target is mitochondria.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_HepG2_MitoticArrest_24h_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_HepG2_MitoticArrest_24h_up assay is as follows: anti-phospho-histone-H3 antibody is used to tag and quantify the level of phosphorylated H3 histone, family 3A protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:H3F3A | GeneID:3020 | Uniprot_SwissProt_Accession:P84243]. The biological focus is gain/loss of cell cycle and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_HepG2_MitoticArrest_72h_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_HepG2_MitoticArrest_72h_up assay is as follows: anti-phospho-histone-H3 antibody is used to tag and quantify the level of phosphorylated H3 histone, family 3A protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:H3F3A | GeneID:3020 | Uniprot_SwissProt_Accession:P84243]. The biological focus is gain/loss of cell cycle and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_HepG2_NuclearSize_24h_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_HepG2_NuclearSize_24h_dn assay is as follows: Hoechst-33342 dye is used as a stain for DNA to understand morphology in the system. The biological focus is gain/loss of cell cycle and the technological target is dna-unspecified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_HepG2_NuclearSize_72h_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_HepG2_NuclearSize_72h_dn assay is as follows: Hoechst-33342 dye is used as a stain for DNA to understand morphology in the system. The biological focus is gain/loss of cell cycle and the technological target is dna-unspecified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_HepG2_NuclearSize_72h_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_HepG2_NuclearSize_72h_up assay is as follows: Hoechst-33342 dye is used as a stain for DNA to understand morphology in the system. The biological focus is gain/loss of cell cycle and the technological target is dna-unspecified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_HepG2_OxidativeStress_24h_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_HepG2_OxidativeStress_24h_up assay is as follows: Measures level of H2A phosphorylation in HepG2 cells after 24 hours, a marker for oxidative stress.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_HepG2_OxidativeStress_72h_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_HepG2_OxidativeStress_72h_up assay is as follows: Measures level of H2A phosphorylation in HepG2 cells after 72 hours, a marker for oxidative stress.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_HepG2_StressKinase_1h_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_HepG2_StressKinase_1h_up assay is as follows: anti-phospho-c-jun antibody is used to tag and quantify the level of phosphorylated jun proto-oncogene protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:JUN | GeneID:3725 | Uniprot_SwissProt_Accession:P05412]. The biological focus is gain/loss of oxidative phosphorylation and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_HepG2_StressKinase_24h_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_HepG2_StressKinase_24h_up assay is as follows: anti-phospho-c-jun antibody is used to tag and quantify the level of phosphorylated jun proto-oncogene protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:JUN | GeneID:3725 | Uniprot_SwissProt_Accession:P05412]. The biological focus is gain/loss of oxidative phosphorylation and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_HepG2_StressKinase_72h_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_HepG2_StressKinase_72h_up assay is as follows: anti-phospho-c-jun antibody is used to tag and quantify the level of phosphorylated jun proto-oncogene protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:JUN | GeneID:3725 | Uniprot_SwissProt_Accession:P05412]. The biological focus is gain/loss of oxidative phosphorylation and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_HepG2_p53Act_24h_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_HepG2_p53Act_24h_up assay is as follows: anti-p53 antibody is used to tag and quantify the level of tumor protein p53 protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:TP53 | GeneID:7157 | Uniprot_SwissProt_Accession:P04637]. The biological focus is gain/loss of cell death and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_HepG2_p53Act_72h_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_HepG2_p53Act_72h_up assay is as follows: anti-p53 antibody is used to tag and quantify the level of tumor protein p53 protein. Changes in the signals are indicative of protein expression changes as a cellular response to stress in the system [GeneSymbol:TP53 | GeneID:7157 | Uniprot_SwissProt_Accession:P04637]. The biological focus is gain/loss of cell death and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_Hepat_Apoptosis_24hr_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_Hepat_Apoptosis_24hr_up assay is as follows: Measures levels of apoptosis, or programmed cell death, in liver cells after 24 hours.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_Hepat_Apoptosis_48hr_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_Hepat_Apoptosis_48hr_up assay is as follows: Measures levels of apoptosis, or programmed cell death, in liver cells after 48 hours.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_Hepat_CellLoss_24hr_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_Hepat_CellLoss_24hr_dn assay is as follows: Measures levels of cell loss, whether by death, migration, or reduced proliferation, in liver cells after 24 hours.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_Hepat_CellLoss_48hr_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_Hepat_CellLoss_48hr_dn assay is as follows: Measures levels of cell loss, whether by death, migration, or reduced proliferation, in liver cells after 48 hours.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_Hepat_DNADamage_24hr_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_Hepat_DNADamage_24hr_up assay is as follows: Measures levels of DNA damage in liver cells after 24 hours.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_Hepat_DNADamage_48hr_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_Hepat_DNADamage_48hr_up assay is as follows: Measures levels of DNA damage in liver cells after 48 hours.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_Hepat_DNATexture_24hr_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_Hepat_DNATexture_24hr_up assay is as follows: Measures DNA texture (spatial arrangement and relationships of DNA) in liver cells after 24 hours.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_Hepat_DNATexture_48hr_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_Hepat_DNATexture_48hr_up assay is as follows: Measures DNA texture (spatial arrangement and relationships of DNA) in liver cells after 48 hours.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_Hepat_MitoFxnI_1hr_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_Hepat_MitoFxnI_1hr_dn assay is as follows: Measures functionality of mitochondria in liver cells after 1 hour.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_Hepat_MitoFxnI_24hr_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_Hepat_MitoFxnI_24hr_dn assay is as follows: Measures functionality of mitochondria in liver cells after 24 hours.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_Hepat_MitoFxnI_48hr_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_Hepat_MitoFxnI_48hr_dn assay is as follows: Measures functionality of mitochondria in liver cells after 48 hours.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_Hepat_NuclearSize_24hr_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_Hepat_NuclearSize_24hr_dn assay is as follows: Measures nucleus size in liver cells after 24 hours.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_Hepat_NuclearSize_48hr_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_Hepat_NuclearSize_48hr_dn assay is as follows: Measures nucleus size in liver cells after 48 hours.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_Hepat_Steatosis_24hr_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_Hepat_Steatosis_24hr_up assay is as follows: Measures steatosis, or fat accumulation, in liver cells after 24 hours.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_APR_Hepat_Steatosis_48hr_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the APR_Hepat_Steatosis_48hr_up assay is as follows: Measures steatosis, or fat accumulation, in liver cells after 48 hours.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_AP_1_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_AP_1_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene AP-1, which is responsive to the endogenous human FBJ murine osteosarcoma viral oncogene homolog and jun proto-oncogene [GeneSymbol:FOS & JUN | GeneID:2353 & 3725 | Uniprot_SwissProt_Accession:P01100 & P05412]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_AP_1_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_AP_1_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene AP-1, which is responsive to the endogenous human FBJ murine osteosarcoma viral oncogene homolog and jun proto-oncogene [GeneSymbol:FOS & JUN | GeneID:2353 & 3725 | Uniprot_SwissProt_Accession:P01100 & P05412]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_AP_2_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_AP_2_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene AP-2, which is responsive to the endogenous human transcription factor AP-2 alpha (activating enhancer binding protein 2 alpha) and transcription factor AP-2 beta (activating enhancer binding protein 2 beta) and transcription factor AP-2 delta (activating enhancer binding protein 2 delta) [GeneSymbol:TFAP2A & TFAP2B & TFAP2D | GeneID:7020 & 7021 & 83741 | Uniprot_SwissProt_Accession:P05549 & Q92481 & Q7Z6R9]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_AP_2_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_AP_2_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene AP-2, which is responsive to the endogenous human transcription factor AP-2 alpha (activating enhancer binding protein 2 alpha) and transcription factor AP-2 beta (activating enhancer binding protein 2 beta) and transcription factor AP-2 delta (activating enhancer binding protein 2 delta) [GeneSymbol:TFAP2A & TFAP2B & TFAP2D | GeneID:7020 & 7021 & 83741 | Uniprot_SwissProt_Accession:P05549 & Q92481 & Q7Z6R9]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_AR_TRANS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_AR_TRANS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-AR, also known as human androgen receptor [GeneSymbol:AR | GeneID:367 | Uniprot_SwissProt_Accession:P10275]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_AR_TRANS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_AR_TRANS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-AR, also known as human androgen receptor [GeneSymbol:AR | GeneID:367 | Uniprot_SwissProt_Accession:P10275]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_Ahr_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_Ahr_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element AhRE, which is responsive to the endogenous human aryl hydrocarbon receptor [GeneSymbol:AHR | GeneID:196 | Uniprot_SwissProt_Accession:P35869]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_Ahr_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_Ahr_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element AhRE, which is responsive to the endogenous human aryl hydrocarbon receptor [GeneSymbol:AHR | GeneID:196 | Uniprot_SwissProt_Accession:P35869]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_BRE_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_BRE_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element BRE, which is responsive to the endogenous human SMAD family member 1 [GeneSymbol:SMAD1 | GeneID:4086 | Uniprot_SwissProt_Accession:Q15797]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_BRE_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_BRE_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element BRE, which is responsive to the endogenous human SMAD family member 1 [GeneSymbol:SMAD1 | GeneID:4086 | Uniprot_SwissProt_Accession:Q15797]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_CAR_TRANS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_CAR_TRANS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-CAR, also known as human nuclear receptor subfamily 1, group I, member 3 [GeneSymbol:NR1I3 | GeneID:9970 | Uniprot_SwissProt_Accession:Q14994]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_CAR_TRANS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_CAR_TRANS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-CAR, also known as human nuclear receptor subfamily 1, group I, member 3 [GeneSymbol:NR1I3 | GeneID:9970 | Uniprot_SwissProt_Accession:Q14994]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_CMV_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_CMV_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene CMV, which is used as an internal marker. The biological focus is none of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_CMV_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_CMV_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene CMV, which is used as an internal marker. The biological focus is none of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_CRE_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_CRE_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element CRE, which is responsive to the endogenous human cAMP responsive element binding protein 3 [GeneSymbol:CREB3 | GeneID:10488 | Uniprot_SwissProt_Accession:O43889]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_CRE_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_CRE_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element CRE, which is responsive to the endogenous human cAMP responsive element binding protein 3 [GeneSymbol:CREB3 | GeneID:10488 | Uniprot_SwissProt_Accession:O43889]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_C_EBP_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_C_EBP_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene C/EBP, which is responsive to the endogenous human CCAAT/enhancer binding protein (C/EBP), beta [GeneSymbol:CEBPB | GeneID:1051 | Uniprot_SwissProt_Accession:P17676]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_C_EBP_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_C_EBP_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene C/EBP, which is responsive to the endogenous human CCAAT/enhancer binding protein (C/EBP), beta [GeneSymbol:CEBPB | GeneID:1051 | Uniprot_SwissProt_Accession:P17676]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_DR4_LXR_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_DR4_LXR_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element LXRE, which is responsive to the endogenous human nuclear receptor subfamily 1, group H, member 2 and nuclear receptor subfamily 1, group H, member 3 [GeneSymbol:NR1H2 & NR1H3 | GeneID:7376 & 10062 | Uniprot_SwissProt_Accession:P55055 & Q13133]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_DR4_LXR_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_DR4_LXR_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element LXRE, which is responsive to the endogenous human nuclear receptor subfamily 1, group H, member 2 and nuclear receptor subfamily 1, group H, member 3 [GeneSymbol:NR1H2 & NR1H3 | GeneID:7376 & 10062 | Uniprot_SwissProt_Accession:P55055 & Q13133]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_DR5_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_DR5_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element RARE, which is responsive to the endogenous human retinoic acid receptor, alpha and retinoic acid receptor, beta and retinoic acid receptor, gamma [GeneSymbol:RARA & RARB & RARG | GeneID:5914 & 5915 & 5916 | Uniprot_SwissProt_Accession:P10276 & P10826 & P13631]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_DR5_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_DR5_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element RARE, which is responsive to the endogenous human retinoic acid receptor, alpha and retinoic acid receptor, beta and retinoic acid receptor, gamma [GeneSymbol:RARA & RARB & RARG | GeneID:5914 & 5915 & 5916 | Uniprot_SwissProt_Accession:P10276 & P10826 & P13631]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_E2F_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_E2F_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene E2F, which is responsive to the endogenous human E2F transcription factor 1 [GeneSymbol:E2F1 | GeneID:1869 | Uniprot_SwissProt_Accession:Q01094]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_E2F_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_E2F_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene E2F, which is responsive to the endogenous human E2F transcription factor 1 [GeneSymbol:E2F1 | GeneID:1869 | Uniprot_SwissProt_Accession:Q01094]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_EGR_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_EGR_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene EGR, which is responsive to the endogenous human early growth response 1 [GeneSymbol:EGR1 | GeneID:1958 | Uniprot_SwissProt_Accession:P18146]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_ERE_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_ERE_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element ERE, which is responsive to the endogenous human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_ERE_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_ERE_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element ERE, which is responsive to the endogenous human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_ERRa_TRANS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_ERRa_TRANS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-ERRa, also known as human estrogen-related receptor alpha [GeneSymbol:ESRRA | GeneID:2101 | Uniprot_SwissProt_Accession:P11474]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_ERRg_TRANS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_ERRg_TRANS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-ERRg, also known as human estrogen-related receptor gamma [GeneSymbol:ESRRG | GeneID:2104 | Uniprot_SwissProt_Accession:P62508]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_ERRg_TRANS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_ERRg_TRANS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-ERRg, also known as human estrogen-related receptor gamma [GeneSymbol:ESRRG | GeneID:2104 | Uniprot_SwissProt_Accession:P62508]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_ERa_TRANS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_ERa_TRANS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-ERa, also known as human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_E_Box_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_E_Box_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Ebox, which is responsive to the endogenous human upstream transcription factor 1 [GeneSymbol:USF1 | GeneID:7391 | Uniprot_SwissProt_Accession:P22415]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_E_Box_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_E_Box_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Ebox, which is responsive to the endogenous human upstream transcription factor 1 [GeneSymbol:USF1 | GeneID:7391 | Uniprot_SwissProt_Accession:P22415]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_Ets_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_Ets_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Ets, which is responsive to the endogenous human v-ets avian erythroblastosis virus E26 oncogene homolog 1 [GeneSymbol:ETS1 | GeneID:2113 | Uniprot_SwissProt_Accession:P14921]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_Ets_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_Ets_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Ets, which is responsive to the endogenous human v-ets avian erythroblastosis virus E26 oncogene homolog 1 [GeneSymbol:ETS1 | GeneID:2113 | Uniprot_SwissProt_Accession:P14921]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_FXR_TRANS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_FXR_TRANS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-FXR, also known as human nuclear receptor subfamily 1, group H, member 4 [GeneSymbol:NR1H4 | GeneID:9971 | Uniprot_SwissProt_Accession:Q96RI1]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_FoxA2_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_FoxA2_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene FoxA, which is responsive to the endogenous human forkhead box A2 [GeneSymbol:FOXA2 | GeneID:3170 | Uniprot_SwissProt_Accession:Q9Y261]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_FoxA2_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_FoxA2_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene FoxA, which is responsive to the endogenous human forkhead box A2 [GeneSymbol:FOXA2 | GeneID:3170 | Uniprot_SwissProt_Accession:Q9Y261]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_FoxO_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_FoxO_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene FoxO, which is responsive to the endogenous human forkhead box O1 and forkhead box O3 [GeneSymbol:FOXO1 & FOXO3 | GeneID:2308 & 2309 | Uniprot_SwissProt_Accession:Q12778 & O43524]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_FoxO_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_FoxO_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene FoxO, which is responsive to the endogenous human forkhead box O1 and forkhead box O3 [GeneSymbol:FOXO1 & FOXO3 | GeneID:2308 & 2309 | Uniprot_SwissProt_Accession:Q12778 & O43524]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_GAL4_TRANS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_GAL4_TRANS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-gal4, which is used as an internal marker. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_GATA_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_GATA_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene GATA, which is responsive to the endogenous human GATA binding protein 1 (globin transcription factor 1) [GeneSymbol:GATA1 | GeneID:2623 | Uniprot_SwissProt_Accession:P15976]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_GATA_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_GATA_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene GATA, which is responsive to the endogenous human GATA binding protein 1 (globin transcription factor 1) [GeneSymbol:GATA1 | GeneID:2623 | Uniprot_SwissProt_Accession:P15976]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_GLI_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_GLI_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene GLI, which is responsive to the endogenous human GLI family zinc finger 1 [GeneSymbol:GLI1 | GeneID:2735 | Uniprot_SwissProt_Accession:P08151]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_GLI_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_GLI_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene GLI, which is responsive to the endogenous human GLI family zinc finger 1 [GeneSymbol:GLI1 | GeneID:2735 | Uniprot_SwissProt_Accession:P08151]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_GRE_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_GRE_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element GRE, which is responsive to the endogenous human nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) [GeneSymbol:NR3C1 | GeneID:2908 | Uniprot_SwissProt_Accession:P04150]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_GRE_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_GRE_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element GRE, which is responsive to the endogenous human nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) [GeneSymbol:NR3C1 | GeneID:2908 | Uniprot_SwissProt_Accession:P04150]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_GR_TRANS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_GR_TRANS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-GR, also known as human nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) [GeneSymbol:NR3C1 | GeneID:2908 | Uniprot_SwissProt_Accession:P04150]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_GR_TRANS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_GR_TRANS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-GR, also known as human nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) [GeneSymbol:NR3C1 | GeneID:2908 | Uniprot_SwissProt_Accession:P04150]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_HIF1a_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_HIF1a_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene HIF1a, which is responsive to the endogenous human hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) [GeneSymbol:HIF1A | GeneID:3091 | Uniprot_SwissProt_Accession:Q16665]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_HIF1a_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_HIF1a_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene HIF1a, which is responsive to the endogenous human hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) [GeneSymbol:HIF1A | GeneID:3091 | Uniprot_SwissProt_Accession:Q16665]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_HNF4a_TRANS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_HNF4a_TRANS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-HNF4a, also known as human hepatocyte nuclear factor 4, alpha [GeneSymbol:HNF4A | GeneID:3172 | Uniprot_SwissProt_Accession:P41235]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_HNF4a_TRANS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_HNF4a_TRANS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-HNF4a, also known as human hepatocyte nuclear factor 4, alpha [GeneSymbol:HNF4A | GeneID:3172 | Uniprot_SwissProt_Accession:P41235]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_HNF6_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_HNF6_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene HNF6, which is responsive to the endogenous human one cut homeobox 1 [GeneSymbol:ONECUT1 | GeneID:3175 | Uniprot_SwissProt_Accession:Q9UBC0]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_HNF6_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_HNF6_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene HNF6, which is responsive to the endogenous human one cut homeobox 1 [GeneSymbol:ONECUT1 | GeneID:3175 | Uniprot_SwissProt_Accession:Q9UBC0]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_HSE_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_HSE_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene HSE, which is responsive to the endogenous human heat shock transcription factor 1 [GeneSymbol:HSF1 | GeneID:3297 | Uniprot_SwissProt_Accession:Q00613]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_HSE_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_HSE_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene HSE, which is responsive to the endogenous human heat shock transcription factor 1 [GeneSymbol:HSF1 | GeneID:3297 | Uniprot_SwissProt_Accession:Q00613]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_IR1_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_IR1_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene IR1, which is responsive to the endogenous human nuclear receptor subfamily 1, group H, member 4 [GeneSymbol:NR1H4 | GeneID:9971 | Uniprot_SwissProt_Accession:Q96RI1]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_IR1_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_IR1_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene IR1, which is responsive to the endogenous human nuclear receptor subfamily 1, group H, member 4 [GeneSymbol:NR1H4 | GeneID:9971 | Uniprot_SwissProt_Accession:Q96RI1]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_ISRE_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_ISRE_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element ISRE, which is responsive to the endogenous human interferon regulatory factor 1 [GeneSymbol:IRF1 | GeneID:3659 | Uniprot_SwissProt_Accession:P10914]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_ISRE_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_ISRE_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element ISRE, which is responsive to the endogenous human interferon regulatory factor 1 [GeneSymbol:IRF1 | GeneID:3659 | Uniprot_SwissProt_Accession:P10914]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_LXRa_TRANS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_LXRa_TRANS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-LXRa, also known as human nuclear receptor subfamily 1, group H, member 3 [GeneSymbol:NR1H3 | GeneID:10062 | Uniprot_SwissProt_Accession:Q13133]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_LXRa_TRANS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_LXRa_TRANS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-LXRa, also known as human nuclear receptor subfamily 1, group H, member 3 [GeneSymbol:NR1H3 | GeneID:10062 | Uniprot_SwissProt_Accession:Q13133]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_LXRb_TRANS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_LXRb_TRANS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-LXRb, also known as human nuclear receptor subfamily 1, group H, member 2 [GeneSymbol:NR1H2 | GeneID:7376 | Uniprot_SwissProt_Accession:P55055]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_LXRb_TRANS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_LXRb_TRANS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-LXRb, also known as human nuclear receptor subfamily 1, group H, member 2 [GeneSymbol:NR1H2 | GeneID:7376 | Uniprot_SwissProt_Accession:P55055]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_MRE_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_MRE_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element MRE, which is responsive to the endogenous human metal-regulatory transcription factor 1 [GeneSymbol:MTF1 | GeneID:4520 | Uniprot_SwissProt_Accession:Q14872]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_M_06_TRANS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_M_06_TRANS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-M_06, which is used as an internal marker. The biological focus is none of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_M_19_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_M_19_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene M_19, which is used as an internal marker. The biological focus is none of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_M_19_TRANS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_M_19_TRANS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-M_19, which is used as an internal marker. The biological focus is none of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_M_19_TRANS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_M_19_TRANS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-M_19, which is used as an internal marker. The biological focus is none of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_M_32_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_M_32_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene M_32, which is used as an internal marker. The biological focus is none of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_M_32_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_M_32_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene M_32, which is used as an internal marker. The biological focus is none of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_M_32_TRANS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_M_32_TRANS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-M_32, which is used as an internal marker. The biological focus is none of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_M_32_TRANS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_M_32_TRANS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-M_32, which is used as an internal marker. The biological focus is none of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_M_61_TRANS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_M_61_TRANS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-M_61, which is used as an internal marker. The biological focus is none of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_Myb_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_Myb_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Myb, which is responsive to the endogenous human v-myb avian myeloblastosis viral oncogene homolog [GeneSymbol:MYB | GeneID:4602 | Uniprot_SwissProt_Accession:P10242]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_Myb_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_Myb_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Myb, which is responsive to the endogenous human v-myb avian myeloblastosis viral oncogene homolog [GeneSymbol:MYB | GeneID:4602 | Uniprot_SwissProt_Accession:P10242]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_Myc_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_Myc_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Myc, which is responsive to the endogenous human v-myc avian myelocytomatosis viral oncogene homolog [GeneSymbol:MYC | GeneID:4609 | Uniprot_SwissProt_Accession:P01106]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_Myc_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_Myc_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Myc, which is responsive to the endogenous human v-myc avian myelocytomatosis viral oncogene homolog [GeneSymbol:MYC | GeneID:4609 | Uniprot_SwissProt_Accession:P01106]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_NFI_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_NFI_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene NFI, which is responsive to the endogenous human nuclear factor I/A [GeneSymbol:NFIA | GeneID:4774 | Uniprot_SwissProt_Accession:Q12857]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_NFI_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_NFI_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene NFI, which is responsive to the endogenous human nuclear factor I/A [GeneSymbol:NFIA | GeneID:4774 | Uniprot_SwissProt_Accession:Q12857]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_NF_kB_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_NF_kB_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene NF-kB, which is responsive to the endogenous human nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 [GeneSymbol:NFKB1 | GeneID:4790 | Uniprot_SwissProt_Accession:P19838]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_NF_kB_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_NF_kB_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene NF-kB, which is responsive to the endogenous human nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 [GeneSymbol:NFKB1 | GeneID:4790 | Uniprot_SwissProt_Accession:P19838]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_NRF1_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_NRF1_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene NRF1, which is responsive to the endogenous human nuclear respiratory factor 1 [GeneSymbol:NRF1 | GeneID:4899 | Uniprot_SwissProt_Accession:Q16656]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_NRF1_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_NRF1_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene NRF1, which is responsive to the endogenous human nuclear respiratory factor 1 [GeneSymbol:NRF1 | GeneID:4899 | Uniprot_SwissProt_Accession:Q16656]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_NRF2_ARE_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_NRF2_ARE_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element ARE, which is responsive to the endogenous human nuclear factor, erythroid 2-like 2 [GeneSymbol:NFE2L2 | GeneID:4780 | Uniprot_SwissProt_Accession:Q16236]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_NRF2_ARE_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_NRF2_ARE_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element ARE, which is responsive to the endogenous human nuclear factor, erythroid 2-like 2 [GeneSymbol:NFE2L2 | GeneID:4780 | Uniprot_SwissProt_Accession:Q16236]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_NURR1_TRANS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_NURR1_TRANS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-NURR1, also known as human nuclear receptor subfamily 4, group A, member 2 [GeneSymbol:NR4A2 | GeneID:4929 | Uniprot_SwissProt_Accession:P43354]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_NURR1_TRANS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_NURR1_TRANS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-NURR1, also known as human nuclear receptor subfamily 4, group A, member 2 [GeneSymbol:NR4A2 | GeneID:4929 | Uniprot_SwissProt_Accession:P43354]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_Oct_MLP_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_Oct_MLP_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Oct, which is responsive to the endogenous human POU class 2 homeobox 1 [GeneSymbol:POU2F1 | GeneID:5451 | Uniprot_SwissProt_Accession:P14859]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_Oct_MLP_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_Oct_MLP_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Oct, which is responsive to the endogenous human POU class 2 homeobox 1 [GeneSymbol:POU2F1 | GeneID:5451 | Uniprot_SwissProt_Accession:P14859]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_PBREM_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_PBREM_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene PBREM, which is responsive to the endogenous human nuclear receptor subfamily 1, group I, member 3 [GeneSymbol:NR1I3 | GeneID:9970 | Uniprot_SwissProt_Accession:Q14994]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_PBREM_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_PBREM_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene PBREM, which is responsive to the endogenous human nuclear receptor subfamily 1, group I, member 3 [GeneSymbol:NR1I3 | GeneID:9970 | Uniprot_SwissProt_Accession:Q14994]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_PPARa_TRANS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_PPARa_TRANS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-PPARa, also known as human peroxisome proliferator-activated receptor alpha [GeneSymbol:PPARA | GeneID:5465 | Uniprot_SwissProt_Accession:Q07869]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_PPARa_TRANS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_PPARa_TRANS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-PPARa, also known as human peroxisome proliferator-activated receptor alpha [GeneSymbol:PPARA | GeneID:5465 | Uniprot_SwissProt_Accession:Q07869]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_PPARd_TRANS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_PPARd_TRANS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-PPARd, also known as human peroxisome proliferator-activated receptor delta [GeneSymbol:PPARD | GeneID:5467 | Uniprot_SwissProt_Accession:Q03181]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_PPARg_TRANS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_PPARg_TRANS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-PPARg, also known as human peroxisome proliferator-activated receptor gamma [GeneSymbol:PPARG | GeneID:5468 | Uniprot_SwissProt_Accession:P37231]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_PPRE_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_PPRE_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element PPRE, which is responsive to the endogenous human peroxisome proliferator-activated receptor alpha and peroxisome proliferator-activated receptor delta and peroxisome proliferator-activated receptor gamma [GeneSymbol:PPARA & PPARD & PPARG | GeneID:5465 & 5467 & 5468 | Uniprot_SwissProt_Accession:Q07869 & Q03181 & P37231]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_PPRE_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_PPRE_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element PPRE, which is responsive to the endogenous human peroxisome proliferator-activated receptor alpha and peroxisome proliferator-activated receptor delta and peroxisome proliferator-activated receptor gamma [GeneSymbol:PPARA & PPARD & PPARG | GeneID:5465 & 5467 & 5468 | Uniprot_SwissProt_Accession:Q07869 & Q03181 & P37231]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_PXRE_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_PXRE_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element PXRE, which is responsive to the endogenous human nuclear receptor subfamily 1, group I, member 2 [GeneSymbol:NR1I2 | GeneID:8856 | Uniprot_SwissProt_Accession:O75469]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_PXRE_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_PXRE_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element PXRE, which is responsive to the endogenous human nuclear receptor subfamily 1, group I, member 2 [GeneSymbol:NR1I2 | GeneID:8856 | Uniprot_SwissProt_Accession:O75469]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_PXR_TRANS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_PXR_TRANS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-PXR, also known as human nuclear receptor subfamily 1, group I, member 2 [GeneSymbol:NR1I2 | GeneID:8856 | Uniprot_SwissProt_Accession:O75469]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_PXR_TRANS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_PXR_TRANS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-PXR, also known as human nuclear receptor subfamily 1, group I, member 2 [GeneSymbol:NR1I2 | GeneID:8856 | Uniprot_SwissProt_Accession:O75469]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_Pax6_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_Pax6_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Pax, which is responsive to the endogenous human paired box 6 [GeneSymbol:PAX6 | GeneID:5080 | Uniprot_SwissProt_Accession:P26367]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_RARa_TRANS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_RARa_TRANS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-RARa, also known as human retinoic acid receptor, alpha [GeneSymbol:RARA | GeneID:5914 | Uniprot_SwissProt_Accession:P10276]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_RARa_TRANS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_RARa_TRANS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-RARa, also known as human retinoic acid receptor, alpha [GeneSymbol:RARA | GeneID:5914 | Uniprot_SwissProt_Accession:P10276]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_RARb_TRANS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_RARb_TRANS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-RARb, also known as human retinoic acid receptor, beta [GeneSymbol:RARB | GeneID:5915 | Uniprot_SwissProt_Accession:P10826]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_RARb_TRANS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_RARb_TRANS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-RARb, also known as human retinoic acid receptor, beta [GeneSymbol:RARB | GeneID:5915 | Uniprot_SwissProt_Accession:P10826]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_RARg_TRANS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_RARg_TRANS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-RARg, also known as human retinoic acid receptor, gamma [GeneSymbol:RARG | GeneID:5916 | Uniprot_SwissProt_Accession:P13631]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_RARg_TRANS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_RARg_TRANS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-RARg, also known as human retinoic acid receptor, gamma [GeneSymbol:RARG | GeneID:5916 | Uniprot_SwissProt_Accession:P13631]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_RORE_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_RORE_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element RORE, which is responsive to the endogenous human RAR-related orphan receptor A and RAR-related orphan receptor B and RAR-related orphan receptor C [GeneSymbol:RORA & RORB & RORC | GeneID:6095 & 6096 & 6097 | Uniprot_SwissProt_Accession:P35398 & Q92753 & P51449]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_RORE_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_RORE_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element RORE, which is responsive to the endogenous human RAR-related orphan receptor A and RAR-related orphan receptor B and RAR-related orphan receptor C [GeneSymbol:RORA & RORB & RORC | GeneID:6095 & 6096 & 6097 | Uniprot_SwissProt_Accession:P35398 & Q92753 & P51449]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_RORb_TRANS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_RORb_TRANS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-RORb, also known as human RAR-related orphan receptor B [GeneSymbol:RORB | GeneID:6096 | Uniprot_SwissProt_Accession:Q92753]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_RORg_TRANS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_RORg_TRANS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-RORg, also known as human RAR-related orphan receptor C [GeneSymbol:RORC | GeneID:6097 | Uniprot_SwissProt_Accession:P51449]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_RORg_TRANS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_RORg_TRANS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-RORg, also known as human RAR-related orphan receptor C [GeneSymbol:RORC | GeneID:6097 | Uniprot_SwissProt_Accession:P51449]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_RXRa_TRANS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_RXRa_TRANS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-RXRa, also known as human retinoid X receptor, alpha [GeneSymbol:RXRA | GeneID:6256 | Uniprot_SwissProt_Accession:P19793]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_RXRa_TRANS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_RXRa_TRANS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-RXRa, also known as human retinoid X receptor, alpha [GeneSymbol:RXRA | GeneID:6256 | Uniprot_SwissProt_Accession:P19793]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_RXRb_TRANS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_RXRb_TRANS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-RXRb, also known as human retinoid X receptor, beta [GeneSymbol:RXRB | GeneID:6257 | Uniprot_SwissProt_Accession:P28702]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_RXRb_TRANS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_RXRb_TRANS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-RXRb, also known as human retinoid X receptor, beta [GeneSymbol:RXRB | GeneID:6257 | Uniprot_SwissProt_Accession:P28702]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_SREBP_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_SREBP_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene SREBP, which is responsive to the endogenous human sterol regulatory element binding transcription factor 1 [GeneSymbol:SREBF1 | GeneID:6720 | Uniprot_SwissProt_Accession:P36956]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_SREBP_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_SREBP_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene SREBP, which is responsive to the endogenous human sterol regulatory element binding transcription factor 1 [GeneSymbol:SREBF1 | GeneID:6720 | Uniprot_SwissProt_Accession:P36956]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_STAT3_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_STAT3_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene STAT, which is responsive to the endogenous human signal transducer and activator of transcription 3 (acute-phase response factor) [GeneSymbol:STAT3 | GeneID:6774 | Uniprot_SwissProt_Accession:P40763]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_STAT3_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_STAT3_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene STAT, which is responsive to the endogenous human signal transducer and activator of transcription 3 (acute-phase response factor) [GeneSymbol:STAT3 | GeneID:6774 | Uniprot_SwissProt_Accession:P40763]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_Sox_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_Sox_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene SOX, which is responsive to the endogenous human SRY (sex determining region Y)-box 1 [GeneSymbol:SOX1 | GeneID:6656 | Uniprot_SwissProt_Accession:O00570]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_Sox_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_Sox_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene SOX, which is responsive to the endogenous human SRY (sex determining region Y)-box 1 [GeneSymbol:SOX1 | GeneID:6656 | Uniprot_SwissProt_Accession:O00570]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_Sp1_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_Sp1_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Sp1, which is responsive to the endogenous human Sp1 transcription factor [GeneSymbol:SP1 | GeneID:6667 | Uniprot_SwissProt_Accession:P08047]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_Sp1_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_Sp1_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Sp1, which is responsive to the endogenous human Sp1 transcription factor [GeneSymbol:SP1 | GeneID:6667 | Uniprot_SwissProt_Accession:P08047]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_TAL_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_TAL_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene TAL, which is used as a basal promoter. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_TAL_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_TAL_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene TAL, which is used as a basal promoter. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_TA_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_TA_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene TA, which is used as a basal promoter. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_TA_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_TA_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene TA, which is used as a basal promoter. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_TCF_b_cat_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_TCF_b_cat_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene TCF/b-cat, which is responsive to the endogenous human transcription factor 7 (T-cell specific, HMG-box) and transcription factor 7-like 2 (T-cell specific, HMG-box) and lymphoid enhancer-binding factor 1 and transcription factor 7-like 1 (T-cell specific, HMG-box) [GeneSymbol:TCF7 & TCF7L2 & LEF1 & TCF7L1 | GeneID:6932 & 6934 & 51176 & 83439 | Uniprot_SwissProt_Accession:P36402 & Q9NQB0 & Q9UJU2 & Q9HCS4]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_TCF_b_cat_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_TCF_b_cat_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene TCF/b-cat, which is responsive to the endogenous human transcription factor 7 (T-cell specific, HMG-box) and transcription factor 7-like 2 (T-cell specific, HMG-box) and lymphoid enhancer-binding factor 1 and transcription factor 7-like 1 (T-cell specific, HMG-box) [GeneSymbol:TCF7 & TCF7L2 & LEF1 & TCF7L1 | GeneID:6932 & 6934 & 51176 & 83439 | Uniprot_SwissProt_Accession:P36402 & Q9NQB0 & Q9UJU2 & Q9HCS4]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_TGFb_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_TGFb_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene TGF, which is responsive to the endogenous human transforming growth factor, beta 1 [GeneSymbol:TGFB1 | GeneID:7040 | Uniprot_SwissProt_Accession:P01137]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_TGFb_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_TGFb_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene TGF, which is responsive to the endogenous human transforming growth factor, beta 1 [GeneSymbol:TGFB1 | GeneID:7040 | Uniprot_SwissProt_Accession:P01137]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_THRa1_TRANS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_THRa1_TRANS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-THRa, also known as human thyroid hormone receptor, alpha [GeneSymbol:THRA | GeneID:7067 | Uniprot_SwissProt_Accession:P10827]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_THRa1_TRANS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_THRa1_TRANS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-THRa, also known as human thyroid hormone receptor, alpha [GeneSymbol:THRA | GeneID:7067 | Uniprot_SwissProt_Accession:P10827]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_VDRE_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_VDRE_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element VDRE, which is responsive to the endogenous human vitamin D (1,25- dihydroxyvitamin D3) receptor [GeneSymbol:VDR | GeneID:7421 | Uniprot_SwissProt_Accession:P11473]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_VDRE_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_VDRE_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene response element VDRE, which is responsive to the endogenous human vitamin D (1,25- dihydroxyvitamin D3) receptor [GeneSymbol:VDR | GeneID:7421 | Uniprot_SwissProt_Accession:P11473]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_VDR_TRANS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_VDR_TRANS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-VDR, also known as human vitamin D (1,25- dihydroxyvitamin D3) receptor [GeneSymbol:VDR | GeneID:7421 | Uniprot_SwissProt_Accession:P11473]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_VDR_TRANS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_VDR_TRANS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the transfected trans-acting reporter gene and exogenous transcription factor GAL4-VDR, also known as human vitamin D (1,25- dihydroxyvitamin D3) receptor [GeneSymbol:VDR | GeneID:7421 | Uniprot_SwissProt_Accession:P11473]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_XTT_Cytotoxicity_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_XTT_Cytotoxicity_up assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction involving the key substrate [XTT reagent] are correlated to the viability of the mitochondria in the system. The biological focus is loss of cell death and the technological target is mitochondria.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_Xbp1_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_Xbp1_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Xbp1, which is responsive to the endogenous human X-box binding protein 1 [GeneSymbol:XBP1 | GeneID:7494 | Uniprot_SwissProt_Accession:P17861]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_Xbp1_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_Xbp1_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene Xbp1, which is responsive to the endogenous human X-box binding protein 1 [GeneSymbol:XBP1 | GeneID:7494 | Uniprot_SwissProt_Accession:P17861]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_p53_CIS_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_p53_CIS_dn assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene p53, which is responsive to the endogenous human tumor protein p53 [GeneSymbol:TP53 | GeneID:7157 | Uniprot_SwissProt_Accession:P04637]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_ATG_p53_CIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the ATG_p53_CIS_up assay is as follows: Changes to fluorescence intensity signals are indicative of inducible changes in transcription factor activity. This is quantified by the level of mRNA reporter sequence unique to the cis-acting reporter gene p53, which is responsive to the endogenous human tumor protein p53 [GeneSymbol:TP53 | GeneID:7157 | Uniprot_SwissProt_Accession:P04637]. The biological focus is gain of regulation of transcription factor activity and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_3C_Eselectin_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_3C_Eselectin_down assay is as follows: E-selectin antibody is used to tag and quantify the level of selectin E protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:SELE | GeneID:6401 | Uniprot_SwissProt_Accession:P16581]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_3C_HLADR_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_3C_HLADR_down assay is as follows: HLA-DR antibody is used to tag and quantify the level of major histocompatibility complex, class II, DR alpha protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:HLA-DRA | GeneID:3122 | Uniprot_SwissProt_Accession:P01903]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_3C_ICAM1_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_3C_ICAM1_down assay is as follows: ICAM-1 antibody is used to tag and quantify the level of intercellular adhesion molecule 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:ICAM1 | GeneID:3383 | Uniprot_SwissProt_Accession:P05362]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_3C_IL8_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_3C_IL8_down assay is as follows: IL-8 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 8 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:CXCL8 | GeneID:3576 | Uniprot_SwissProt_Accession:P10145]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_3C_MCP1_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_3C_MCP1_down assay is as follows: MCP-1 antibody is used to tag and quantify the level of chemokine (C-C motif) ligand 2 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:CCL2 | GeneID:6347 | Uniprot_SwissProt_Accession:P13500]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_3C_MIG_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_3C_MIG_down assay is as follows: MIG antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 9 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:CXCL9 | GeneID:4283 | Uniprot_SwissProt_Accession:Q07325]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_3C_Proliferation_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_3C_Proliferation_down assay is as follows: Proliferation in the 3C system is a measure of endothelial cell profliferation which is important to the process of wound healing and angiogensis. The biological focus is gain/loss of cell proliferation and the technological target is protein-unspecified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_3C_SRB_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_3C_SRB_down assay is as follows: SRB in the 3C system is a measure of the total protein content of venular endothelial cells. Cell viability of adherent cells is measured by Sulforhodamine B (SRB) staining, a method that determines cell density by measuring total protein content of test wells. The biological focus is gain/loss of cell death and the technological target is protein-unspecified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_3C_Thrombomodulin_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_3C_Thrombomodulin_down assay is as follows: Thrombomodulin antibody is used to tag and quantify the level of thrombomodulin protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:THBD | GeneID:7056 | Uniprot_SwissProt_Accession:P07204]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_3C_Thrombomodulin_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_3C_Thrombomodulin_up assay is as follows: Thrombomodulin antibody is used to tag and quantify the level of thrombomodulin protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:THBD | GeneID:7056 | Uniprot_SwissProt_Accession:P07204]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_3C_TissueFactor_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_3C_TissueFactor_down assay is as follows: Tissue Factor antibody is used to tag and quantify the level of coagulation factor III (thromboplastin, tissue factor) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:F3 | GeneID:2152 | Uniprot_SwissProt_Accession:P13726]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_3C_TissueFactor_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_3C_TissueFactor_up assay is as follows: Tissue Factor antibody is used to tag and quantify the level of coagulation factor III (thromboplastin, tissue factor) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:F3 | GeneID:2152 | Uniprot_SwissProt_Accession:P13726]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_3C_VCAM1_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_3C_VCAM1_down assay is as follows: VCAM-1 antibody is used to tag and quantify the level of vascular cell adhesion molecule 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:VCAM1 | GeneID:7412 | Uniprot_SwissProt_Accession:P19320]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_3C_Vis_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_3C_Vis_down assay is as follows: Visual microscropy is used to quantify changes to the morphology of the cells. The biological focus is gain/loss of cell morphology and the technological target is cellular.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_3C_uPAR_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_3C_uPAR_down assay is as follows: uPAR antibody is used to tag and quantify the level of plasminogen activator, urokinase receptor protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:PLAUR | GeneID:5329 | Uniprot_SwissProt_Accession:Q03405]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_4H_Eotaxin3_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_4H_Eotaxin3_down assay is as follows: Eotaxin-3 antibody is used to tag and quantify the level of chemokine (C-C motif) ligand 26 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from histamine and IL4 [GeneSymbol:CCL26 | GeneID:10344 | Uniprot_SwissProt_Accession:Q9Y258]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_4H_MCP1_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_4H_MCP1_down assay is as follows: MCP-1 antibody is used to tag and quantify the level of chemokine (C-C motif) ligand 2 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from histamine and IL4 [GeneSymbol:CCL2 | GeneID:6347 | Uniprot_SwissProt_Accession:P13500]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_4H_Pselectin_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_4H_Pselectin_down assay is as follows: P-Selectin antibody is used to tag and quantify the level of selectin P (granule membrane protein 140kDa, antigen CD62) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from histamine and IL4 [GeneSymbol:SELP | GeneID:6403 | Uniprot_SwissProt_Accession:P16109]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_4H_Pselectin_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_4H_Pselectin_up assay is as follows: P-Selectin antibody is used to tag and quantify the level of selectin P (granule membrane protein 140kDa, antigen CD62) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from histamine and IL4 [GeneSymbol:SELP | GeneID:6403 | Uniprot_SwissProt_Accession:P16109]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_4H_SRB_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_4H_SRB_down assay is as follows: SRB in the 4H system is a measure of the total protein content of venular endothelial cells. Cell viability of adherent cells is measured by Sulforhodamine B (SRB) staining, a method that determines cell density by measuring total protein content of test wells. The biological focus is gain/loss of cell death and the technological target is protein-unspecified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_4H_VCAM1_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_4H_VCAM1_down assay is as follows: VCAM-1 antibody is used to tag and quantify the level of vascular cell adhesion molecule 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from histamine and IL4 [GeneSymbol:VCAM1 | GeneID:7412 | Uniprot_SwissProt_Accession:P19320]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_4H_VEGFRII_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_4H_VEGFRII_down assay is as follows: VEGFRII antibody is used to tag and quantify the level of kinase insert domain receptor (a type III receptor tyrosine kinase) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from histamine and IL4 [GeneSymbol:KDR | GeneID:3791 | Uniprot_SwissProt_Accession:P35968]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_4H_uPAR_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_4H_uPAR_down assay is as follows: uPAR antibody is used to tag and quantify the level of plasminogen activator, urokinase receptor protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from histamine and IL4 [GeneSymbol:PLAUR | GeneID:5329 | Uniprot_SwissProt_Accession:Q03405]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_4H_uPAR_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_4H_uPAR_up assay is as follows: uPAR antibody is used to tag and quantify the level of plasminogen activator, urokinase receptor protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from histamine and IL4 [GeneSymbol:PLAUR | GeneID:5329 | Uniprot_SwissProt_Accession:Q03405]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_BE3C_HLADR_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_BE3C_HLADR_down assay is as follows: HLA-DR antibody is used to tag and quantify the level of major histocompatibility complex, class II, DR alpha protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:HLA-DRA | GeneID:3122 | Uniprot_SwissProt_Accession:P01903]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_BE3C_IL1a_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_BE3C_IL1a_down assay is as follows: IL-1a antibody is used to tag and quantify the level of interleukin 1, alpha protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:IL1A | GeneID:3552 | Uniprot_SwissProt_Accession:P01583]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_BE3C_IP10_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_BE3C_IP10_down assay is as follows: IP-10 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 10 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:CXCL10 | GeneID:3627 | Uniprot_SwissProt_Accession:P02778]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_BE3C_MIG_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_BE3C_MIG_down assay is as follows: MIG antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 9 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:CXCL9 | GeneID:4283 | Uniprot_SwissProt_Accession:Q07325]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_BE3C_MMP1_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_BE3C_MMP1_down assay is as follows: MMP-1 antibody is used to tag and quantify the level of matrix metallopeptidase 1 (interstitial collagenase) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:MMP1 | GeneID:4312 | Uniprot_SwissProt_Accession:P03956]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_BE3C_MMP1_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_BE3C_MMP1_up assay is as follows: MMP-1 antibody is used to tag and quantify the level of matrix metallopeptidase 1 (interstitial collagenase) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:MMP1 | GeneID:4312 | Uniprot_SwissProt_Accession:P03956]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_BE3C_PAI1_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_BE3C_PAI1_down assay is as follows: PAI-1 antibody is used to tag and quantify the level of serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:SERPINE1 | GeneID:5054 | Uniprot_SwissProt_Accession:P05121]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_BE3C_SRB_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_BE3C_SRB_down assay is as follows: SRB in the BE3C system is a measure of the total protein content of bronchial epithelial cells. Cell viability of adherent cells is measured by Sulforhodamine B (SRB) staining, a method that determines cell density by measuring total protein content of test wells. The biological focus is gain/loss of cell death and the technological target is protein-unspecified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_BE3C_TGFb1_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_BE3C_TGFb1_down assay is as follows: TGF-b1 antibody is used to tag and quantify the level of transforming growth factor, beta 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:TGFB1 | GeneID:7040 | Uniprot_SwissProt_Accession:P01137]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_BE3C_tPA_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_BE3C_tPA_down assay is as follows: tPA antibody is used to tag and quantify the level of plasminogen activator, tissue protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:PLAT | GeneID:5327 | Uniprot_SwissProt_Accession:P00750]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_BE3C_uPAR_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_BE3C_uPAR_down assay is as follows: uPAR antibody is used to tag and quantify the level of plasminogen activator, urokinase receptor protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:PLAUR | GeneID:5329 | Uniprot_SwissProt_Accession:Q03405]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_BE3C_uPAR_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_BE3C_uPAR_up assay is as follows: uPAR antibody is used to tag and quantify the level of plasminogen activator, urokinase receptor protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:PLAUR | GeneID:5329 | Uniprot_SwissProt_Accession:Q03405]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_BE3C_uPA_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_BE3C_uPA_down assay is as follows: uPA antibody is used to tag and quantify the level of plasminogen activator, urokinase protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:PLAU | GeneID:5328 | Uniprot_SwissProt_Accession:P00749]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_CASM3C_HLADR_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_CASM3C_HLADR_down assay is as follows: HLA-DR antibody is used to tag and quantify the level of major histocompatibility complex, class II, DR alpha protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:HLA-DRA | GeneID:3122 | Uniprot_SwissProt_Accession:P01903]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_CASM3C_IL6_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_CASM3C_IL6_down assay is as follows: IL-6 antibody is used to tag and quantify the level of interleukin 6 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:IL6 | GeneID:3569 | Uniprot_SwissProt_Accession:P05231]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_CASM3C_IL6_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_CASM3C_IL6_up assay is as follows: IL-6 antibody is used to tag and quantify the level of interleukin 6 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:IL6 | GeneID:3569 | Uniprot_SwissProt_Accession:P05231]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_CASM3C_IL8_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_CASM3C_IL8_down assay is as follows: IL-8 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 8 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:CXCL8 | GeneID:3576 | Uniprot_SwissProt_Accession:P10145]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_CASM3C_LDLR_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_CASM3C_LDLR_down assay is as follows: LDLR antibody is used to tag and quantify the level of low density lipoprotein receptor protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:LDLR | GeneID:3949 | Uniprot_SwissProt_Accession:P01130]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_CASM3C_LDLR_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_CASM3C_LDLR_up assay is as follows: LDLR antibody is used to tag and quantify the level of low density lipoprotein receptor protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:LDLR | GeneID:3949 | Uniprot_SwissProt_Accession:P01130]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_CASM3C_MCP1_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_CASM3C_MCP1_down assay is as follows: MCP-1 antibody is used to tag and quantify the level of chemokine (C-C motif) ligand 2 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:CCL2 | GeneID:6347 | Uniprot_SwissProt_Accession:P13500]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_CASM3C_MCP1_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_CASM3C_MCP1_up assay is as follows: MCP-1 antibody is used to tag and quantify the level of chemokine (C-C motif) ligand 2 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:CCL2 | GeneID:6347 | Uniprot_SwissProt_Accession:P13500]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_CASM3C_MCSF_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_CASM3C_MCSF_down assay is as follows: M-CSF antibody is used to tag and quantify the level of colony stimulating factor 1 (macrophage) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:CSF1 | GeneID:1435 | Uniprot_SwissProt_Accession:P09603]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_CASM3C_MCSF_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_CASM3C_MCSF_up assay is as follows: M-CSF antibody is used to tag and quantify the level of colony stimulating factor 1 (macrophage) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:CSF1 | GeneID:1435 | Uniprot_SwissProt_Accession:P09603]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_CASM3C_MIG_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_CASM3C_MIG_down assay is as follows: MIG antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 9 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:CXCL9 | GeneID:4283 | Uniprot_SwissProt_Accession:Q07325]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_CASM3C_Proliferation_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_CASM3C_Proliferation_down assay is as follows: Proliferation in the CASM3C system is a measure of coronary artery smooth muscle cell proliferation which is important to the process of vasacular biology and restenosis. The biological focus is gain/loss of cell proliferation and the technological target is protein-unspecified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_CASM3C_Proliferation_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_CASM3C_Proliferation_up assay is as follows: Proliferation in the CASM3C system is a measure of coronary artery smooth muscle cell proliferation which is important to the process of vasacular biology and restenosis. The biological focus is gain/loss of cell proliferation and the technological target is protein-unspecified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_CASM3C_SAA_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_CASM3C_SAA_down assay is as follows: Serum Amyloid A (SAA) is a member of the apolipoprotein family that is an acute phase reactant. SAA is categorized as an inflammation-related activity in the CASM3C system modeling Th1 vascular smooth muscle inflammation. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:SAA1 | GeneID:6288 | Uniprot_SwissProt_Accession:P0DJI8]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_CASM3C_SAA_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_CASM3C_SAA_up assay is as follows: Serum Amyloid A (SAA) is a member of the apolipoprotein family that is an acute phase reactant. SAA is categorized as an inflammation-related activity in the CASM3C system modeling Th1 vascular smooth muscle inflammation. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:SAA1 | GeneID:6288 | Uniprot_SwissProt_Accession:P0DJI8]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_CASM3C_SRB_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_CASM3C_SRB_down assay is as follows: SRB in the CASM3C system is a measure of the total protein content of coronary artery smooth muscle cells. Cell viability of adherent cells is measured by Sulforhodamine B (SRB) staining, a method that determines cell density by measuring total protein content of test wells. The biological focus is gain/loss of cell death and the technological target is protein-unspecified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_CASM3C_Thrombomodulin_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_CASM3C_Thrombomodulin_down assay is as follows: Thrombomodulin antibody is used to tag and quantify the level of thrombomodulin protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:THBD | GeneID:7056 | Uniprot_SwissProt_Accession:P07204]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_CASM3C_Thrombomodulin_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_CASM3C_Thrombomodulin_up assay is as follows: Thrombomodulin antibody is used to tag and quantify the level of thrombomodulin protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:THBD | GeneID:7056 | Uniprot_SwissProt_Accession:P07204]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_CASM3C_TissueFactor_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_CASM3C_TissueFactor_down assay is as follows: Tissue Factor antibody is used to tag and quantify the level of coagulation factor III (thromboplastin, tissue factor) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:F3 | GeneID:2152 | Uniprot_SwissProt_Accession:P13726]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_CASM3C_VCAM1_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_CASM3C_VCAM1_down assay is as follows: VCAM-1 antibody is used to tag and quantify the level of vascular cell adhesion molecule 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:VCAM1 | GeneID:7412 | Uniprot_SwissProt_Accession:P19320]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_CASM3C_VCAM1_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_CASM3C_VCAM1_up assay is as follows: VCAM-1 antibody is used to tag and quantify the level of vascular cell adhesion molecule 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:VCAM1 | GeneID:7412 | Uniprot_SwissProt_Accession:P19320]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_CASM3C_uPAR_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_CASM3C_uPAR_down assay is as follows: uPAR antibody is used to tag and quantify the level of plasminogen activator, urokinase receptor protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:PLAUR | GeneID:5329 | Uniprot_SwissProt_Accession:Q03405]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_CASM3C_uPAR_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_CASM3C_uPAR_up assay is as follows: uPAR antibody is used to tag and quantify the level of plasminogen activator, urokinase receptor protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines [GeneSymbol:PLAUR | GeneID:5329 | Uniprot_SwissProt_Accession:Q03405]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_KF3CT_ICAM1_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_KF3CT_ICAM1_down assay is as follows: ICAM-1 antibody is used to tag and quantify the level of intercellular adhesion molecule 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:ICAM1 | GeneID:3383 | Uniprot_SwissProt_Accession:P05362]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_KF3CT_IL1a_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_KF3CT_IL1a_down assay is as follows: IL-1a antibody is used to tag and quantify the level of interleukin 1, alpha protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:IL1A | GeneID:3552 | Uniprot_SwissProt_Accession:P01583]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_KF3CT_IP10_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_KF3CT_IP10_down assay is as follows: IP-10 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 10 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:CXCL10 | GeneID:3627 | Uniprot_SwissProt_Accession:P02778]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_KF3CT_IP10_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_KF3CT_IP10_up assay is as follows: IP-10 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 10 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:CXCL10 | GeneID:3627 | Uniprot_SwissProt_Accession:P02778]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_KF3CT_MCP1_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_KF3CT_MCP1_down assay is as follows: MCP-1 antibody is used to tag and quantify the level of chemokine (C-C motif) ligand 2 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:CCL2 | GeneID:6347 | Uniprot_SwissProt_Accession:P13500]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_KF3CT_MCP1_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_KF3CT_MCP1_up assay is as follows: MCP-1 antibody is used to tag and quantify the level of chemokine (C-C motif) ligand 2 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:CCL2 | GeneID:6347 | Uniprot_SwissProt_Accession:P13500]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_KF3CT_MMP9_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_KF3CT_MMP9_down assay is as follows: MMP-9 antibody is used to tag and quantify the level of matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:MMP9 | GeneID:4318 | Uniprot_SwissProt_Accession:P14780]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_KF3CT_SRB_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_KF3CT_SRB_down assay is as follows: 0.1% sulforhodamine is used to tag and quantify the total protein levels in the system. Changes to these absorbance signals can be indicative of the viability in the system when conditioned to simulate proinflammation from cytokines and TGFb. The biological focus is gain/loss of cell death and the technological target is protein-unspecified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_KF3CT_TGFb1_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_KF3CT_TGFb1_down assay is as follows: TGF-b1 antibody is used to tag and quantify the level of transforming growth factor, beta 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:TGFB1 | GeneID:7040 | Uniprot_SwissProt_Accession:P01137]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_KF3CT_TIMP2_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_KF3CT_TIMP2_down assay is as follows: TIMP-2 antibody is used to tag and quantify the level of TIMP metallopeptidase inhibitor 2 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:TIMP2 | GeneID:7077 | Uniprot_SwissProt_Accession:Q96MC4]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_KF3CT_uPA_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_KF3CT_uPA_down assay is as follows: uPA antibody is used to tag and quantify the level of plasminogen activator, urokinase protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and TGFb [GeneSymbol:PLAU | GeneID:5328 | Uniprot_SwissProt_Accession:P00749]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_LPS_CD40_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_LPS_CD40_down assay is as follows: CD40 antibody is used to tag and quantify the level of CD40 molecule, TNF receptor superfamily member 5 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:CD40 | GeneID:958 | Uniprot_SwissProt_Accession:P25942]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_LPS_Eselectin_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_LPS_Eselectin_down assay is as follows: E-selectin antibody is used to tag and quantify the level of selectin E protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:SELE | GeneID:6401 | Uniprot_SwissProt_Accession:P16581]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_LPS_Eselectin_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_LPS_Eselectin_up assay is as follows: E-selectin antibody is used to tag and quantify the level of selectin E protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:SELE | GeneID:6401 | Uniprot_SwissProt_Accession:P16581]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_LPS_IL1a_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_LPS_IL1a_down assay is as follows: IL-a antibody is used to tag and quantify the level of interleukin 1, alpha protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:IL1A | GeneID:3552 | Uniprot_SwissProt_Accession:P01583]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_LPS_IL1a_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_LPS_IL1a_up assay is as follows: IL-a antibody is used to tag and quantify the level of interleukin 1, alpha protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:IL1A | GeneID:3552 | Uniprot_SwissProt_Accession:P01583]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_LPS_IL8_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_LPS_IL8_down assay is as follows: IL-8 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 8 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:CXCL8 | GeneID:3576 | Uniprot_SwissProt_Accession:P10145]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_LPS_IL8_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_LPS_IL8_up assay is as follows: IL-8 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 8 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:CXCL8 | GeneID:3576 | Uniprot_SwissProt_Accession:P10145]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_LPS_MCP1_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_LPS_MCP1_down assay is as follows: MCP-1 antibody is used to tag and quantify the level of chemokine (C-C motif) ligand 2 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:CCL2 | GeneID:6347 | Uniprot_SwissProt_Accession:P13500]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_LPS_MCSF_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_LPS_MCSF_down assay is as follows: M-CSF antibody is used to tag and quantify the level of colony stimulating factor 1 (macrophage) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:CSF1 | GeneID:1435 | Uniprot_SwissProt_Accession:P09603]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_LPS_PGE2_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_LPS_PGE2_down assay is as follows: PGE2 antibody is used to tag and quantify the level of prostaglandin E receptor 2 (subtype EP2), 53kDa protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:PTGER2 | GeneID:5732 | Uniprot_SwissProt_Accession:P43116]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_LPS_PGE2_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_LPS_PGE2_up assay is as follows: PGE2 antibody is used to tag and quantify the level of prostaglandin E receptor 2 (subtype EP2), 53kDa protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:PTGER2 | GeneID:5732 | Uniprot_SwissProt_Accession:P43116]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_LPS_SRB_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_LPS_SRB_down assay is as follows: 0.1% sulforhodamine is used to tag and quantify the total protein levels in the system. Changes to these absorbance signals can be indicative of the viability in the system when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator. The biological focus is gain/loss of cell death and the technological target is protein-unspecified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_LPS_TNFa_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_LPS_TNFa_down assay is as follows: TNF-a antibody is used to tag and quantify the level of tumor necrosis factor protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:TNF | GeneID:7124 | Uniprot_SwissProt_Accession:P01375]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_LPS_TNFa_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_LPS_TNFa_up assay is as follows: TNF-a antibody is used to tag and quantify the level of tumor necrosis factor protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:TNF | GeneID:7124 | Uniprot_SwissProt_Accession:P01375]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_LPS_TissueFactor_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_LPS_TissueFactor_down assay is as follows: CD142 Tissue Factor antibody is used to tag and quantify the level of coagulation factor III (thromboplastin, tissue factor) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:F3 | GeneID:2152 | Uniprot_SwissProt_Accession:P13726]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_LPS_TissueFactor_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_LPS_TissueFactor_up assay is as follows: CD142 Tissue Factor antibody is used to tag and quantify the level of coagulation factor III (thromboplastin, tissue factor) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:F3 | GeneID:2152 | Uniprot_SwissProt_Accession:P13726]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_LPS_VCAM1_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_LPS_VCAM1_down assay is as follows: VCAM-1 antibody is used to tag and quantify the level of vascular cell adhesion molecule 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from Toll-like receptor (TLR4) activator [GeneSymbol:VCAM1 | GeneID:7412 | Uniprot_SwissProt_Accession:P19320]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_SAg_CD38_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_SAg_CD38_down assay is as follows: CD38 antibody is used to tag and quantify the level of CD38 molecule protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation [GeneSymbol:CD38 | GeneID:952 | Uniprot_SwissProt_Accession:P28907]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_SAg_CD40_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_SAg_CD40_down assay is as follows: CD40 antibody is used to tag and quantify the level of CD40 molecule, TNF receptor superfamily member 5 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation [GeneSymbol:CD40 | GeneID:958 | Uniprot_SwissProt_Accession:P25942]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_SAg_CD69_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_SAg_CD69_down assay is as follows: CD69 antibody is used to tag and quantify the level of CD69 molecule protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation [GeneSymbol:CD69 | GeneID:969 | Uniprot_SwissProt_Accession:Q07108]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_SAg_Eselectin_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_SAg_Eselectin_down assay is as follows: E-selectin antibody is used to tag and quantify the level of selectin E protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation [GeneSymbol:SELE | GeneID:6401 | Uniprot_SwissProt_Accession:P16581]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_SAg_Eselectin_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_SAg_Eselectin_up assay is as follows: E-selectin antibody is used to tag and quantify the level of selectin E protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation [GeneSymbol:SELE | GeneID:6401 | Uniprot_SwissProt_Accession:P16581]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_SAg_IL8_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_SAg_IL8_down assay is as follows: IL-8 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 8 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation [GeneSymbol:CXCL8 | GeneID:3576 | Uniprot_SwissProt_Accession:P10145]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_SAg_IL8_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_SAg_IL8_up assay is as follows: IL-8 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 8 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation [GeneSymbol:CXCL8 | GeneID:3576 | Uniprot_SwissProt_Accession:P10145]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_SAg_MCP1_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_SAg_MCP1_down assay is as follows: MCP-1 antibody is used to tag and quantify the level of chemokine (C-C motif) ligand 2 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation [GeneSymbol:CCL2 | GeneID:6347 | Uniprot_SwissProt_Accession:P13500]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_SAg_MIG_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_SAg_MIG_down assay is as follows: MIG antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 9 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation [GeneSymbol:CXCL9 | GeneID:4283 | Uniprot_SwissProt_Accession:Q07325]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_SAg_PBMCCytotoxicity_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_SAg_PBMCCytotoxicity_down assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction involving the key substrate [Alamar blue] are correlated to the viability of the cells in the system. The biological focus is gain/loss of cell death and the technological target is cellular.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_SAg_PBMCCytotoxicity_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_SAg_PBMCCytotoxicity_up assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction involving the key substrate [Alamar blue] are correlated to the viability of the cells in the system. The biological focus is gain/loss of cell death and the technological target is cellular.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_SAg_Proliferation_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_SAg_Proliferation_down assay is as follows: 0.1% sulforhodamine is used to tag and quantify the total protein levels in the system. Changes to these absorbance signals can be indicative of the viability in the system when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation. The biological focus is gain/loss of cell proliferation and the technological target is protein-unspecified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_SAg_SRB_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_SAg_SRB_down assay is as follows: 0.1% sulforhodamine is used to tag and quantify the total protein levels in the system. Changes to these absorbance signals can be indicative of the viability in the system when conditioned to simulate proinflammation from T-cell Receptor (TCR) activation. The biological focus is gain/loss of cell death and the technological target is protein-unspecified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_hDFCGF_CollagenIII_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_hDFCGF_CollagenIII_down assay is as follows: Collagen antibody is used to tag and quantify the level of collagen, type III, alpha 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:COL3A1 | GeneID:1281 | Uniprot_SwissProt_Accession:P02461]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_hDFCGF_EGFR_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_hDFCGF_EGFR_down assay is as follows: EGFR antibody is used to tag and quantify the level of epidermal growth factor receptor protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:EGFR | GeneID:1956 | Uniprot_SwissProt_Accession:P00533]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_hDFCGF_EGFR_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_hDFCGF_EGFR_up assay is as follows: EGFR antibody is used to tag and quantify the level of epidermal growth factor receptor protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:EGFR | GeneID:1956 | Uniprot_SwissProt_Accession:P00533]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_hDFCGF_IL8_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_hDFCGF_IL8_down assay is as follows: IL-8 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 8 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:CXCL8 | GeneID:3576 | Uniprot_SwissProt_Accession:P10145]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_hDFCGF_IP10_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_hDFCGF_IP10_down assay is as follows: IP-10 antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 10 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:CXCL10 | GeneID:3627 | Uniprot_SwissProt_Accession:P02778]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_hDFCGF_MCSF_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_hDFCGF_MCSF_down assay is as follows: M-CSF antibody is used to tag and quantify the level of colony stimulating factor 1 (macrophage) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:CSF1 | GeneID:1435 | Uniprot_SwissProt_Accession:P09603]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_hDFCGF_MIG_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_hDFCGF_MIG_down assay is as follows: MIG antibody is used to tag and quantify the level of chemokine (C-X-C motif) ligand 9 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:CXCL9 | GeneID:4283 | Uniprot_SwissProt_Accession:Q07325]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_hDFCGF_MMP1_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_hDFCGF_MMP1_down assay is as follows: MMP-1 antibody is used to tag and quantify the level of matrix metallopeptidase 1 (interstitial collagenase) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:MMP1 | GeneID:4312 | Uniprot_SwissProt_Accession:P03956]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_hDFCGF_MMP1_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_hDFCGF_MMP1_up assay is as follows: MMP-1 antibody is used to tag and quantify the level of matrix metallopeptidase 1 (interstitial collagenase) protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:MMP1 | GeneID:4312 | Uniprot_SwissProt_Accession:P03956]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_hDFCGF_PAI1_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_hDFCGF_PAI1_down assay is as follows: PAI-1 antibody is used to tag and quantify the level of serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:SERPINE1 | GeneID:5054 | Uniprot_SwissProt_Accession:P05121]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_hDFCGF_Proliferation_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_hDFCGF_Proliferation_down assay is as follows: 0.1% sulforhodamine is used to tag and quantify the total protein levels in the system. Changes to these absorbance signals can be indicative of the viability in the system when conditioned to simulate proinflammation from cytokines and growth factors. The biological focus is gain/loss of cell proliferation and the technological target is protein-unspecified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_hDFCGF_SRB_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_hDFCGF_SRB_down assay is as follows: 0.1% sulforhodamine is used to tag and quantify the total protein levels in the system. Changes to these absorbance signals can be indicative of the viability in the system when conditioned to simulate proinflammation from cytokines and growth factors. The biological focus is gain/loss of cell death and the technological target is protein-unspecified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_hDFCGF_TIMP1_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_hDFCGF_TIMP1_down assay is as follows: TIMP-1 antibody is used to tag and quantify the level of TIMP metallopeptidase inhibitor 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:TIMP1 | GeneID:7076 | Uniprot_SwissProt_Accession:P01033]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_BSK_hDFCGF_VCAM1_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the BSK_hDFCGF_VCAM1_down assay is as follows: VCAM-1 antibody is used to tag and quantify the level of vascular cell adhesion molecule 1 protein. Changes in the signals are indicative of protein expression changes when conditioned to simulate proinflammation from cytokines and growth factors [GeneSymbol:VCAM1 | GeneID:7412 | Uniprot_SwissProt_Accession:P19320]. The biological focus is gain/loss of regulation of gene expression and the technological target is protein-specified.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_CEETOX_H295R_11DCORT_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the CEETOX_H295R_11DCORT_dn assay is as follows: CEETOX_H295R_11DCORT, is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The biological focus is gain/loss of regulation of steroid biosynthetic process and the technological target is 11-Deoxycortisol.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_CEETOX_H295R_ANDR_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the CEETOX_H295R_ANDR_dn assay is as follows: CEETOX_H295R_ANDR, is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The biological focus is gain/loss of regulation of steroid biosynthetic process and the technological target is Androstenedione.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_CEETOX_H295R_CORTISOL_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the CEETOX_H295R_CORTISOL_dn assay is as follows: CEETOX_H295R_CORTISOL, is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The biological focus is gain/loss of regulation of steroid biosynthetic process and the technological target is Cortisol.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_CEETOX_H295R_DOC_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the CEETOX_H295R_DOC_dn assay is as follows: CEETOX_H295R_DOC, is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The biological focus is gain/loss of regulation of steroid biosynthetic process and the technological target is 11-Deoxycorticosterone.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_CEETOX_H295R_DOC_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the CEETOX_H295R_DOC_up assay is as follows: CEETOX_H295R_DOC, is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The biological focus is gain/loss of regulation of steroid biosynthetic process and the technological target is 11-Deoxycorticosterone.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_CEETOX_H295R_ESTRADIOL_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the CEETOX_H295R_ESTRADIOL_dn assay is as follows: CEETOX_H295R_ESTRADIOL, is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The biological focus is gain/loss of regulation of steroid biosynthetic process and the technological target is Estradiol.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_CEETOX_H295R_ESTRADIOL_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the CEETOX_H295R_ESTRADIOL_up assay is as follows: CEETOX_H295R_ESTRADIOL, is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The biological focus is gain/loss of regulation of steroid biosynthetic process and the technological target is Estradiol.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_CEETOX_H295R_ESTRONE_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the CEETOX_H295R_ESTRONE_dn assay is as follows: CEETOX_H295R_ESTRONE, is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The biological focus is gain/loss of regulation of steroid biosynthetic process and the technological target is Estrone.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_CEETOX_H295R_ESTRONE_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the CEETOX_H295R_ESTRONE_up assay is as follows: CEETOX_H295R_ESTRONE, is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The biological focus is gain/loss of regulation of steroid biosynthetic process and the technological target is Estrone.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_CEETOX_H295R_OHPREG_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the CEETOX_H295R_OHPREG_up assay is as follows: CEETOX_H295R_OHPREG, is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The biological focus is gain/loss of regulation of steroid biosynthetic process and the technological target is 17alpha-hydroxypregnenolone.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_CEETOX_H295R_OHPROG_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the CEETOX_H295R_OHPROG_dn assay is as follows: CEETOX_H295R_OHPROG, is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The biological focus is gain/loss of regulation of steroid biosynthetic process and the technological target is 17alpha-hydroxyprogesterone.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_CEETOX_H295R_OHPROG_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the CEETOX_H295R_OHPROG_up assay is as follows: CEETOX_H295R_OHPROG, is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The biological focus is gain/loss of regulation of steroid biosynthetic process and the technological target is 17alpha-hydroxyprogesterone.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_CEETOX_H295R_PROG_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the CEETOX_H295R_PROG_up assay is as follows: CEETOX_H295R_PROG, is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The biological focus is gain/loss of regulation of steroid biosynthetic process and the technological target is Progesterone.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_CEETOX_H295R_TESTO_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the CEETOX_H295R_TESTO_dn assay is as follows: CEETOX_H295R_TESTO, is one of 23 assay component(s) measured or calculated from the CEETOX_H295R assay. It is designed to make measurements of hormone induction, a form of inducible reporter, as detected with absorbance signals by HPLC-MS-MS technology. The biological focus is gain/loss of regulation of steroid biosynthetic process and the technological target is Testosterone.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_CLD_ABCB1_48hr": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the CLD_ABCB1_48hr assay is as follows: CLD_ABCB1_48hr, is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology. The biological focus is gain of unknown and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_CLD_ABCG2_48hr": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the CLD_ABCG2_48hr assay is as follows: CLD_ABCG2_48hr, is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology. The biological focus is gain of unknown and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_CLD_CYP1A1_24hr": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the CLD_CYP1A1_24hr assay is as follows: CLD_CYP1A1_24hr, is one of 16 assay component(s) measured or calculated from the CLD_24hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology. The biological focus is gain of unknown and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_CLD_CYP1A1_48hr": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the CLD_CYP1A1_48hr assay is as follows: CLD_CYP1A1_48hr, is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology. The biological focus is gain of unknown and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_CLD_CYP1A1_6hr": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the CLD_CYP1A1_6hr assay is as follows: CLD_CYP1A1_6hr, is one of 16 assay component(s) measured or calculated from the CLD_6hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology. The biological focus is gain of unknown and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_CLD_CYP1A2_24hr": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the CLD_CYP1A2_24hr assay is as follows: CLD_CYP1A2_24hr, is one of 16 assay component(s) measured or calculated from the CLD_24hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology. The biological focus is gain of unknown and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_CLD_CYP1A2_48hr": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the CLD_CYP1A2_48hr assay is as follows: CLD_CYP1A2_48hr, is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology. The biological focus is gain of unknown and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_CLD_CYP1A2_6hr": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the CLD_CYP1A2_6hr assay is as follows: CLD_CYP1A2_6hr, is one of 16 assay component(s) measured or calculated from the CLD_6hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology. The biological focus is gain of unknown and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_CLD_CYP2B6_24hr": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the CLD_CYP2B6_24hr assay is as follows: CLD_CYP2B6_24hr, is one of 16 assay component(s) measured or calculated from the CLD_24hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology. The biological focus is gain of unknown and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_CLD_CYP2B6_48hr": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the CLD_CYP2B6_48hr assay is as follows: CLD_CYP2B6_48hr, is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology. The biological focus is gain of unknown and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_CLD_CYP2B6_6hr": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the CLD_CYP2B6_6hr assay is as follows: CLD_CYP2B6_6hr, is one of 16 assay component(s) measured or calculated from the CLD_6hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology. The biological focus is gain of unknown and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_CLD_CYP3A4_24hr": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the CLD_CYP3A4_24hr assay is as follows: CLD_CYP3A4_24hr, is one of 16 assay component(s) measured or calculated from the CLD_24hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology. The biological focus is gain of unknown and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_CLD_CYP3A4_48hr": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the CLD_CYP3A4_48hr assay is as follows: CLD_CYP3A4_48hr, is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology. The biological focus is gain of unknown and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_CLD_CYP3A4_6hr": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the CLD_CYP3A4_6hr assay is as follows: CLD_CYP3A4_6hr, is one of 16 assay component(s) measured or calculated from the CLD_6hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology. The biological focus is gain of unknown and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_CLD_GSTA2_48hr": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the CLD_GSTA2_48hr assay is as follows: CLD_GSTA2_48hr, is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology. The biological focus is gain of unknown and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_CLD_SULT2A_24hr": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the CLD_SULT2A_24hr assay is as follows: CLD_SULT2A_24hr, is one of 16 assay component(s) measured or calculated from the CLD_24hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology. The biological focus is gain of unknown and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_CLD_SULT2A_48hr": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the CLD_SULT2A_48hr assay is as follows: CLD_SULT2A_48hr, is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology. The biological focus is gain of unknown and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_CLD_UGT1A1_24hr": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the CLD_UGT1A1_24hr assay is as follows: CLD_UGT1A1_24hr, is one of 16 assay component(s) measured or calculated from the CLD_24hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology. The biological focus is gain of unknown and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_CLD_UGT1A1_48hr": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the CLD_UGT1A1_48hr assay is as follows: CLD_UGT1A1_48hr, is one of 16 assay component(s) measured or calculated from the CLD_48hr assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with chemiluminescence signals by Quantitative Nuclease Protection Assay (qNPA) technology. The biological focus is gain of unknown and the technological target is mRNA.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NCCT_HEK293T_CellTiterGLO": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NCCT_HEK293T_CellTiterGLO assay is as follows: Measures the amount of ATP present in HEK293T cells, which indicates whether they are metabolically active.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NCCT_QuantiLum_inhib_2_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NCCT_QuantiLum_inhib_2_dn assay is as follows: Measures the inhibition of luciferase enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NCCT_QuantiLum_inhib_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NCCT_QuantiLum_inhib_dn assay is as follows: Measures the inhibition of luciferase enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NCCT_TPO_AUR_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NCCT_TPO_AUR_dn assay is as follows: Measures inhibition of thyroperoxidase, an enzyme involved in synthesizing thyroid hormones.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NCCT_TPO_GUA_dn": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NCCT_TPO_GUA_dn assay is as follows: Measures inhibition of thyroperoxidase, an enzyme involved in synthesizing thyroid hormones.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NHEERL_ZF_144hpf_TERATOSCORE_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NHEERL_ZF_144hpf_TERATOSCORE_up assay is as follows: Measures developmental toxicity in zebrafish embryos based on malformations and mortality.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ADME_hCYP19A1": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ADME_hCYP19A1 assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:DBOMF+ NADPH -> fluorescein + NADP+] involving the key substrate [Di(benzyloxymethoxy)fluorescein (DBOMF)] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 19, subfamily A, polypeptide 1 [GeneSymbol:CYP19A1 | GeneID:1588 | Uniprot_SwissProt_Accession:P11511]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ADME_hCYP1A1": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ADME_hCYP1A1 assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:BzRes + NADPH --> Res + NADP+] involving the key substrate [Resorufin Benzyl Ether (BzRes)] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 1, subfamily A, polypeptide 1 [GeneSymbol:CYP1A1 | GeneID:1543 | Uniprot_SwissProt_Accession:P04798]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ADME_hCYP1A2": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ADME_hCYP1A2 assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:CEC + NADPH --> 7-hydroxy-3-cyanocoumarin (CHC) + NADP+] involving the key substrate [7-ethoxy-3-cyanocoumarin (CEC)] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 1, subfamily A, polypeptide 2 [GeneSymbol:CYP1A2 | GeneID:1544 | Uniprot_SwissProt_Accession:P05177]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ADME_hCYP2A6": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ADME_hCYP2A6 assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Coumarin + NADPH -> 7-Hydroxycoumarin + NADP+] involving the key substrate [Coumarin] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 2, subfamily A, polypeptide 6 [GeneSymbol:CYP2A6 | GeneID:1548 | Uniprot_SwissProt_Accession:P11509]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ADME_hCYP2B6": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ADME_hCYP2B6 assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:EFC + NADPH --> 7-hydroxy-4-trifluoromethylcoumarin (7-HFC) + NADP+] involving the key substrate [7-ethoxy-4-trifluoromethylcoumarin (EFC)] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 2, subfamily B, polypeptide 6 [GeneSymbol:CYP2B6 | GeneID:1555 | Uniprot_SwissProt_Accession:P20813]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ADME_hCYP2C19": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ADME_hCYP2C19 assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:CEC + NADPH --> 7-hydroxy-3-cyanocoumarin (CHC) + NADP+] involving the key substrate [7-ethoxy-3-cyanocoumarin (CEC)] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 2, subfamily C, polypeptide 19 [GeneSymbol:CYP2C19 | GeneID:1557 | Uniprot_SwissProt_Accession:P33261]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ADME_hCYP2C9": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ADME_hCYP2C9 assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:MFC + NADPH --> 7-hydroxy-4-trifluoromethylcoumarin (7-HFC) + NADP+] involving the key substrate [7-methoxy-4-trifluoromethylcoumarin (MFC)] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 2, subfamily C, polypeptide 9 [GeneSymbol:CYP2C9 | GeneID:1559 | Uniprot_SwissProt_Accession:P11712]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ADME_hCYP2D6": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ADME_hCYP2D6 assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:AMMC + NADPH --> AHMC + NADP+] involving the key substrate [3-[2-(N,N-diethyl-N-methylamino)ethyl]-7-methoxy-4-methylcoumarin (AMMC)] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 2, subfamily D, polypeptide 6 [GeneSymbol:CYP2D6 | GeneID:1565 | Uniprot_SwissProt_Accession:P10635]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ADME_hCYP3A4": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ADME_hCYP3A4 assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:DBF + NADPH --> fluorescein + NADP+] involving the key substrate [Dibenzyl fluorescein (DBF)] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 3, subfamily A, polypeptide 4 [GeneSymbol:CYP3A4 | GeneID:1576 | Uniprot_SwissProt_Accession:P08684]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ADME_hCYP4F12": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ADME_hCYP4F12 assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:BzRes + NADPH --> Res + NADP+] involving the key substrate [Resorufin Benzyl Ether (BzRes)] are indicative of changes in enzyme function and kinetics for the human cytochrome P450, family 4, subfamily F, polypeptide 12 [GeneSymbol:CYP4F12 | GeneID:66002 | Uniprot_SwissProt_Accession:Q9HCS2]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ADME_rCYP2C12": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ADME_rCYP2C12 assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:BOMCC + NADPH --> 7-hydroxy-3-cyanocoumarin (CHC) + NADP+] involving the key substrate [7-benzyloxymethoxy-3-cyanocoumarin (BOMCC)] are indicative of changes in enzyme function and kinetics for the Norway rat cytochrome P450, family 2, subfamily c, polypeptide 12 [GeneSymbol:Cyp2c12 | GeneID:25011 | Uniprot_SwissProt_Accession:P11510]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ENZ_hAChE": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ENZ_hAChE assay is as follows: Changes to absorbance signals produced from an enzymatic reaction [Reaction:Acetylthiocholine-->Acetate +Thiocholine | Thiocholine + DTNB (Ellman\"s Reagent)--> 5-thio-2-nitrobenzoic acid (yellow)] involving the key substrate [acetylthiocholine] are indicative of changes in enzyme function and kinetics for the human acetylcholinesterase (Yt blood group) [GeneSymbol:ACHE | GeneID:43 | Uniprot_SwissProt_Accession:P22303]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ENZ_hAMPKa1": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ENZ_hAMPKa1 assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human protein kinase, AMP-activated, alpha 1 catalytic subunit [GeneSymbol:PRKAA1 | GeneID:5562 | Uniprot_SwissProt_Accession:Q13131]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ENZ_hAurA": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ENZ_hAurA assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human aurora kinase A [GeneSymbol:AURKA | GeneID:6790 | Uniprot_SwissProt_Accession:O14965]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ENZ_hBACE": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ENZ_hBACE assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Rh-EVNLDAEFK-Quencher (weak fluorescence)+BACE --> Rh-ENVL(increased fluorescence) + DAEFK-Quencher] involving the key substrate [Rh-EVNLDAEFK-Quencher] are indicative of changes in enzyme function and kinetics for the human beta-site APP-cleaving enzyme 1 [GeneSymbol:BACE1 | GeneID:23621 | Uniprot_SwissProt_Accession:P56817]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ENZ_hCASP5": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ENZ_hCASP5 assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:LEHD-AFC --> LEHD+ AFC(fluorescent)] involving the key substrate [7-amino-4-trifluoromethylcoumarin-tagged LEHD] are indicative of changes in enzyme function and kinetics for the human caspase 5, apoptosis-related cysteine peptidase [GeneSymbol:CASP5 | GeneID:838 | Uniprot_SwissProt_Accession:P51878]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ENZ_hCK1D": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ENZ_hCK1D assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human casein kinase 1, delta [GeneSymbol:CSNK1D | GeneID:1453 | Uniprot_SwissProt_Accession:P48730]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ENZ_hDUSP3": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ENZ_hDUSP3 assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:DiFMUP(non-fluorescent) --> DiFMU] involving the key substrate [6,8-difluoro-4-methylumbelliferyl] are indicative of changes in enzyme function and kinetics for the human dual specificity phosphatase 3 [GeneSymbol:DUSP3 | GeneID:1845 | Uniprot_SwissProt_Accession:P51452]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ENZ_hES": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ENZ_hES assay is as follows: Changes to absorbance signals are produced from enzymatic reactions [Reaction:Acetylthiocholine-->Acetate +Thiocholine | Thiocholine + DTNB (Ellman\"s Reagent)--> 5-thio-2-nitrobenzoic acid (yellow)] involving the key substrates [acetylthiocholine and Ellman\"s reagent (DTNB)]. These indicate changes to the enzyme function for the human butyrylcholinesterase [GeneSymbol:BCHE | GeneID:590 | Uniprot_SwissProt_Accession:P06276]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ENZ_hElastase": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ENZ_hElastase assay is as follows: Changes to absorbance signals produced from an enzymatic reaction involving the key substrate [MeO-Suc-Ala-Ala-Pro-Val-p-Nitroanilide] are indicative of changes in enzyme function and kinetics for the human elastase, neutrophil expressed [GeneSymbol:ELANE | GeneID:1991 | Uniprot_SwissProt_Accession:P08246]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ENZ_hFGFR1": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ENZ_hFGFR1 assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in receptor function and kinetics for the human fibroblast growth factor receptor 1 [GeneSymbol:FGFR1 | GeneID:2260 | Uniprot_SwissProt_Accession:P11362]. The biological focus is loss of regulation of catalytic activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ENZ_hGSK3b": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ENZ_hGSK3b assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in enzyme function and kinetics for the human glycogen synthase kinase 3 beta [GeneSymbol:GSK3B | GeneID:2932 | Uniprot_SwissProt_Accession:P49841]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ENZ_hMMP1": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ENZ_hMMP1 assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:DNPPChaGCHAK(N-Me-Abz)-NH2 --> DNPPChaG + CHAK(N-Me-Abz)-NH2] involving the key substrate [DNP-Pro-(b-cyclohexylalanyl)-Gly-Cys(Me)-His-Ala-Lys(N-Me-2-aminobenzoyl(anthraniloyl))-NH2] are indicative of changes in enzyme function and kinetics for the human matrix metallopeptidase 1 (interstitial collagenase) [GeneSymbol:MMP1 | GeneID:4312 | Uniprot_SwissProt_Accession:P03956]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ENZ_hMMP13": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ENZ_hMMP13 assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:McaPLGLDpaARNH2 --> McaPLG + LDpaARNH2] involving the key substrate [Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2] are indicative of changes in enzyme function and kinetics for the human matrix metallopeptidase 13 (collagenase 3) [GeneSymbol:MMP13 | GeneID:4322 | Uniprot_SwissProt_Accession:P45452]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ENZ_hMMP2": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ENZ_hMMP2 assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:McaPLGLDpaARNH2 --> McaPLG + LDpaARNH2] involving the key substrate [Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2] are indicative of changes in enzyme function and kinetics for the human matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) [GeneSymbol:MMP2 | GeneID:4313 | Uniprot_SwissProt_Accession:P08253]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ENZ_hMMP3": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ENZ_hMMP3 assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Mca-RPKPVENvalWRK-Dnp-NH2 --> McaRPK + PVENvalWRK(DNP)NH2] involving the key substrate [Mca-Arg-Pro-Lys-Pro-Val-Glu-Nval-Trp-Arg-Lys(Dnp)NH2] are indicative of changes in enzyme function and kinetics for the human matrix metallopeptidase 3 (stromelysin 1, progelatinase) [GeneSymbol:MMP3 | GeneID:4314 | Uniprot_SwissProt_Accession:P08254]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ENZ_hMMP7": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ENZ_hMMP7 assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:McaPLGLDpaARNH2 --> McaPLG + LDpaARNH2] involving the key substrate [Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2] are indicative of changes in enzyme function and kinetics for the human matrix metallopeptidase 7 (matrilysin, uterine) [GeneSymbol:MMP7 | GeneID:4316 | Uniprot_SwissProt_Accession:P09237]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ENZ_hMMP9": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ENZ_hMMP9 assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:DNPPChaGCHAK(N-Me-Abz)-NH2 --> DNPPChaG + CHAK(N-Me-Abz)-NH2] involving the key substrate [DNP-Pro-(b-cyclohexylalanyl)-Gly-Cys(Me)-His-Ala-Lys(N-Me-2-aminobenzoyl(anthraniloyl))-NH2] are indicative of changes in enzyme function and kinetics for the human matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) [GeneSymbol:MMP9 | GeneID:4318 | Uniprot_SwissProt_Accession:P14780]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ENZ_hPDE10": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ENZ_hPDE10 assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescent cyclic AMP --> Flourescent 5?-AMP] involving the key substrate [Fluorescent cyclic AMP] are indicative of changes in enzyme function and kinetics for the human phosphodiesterase 10A [GeneSymbol:PDE10A | GeneID:10846 | Uniprot_SwissProt_Accession:Q9Y233]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ENZ_hPDE4A1": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ENZ_hPDE4A1 assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescent cyclic AMP --> Flourescent 5?-AMP] involving the key substrate [Fluorescent cyclic AMP] are indicative of changes in enzyme function and kinetics for the human phosphodiesterase 4A, cAMP-specific [GeneSymbol:PDE4A | GeneID:5141 | Uniprot_SwissProt_Accession:P27815]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ENZ_hPDE5": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ENZ_hPDE5 assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescent cyclic GMP --> Flourescent 5?-GMP] involving the key substrate [Fluorescent cyclic GMP] are indicative of changes in enzyme function and kinetics for the human phosphodiesterase 5A, cGMP-specific [GeneSymbol:PDE5A | GeneID:8654 | Uniprot_SwissProt_Accession:O76074]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ENZ_hPI3Ka": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ENZ_hPI3Ka assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-PIP2 + ATP --> fluorescein-PIP3 + ADP] involving the key substrate [Fluorescein-labeled PIP2 (phosphoinositol (4,5)bisphosphate)] are indicative of changes in enzyme function and kinetics for the human phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha [GeneSymbol:PIK3CA | GeneID:5290 | Uniprot_SwissProt_Accession:P42336]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ENZ_hPTEN": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ENZ_hPTEN assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-PIP3 --> fluorescein-PIP2] involving the key substrate [Fluorescein-labeled PIP3 (phosphoinositol triphosphate(3,4,5))] are indicative of changes in enzyme function and kinetics for the human phosphatase and tensin homolog [GeneSymbol:PTEN | GeneID:5728 | Uniprot_SwissProt_Accession:P60484]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ENZ_hPTPN11": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ENZ_hPTPN11 assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-phosphopeptide --> fluorescein-peptide] involving the key substrate [Fluorescein-labeled phosphopeptide] are indicative of changes in enzyme function and kinetics for the human protein tyrosine phosphatase, non-receptor type 11 [GeneSymbol:PTPN11 | GeneID:5781 | Uniprot_SwissProt_Accession:Q06124]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ENZ_hPTPN12": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ENZ_hPTPN12 assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-phosphopeptide --> fluorescein-peptide] involving the key substrate [Fluorescein-labeled phosphopeptide] are indicative of changes in enzyme function and kinetics for the human protein tyrosine phosphatase, non-receptor type 12 [GeneSymbol:PTPN12 | GeneID:5782 | Uniprot_SwissProt_Accession:Q05209]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ENZ_hPTPN13": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ENZ_hPTPN13 assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-phosphopeptide --> fluorescein-peptide] involving the key substrate [Fluorescein-labeled phosphopeptide] are indicative of changes in enzyme function and kinetics for the human protein tyrosine phosphatase, non-receptor type 13 (APO-1/CD95 (Fas)-associated phosphatase) [GeneSymbol:PTPN13 | GeneID:5783 | Uniprot_SwissProt_Accession:Q12923]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ENZ_hPTPN9": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ENZ_hPTPN9 assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-phosphopeptide --> fluorescein-peptide] involving the key substrate [Fluorescein-labeled phosphopeptide] are indicative of changes in enzyme function and kinetics for the human protein tyrosine phosphatase, non-receptor type 9 [GeneSymbol:PTPN9 | GeneID:5780 | Uniprot_SwissProt_Accession:P43378]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ENZ_hPTPRC": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ENZ_hPTPRC assay is as follows: Changes to absorbance signals produced from an enzymatic reaction [Reaction:pNPP --> p-nitrophenol] involving the key substrate [para-Nitrophenylphosphate (pNPP)] are indicative of changes in enzyme function and kinetics for the human protein tyrosine phosphatase, receptor type, C [GeneSymbol:PTPRC | GeneID:5788 | Uniprot_SwissProt_Accession:P08575]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ENZ_hSIRT1": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ENZ_hSIRT1 assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein - Acetylated peptide substrate --> Deacetylated peptide product] involving the key substrate [Fluorescein-labeled acetylated-peptide] are indicative of changes in enzyme function and kinetics for the human sirtuin 1 [GeneSymbol:SIRT1 | GeneID:23411 | Uniprot_SwissProt_Accession:Q96EB6]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ENZ_hSIRT2": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ENZ_hSIRT2 assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein - Acetylated peptide substrate --> Deacetylated peptide product] involving the key substrate [Fluorescein-labeled acetylated-peptide] are indicative of changes in enzyme function and kinetics for the human sirtuin 2 [GeneSymbol:SIRT2 | GeneID:22933 | Uniprot_SwissProt_Accession:Q8IXJ6]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ENZ_hTrkA": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ENZ_hTrkA assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in receptor function and kinetics for the human neurotrophic tyrosine kinase, receptor, type 1 [GeneSymbol:NTRK1 | GeneID:4914 | Uniprot_SwissProt_Accession:P04629]. The biological focus is loss of regulation of catalytic activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ENZ_hVEGFR2": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ENZ_hVEGFR2 assay is as follows: Changes to fluorescence intensity signals produced from an enzymatic reaction [Reaction:Fluorescein-peptide + ATP --> fluorescein-phosphopeptide + ADP] involving the key substrate [Fluorescein-labeled peptide] are indicative of changes in receptor function and kinetics for the human kinase insert domain receptor (a type III receptor tyrosine kinase) [GeneSymbol:KDR | GeneID:3791 | Uniprot_SwissProt_Accession:P35968]. The biological focus is loss of regulation of catalytic activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ENZ_oCOX1": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ENZ_oCOX1 assay is as follows: Changes to absorbance signals are produced from enzymatic reactions [Reaction:Arachidonic acid -->ProstaglandinG2 | Reduced TMPD-->TMPD(oxidized)(color 590nm)] involving the key substrates [arachidonic acid and N,N,N,N-tetramethyl-p-Phenylene diamine (TMPD)]. These indicate changes to the enzyme function for the sheep prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) [GeneSymbol:PTGS1 | GeneID:443551 | Uniprot_SwissProt_Accession:P05979]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ENZ_oCOX2": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ENZ_oCOX2 assay is as follows: Changes to absorbance signals are produced from enzymatic reactions [Reaction:Arachidonic acid -->ProstaglandinG2 | Reduced TMPD-->TMPD(oxidized)(color 590nm)] involving the key substrates [arachidonic acid and N,N,N,N-tetramethyl-p-Phenylene diamine (TMPD)]. These indicate changes to the enzyme function for the sheep prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) [GeneSymbol:PTGS2 | GeneID:443460 | Uniprot_SwissProt_Accession:P79208]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ENZ_rAChE": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ENZ_rAChE assay is as follows: Changes to absorbance signals are produced from enzymatic reactions [Reaction:Acetylthiocholine-->Acetate +Thiocholine | Thiocholine + DTNB (Ellman\"s Reagent)--> 5-thio-2-nitrobenzoic acid (yellow)] involving the key substrates [acetylthiocholine and Ellman\"s reagent (DTNB)]. These indicate changes to the enzyme function for the Norway rat acetylcholinesterase [GeneSymbol:Ache | GeneID:83817 | Uniprot_SwissProt_Accession:P37136]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ENZ_rCNOS": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ENZ_rCNOS assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Nitro-L-Arginine] are indicative of a change in enzyme function and kinetics for the Norway rat nitric oxide synthase 1, neuronal [GeneSymbol:Nos1 | GeneID:24598 | Uniprot_SwissProt_Accession:P29476]. The biological focus is loss of receptor binding and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ENZ_rMAOAC": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ENZ_rMAOAC assay is as follows: Changes to scintillation counting signals produced from an enzymatic reaction [Reaction:[14C]-Serotonin --> [14C]-5-hydroxyindoleacetaldehyde(HIA)] involving the key substrate [[14C]-Serotonin (5HT)] are indicative of changes in enzyme function and kinetics for the Norway rat monoamine oxidase A [GeneSymbol:Maoa | GeneID:29253 | Uniprot_SwissProt_Accession:P21396]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ENZ_rMAOAP": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ENZ_rMAOAP assay is as follows: Changes to scintillation counting signals produced from an enzymatic reaction [Reaction:[14C]-Serotonin --> [14C]-5-hydroxyindoleacetaldehyde(HIA)] involving the key substrate [[14C]-Serotonin (5HT)] are indicative of changes in enzyme function and kinetics for the Norway rat monoamine oxidase A [GeneSymbol:Maoa | GeneID:29253 | Uniprot_SwissProt_Accession:P21396]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ENZ_rMAOBC": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ENZ_rMAOBC assay is as follows: Changes to scintillation counting signals produced from an enzymatic reaction [Reaction:[14C]-Phenylethylamine --> [14C]-Phenylacetaldehyde] involving the key substrate [[14C]-Phenylethylamine (PEA)] are indicative of changes in enzyme function and kinetics for the Norway rat monoamine oxidase B [GeneSymbol:Maob | GeneID:25750 | Uniprot_SwissProt_Accession:P19643]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ENZ_rMAOBP": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ENZ_rMAOBP assay is as follows: Changes to scintillation counting signals produced from an enzymatic reaction [Reaction:[14C]-Phenylethylamine --> [14C]-Phenylacetaldehyde] involving the key substrate [[14C]-Phenylethylamine (PEA)] are indicative of changes in enzyme function and kinetics for the Norway rat monoamine oxidase B [GeneSymbol:Maob | GeneID:25750 | Uniprot_SwissProt_Accession:P19643]. The biological focus is loss of regulation of catalytic activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_ENZ_rabI2C": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_ENZ_rabI2C assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-2-BFI] are indicative of a change in enzyme function and kinetics for the rabbit creatine kinase, brain [GeneSymbol:CKB | GeneID:100009085 | Uniprot_SwissProt_Accession:P00567]. The biological focus is loss of receptor binding and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_bAdoR_NonSelective": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_bAdoR_NonSelective assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-5\"-N-ethylcarboxamidoadenosine] are indicative of a change in receptor function and kinetics for the cattle adenosine A1 receptor [GeneSymbol:ADORA1 | GeneID:282133 | Uniprot_SwissProt_Accession:P28190]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_bDR_NonSelective": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_bDR_NonSelective assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Spiperone] are indicative of a change in receptor function and kinetics for the cattle dopamine receptor D1 [GeneSymbol:DRD1 | GeneID:281125 | Uniprot_SwissProt_Accession:Q95136]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_g5HT4": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_g5HT4 assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-GR-113808] are indicative of a change in receptor function and kinetics for the domestic guinea pig 5 hydroxytryptamine (serotonin) receptor 4 [GeneSymbol:Htr4 | GeneID:100135548 | Uniprot_SwissProt_Accession:O70528]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_gH2": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_gH2 assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-Aminopotentidine] are indicative of a change in receptor function and kinetics for the domestic guinea pig histamine receptor H2 [GeneSymbol:Hrh2 | GeneID:100135540 | Uniprot_SwissProt_Accession:P47747]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_gLTB4": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_gLTB4 assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Leukotriene B4] are indicative of a change in receptor function and kinetics for the domestic guinea pig leukotriene B4 receptor [GeneSymbol:Ltb4r | GeneID:100379538 | Uniprot_SwissProt_Accession:NA]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_gLTD4": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_gLTD4 assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Leukotriene D4] are indicative of a change in receptor function and kinetics for the domestic guinea pig cysteinyl leukotriene receptor 1 [GeneSymbol:Cysltr1 | GeneID:100135514 | Uniprot_SwissProt_Accession:Q2NNR5]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_gMPeripheral_NonSelective": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_gMPeripheral_NonSelective assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Quinuclidinyl benzilate] are indicative of a change in receptor function and kinetics for the domestic guinea pig cholinergic receptor, muscarinic 3, cardiac [GeneSymbol:Chrm3 | GeneID:100379235 | Uniprot_SwissProt_Accession:NA]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_gOpiateK": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_gOpiateK assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-U-69593] are indicative of a change in receptor function and kinetics for the domestic guinea pig opioid receptor, kappa 1 [GeneSymbol:Oprk1 | GeneID:100135587 | Uniprot_SwissProt_Accession:P41144]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_h5HT2A": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_h5HT2A assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Ketanserin] are indicative of a change in receptor function and kinetics for the human 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled [GeneSymbol:HTR2A | GeneID:3356 | Uniprot_SwissProt_Accession:P28223]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_h5HT5A": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_h5HT5A assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-lysergic acid diethylamide] are indicative of a change in receptor function and kinetics for the human 5-hydroxytryptamine (serotonin) receptor 5A, G protein-coupled [GeneSymbol:HTR5A | GeneID:3361 | Uniprot_SwissProt_Accession:P47898]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_h5HT6": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_h5HT6 assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-lysergic acid diethylamide] are indicative of a change in receptor function and kinetics for the human 5-hydroxytryptamine (serotonin) receptor 6, G protein-coupled [GeneSymbol:HTR6 | GeneID:3362 | Uniprot_SwissProt_Accession:P50406]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_h5HT7": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_h5HT7 assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-lysergic acid diethylamide] are indicative of a change in receptor function and kinetics for the human 5-hydroxytryptamine (serotonin) receptor 7, adenylate cyclase-coupled [GeneSymbol:HTR7 | GeneID:3363 | Uniprot_SwissProt_Accession:P34969]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_hAT1": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_hAT1 assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [Sar1,[125I-Try4],Ile8-Angiotensin II] are indicative of a change in receptor function and kinetics for the human angiotensin II receptor, type 1 [GeneSymbol:AGTR1 | GeneID:185 | Uniprot_SwissProt_Accession:P30556]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_hAdoRA1": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_hAdoRA1 assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-8-Cyclopentyl-1,3-dipropylxanthine] are indicative of a change in receptor function and kinetics for the human adenosine A1 receptor [GeneSymbol:ADORA1 | GeneID:134 | Uniprot_SwissProt_Accession:P30542]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_hAdoRA2a": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_hAdoRA2a assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-CGS 21680] are indicative of a change in receptor function and kinetics for the human adenosine A2a receptor [GeneSymbol:ADORA2A | GeneID:135 | Uniprot_SwissProt_Accession:P29274]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_hAdra2A": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_hAdra2A assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-MK-912] are indicative of a change in receptor function and kinetics for the human adrenoceptor alpha 2A [GeneSymbol:ADRA2A | GeneID:150 | Uniprot_SwissProt_Accession:P08913]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_hAdra2C": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_hAdra2C assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-MK-912] are indicative of a change in receptor function and kinetics for the human adrenoceptor alpha 2C [GeneSymbol:ADRA2C | GeneID:152 | Uniprot_SwissProt_Accession:P18825]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_hAdrb1": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_hAdrb1 assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-(-)-Iodocyanopindolol] are indicative of a change in receptor function and kinetics for the human adrenoceptor beta 1 [GeneSymbol:ADRB1 | GeneID:153 | Uniprot_SwissProt_Accession:P08588]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_hAdrb2": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_hAdrb2 assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-(-)-Iodocyanopindolol] are indicative of a change in receptor function and kinetics for the human adrenoceptor beta 2, surface [GeneSymbol:ADRB2 | GeneID:154 | Uniprot_SwissProt_Accession:P07550]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_hAdrb3": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_hAdrb3 assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-(-)-Iodocyanopindolol] are indicative of a change in receptor function and kinetics for the human adrenoceptor beta 3 [GeneSymbol:ADRB3 | GeneID:155 | Uniprot_SwissProt_Accession:P13945]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_hDRD1": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_hDRD1 assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-SCH 23390] are indicative of a change in receptor function and kinetics for the human dopamine receptor D1 [GeneSymbol:DRD1 | GeneID:1812 | Uniprot_SwissProt_Accession:P21728]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_hDRD2s": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_hDRD2s assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Raclopride] are indicative of a change in receptor function and kinetics for the human dopamine receptor D2 [GeneSymbol:DRD2 | GeneID:1813 | Uniprot_SwissProt_Accession:P14416]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_hDRD4.4": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_hDRD4.4 assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-YM-09151-2] are indicative of a change in receptor function and kinetics for the human dopamine receptor D4 [GeneSymbol:DRD4 | GeneID:1815 | Uniprot_SwissProt_Accession:P21917]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_hH1": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_hH1 assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Pyrilamine] are indicative of a change in receptor function and kinetics for the human histamine receptor H1 [GeneSymbol:HRH1 | GeneID:3269 | Uniprot_SwissProt_Accession:P35367]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_hLTB4_BLT1": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_hLTB4_BLT1 assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Leukotriene B4] are indicative of a change in receptor function and kinetics for the human leukotriene B4 receptor [GeneSymbol:LTB4R | GeneID:1241 | Uniprot_SwissProt_Accession:Q15722]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_hM1": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_hM1 assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-N-methylscopolamine chloride] are indicative of a change in receptor function and kinetics for the human cholinergic receptor, muscarinic 1 [GeneSymbol:CHRM1 | GeneID:1128 | Uniprot_SwissProt_Accession:P11229]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_hM2": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_hM2 assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-N-methylscopolamine chloride] are indicative of a change in receptor function and kinetics for the human cholinergic receptor, muscarinic 2 [GeneSymbol:CHRM2 | GeneID:1129 | Uniprot_SwissProt_Accession:P08172]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_hM3": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_hM3 assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-N-methylscopolamine chloride] are indicative of a change in receptor function and kinetics for the human cholinergic receptor, muscarinic 3 [GeneSymbol:CHRM3 | GeneID:1131 | Uniprot_SwissProt_Accession:P20309]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_hM4": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_hM4 assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-N-methylscopolamine chloride] are indicative of a change in receptor function and kinetics for the human cholinergic receptor, muscarinic 4 [GeneSymbol:CHRM4 | GeneID:1132 | Uniprot_SwissProt_Accession:P08173]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_hNK2": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_hNK2 assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-Neurokinin A] are indicative of a change in receptor function and kinetics for the human tachykinin receptor 2 [GeneSymbol:TACR2 | GeneID:6865 | Uniprot_SwissProt_Accession:P21452]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_hOpiate_D1": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_hOpiate_D1 assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Naltrindole] are indicative of a change in receptor function and kinetics for the human opioid receptor, delta 1 [GeneSymbol:OPRD1 | GeneID:4985 | Uniprot_SwissProt_Accession:P41143]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_hOpiate_mu": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_hOpiate_mu assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Diprenorphine] are indicative of a change in receptor function and kinetics for the human opioid receptor, mu 1 [GeneSymbol:OPRM1 | GeneID:4988 | Uniprot_SwissProt_Accession:P35372]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_hTXA2": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_hTXA2 assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-SQ 29,548] are indicative of a change in receptor function and kinetics for the human thromboxane A2 receptor [GeneSymbol:TBXA2R | GeneID:6915 | Uniprot_SwissProt_Accession:P21731]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_p5HT2C": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_p5HT2C assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Mesulergine] are indicative of a change in receptor function and kinetics for the human 5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled [GeneSymbol:HTR2C | GeneID:3358 | Uniprot_SwissProt_Accession:P28335]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_r5HT1_NonSelective": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_r5HT1_NonSelective assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Hydroxytryptamine binoxalate] are indicative of a change in receptor function and kinetics for the Norway rat 5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled [GeneSymbol:Htr1a | GeneID:24473 | Uniprot_SwissProt_Accession:P19327]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_r5HT_NonSelective": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_r5HT_NonSelective assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Lysergic acid diethylamide] are indicative of a change in receptor function and kinetics for the Norway rat 5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled [GeneSymbol:Htr1a | GeneID:24473 | Uniprot_SwissProt_Accession:P19327]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_rAdra1B": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_rAdra1B assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-7-Methoxy-Prazosin] are indicative of a change in receptor function and kinetics for the Norway rat adrenoceptor alpha 1B [GeneSymbol:Adra1b | GeneID:24173 | Uniprot_SwissProt_Accession:P15823]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_rAdra1_NonSelective": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_rAdra1_NonSelective assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-7-Methoxy-Prazosin] are indicative of a change in receptor function and kinetics for the Norway rat adrenoceptor alpha 1A [GeneSymbol:Adra1a | GeneID:29412 | Uniprot_SwissProt_Accession:P43140]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_rAdra2_NonSelective": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_rAdra2_NonSelective assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-RX 821002] are indicative of a change in receptor function and kinetics for the Norway rat adrenoceptor alpha 2A [GeneSymbol:Adra2a | GeneID:25083 | Uniprot_SwissProt_Accession:P22909]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_rAdrb_NonSelective": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_rAdrb_NonSelective assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-DHA] are indicative of a change in receptor function and kinetics for the Norway rat adrenoceptor beta 1 [GeneSymbol:Adrb1 | GeneID:24925 | Uniprot_SwissProt_Accession:P18090]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_rNK1": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_rNK1 assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Substance P] are indicative of a change in receptor function and kinetics for the Norway rat tachykinin receptor 1 [GeneSymbol:Tacr1 | GeneID:24807 | Uniprot_SwissProt_Accession:P14600]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_rNK3": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_rNK3 assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-Eledoisin] are indicative of a change in receptor function and kinetics for the Norway rat tachykinin receptor 3 [GeneSymbol:Tacr3 | GeneID:24808 | Uniprot_SwissProt_Accession:P16177]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_rOpiate_NonSelective": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_rOpiate_NonSelective assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Naloxone] are indicative of a change in receptor function and kinetics for the Norway rat opioid receptor, mu 1 [GeneSymbol:Oprm1 | GeneID:25601 | Uniprot_SwissProt_Accession:P33535]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_rOpiate_NonSelectiveNa": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_rOpiate_NonSelectiveNa assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Naloxone] are indicative of a change in receptor binding affinity due to allosteric binding of sodium ions for the Norway rat opioid receptor, mu 1 [GeneSymbol:Oprm1 | GeneID:25601 | Uniprot_SwissProt_Accession:P33535]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_rSST": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_rSST assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-Somatostatin-14 (Tyr11)] are indicative of a change in receptor function and kinetics for the Norway rat somatostatin receptor 1 [GeneSymbol:Sstr1 | GeneID:25033 | Uniprot_SwissProt_Accession:P28646]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_rTRH": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_rTRH assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-(3-methylHis[2])-TRH] are indicative of a change in receptor function and kinetics for the Norway rat thyrotropin releasing hormone receptor [GeneSymbol:Trhr | GeneID:25570 | Uniprot_SwissProt_Accession:Q01717]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_rV1": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_rV1 assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[phenylanyl-3,4,5-3H(N)]-L-Arg8-Vasopressin] are indicative of a change in receptor function and kinetics for the Norway rat arginine vasopressin receptor 1A [GeneSymbol:Avpr1a | GeneID:25107 | Uniprot_SwissProt_Accession:P30560]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_rabPAF": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_rabPAF assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [Hexadecyl-2-[3H]-acetyl-sn-glyceryl-3-phosphorylcholine] are indicative of a change in receptor function and kinetics for the rabbit platelet-activating factor receptor [GeneSymbol:PTAFR | GeneID:100354046 | Uniprot_SwissProt_Accession:NA]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_GPCR_rmAdra2B": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_GPCR_rmAdra2B assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-MK-912] are indicative of a change in receptor function and kinetics for the Norway rat adrenoceptor alpha 2B [GeneSymbol:Adra2b | GeneID:24174 | Uniprot_SwissProt_Accession:P19328]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_IC_hKhERGCh": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_IC_hKhERGCh assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Astemizole] are indicative of a change in receptor function and kinetics for the human potassium voltage-gated channel, subfamily H (eag-related), member 2 [GeneSymbol:KCNH2 | GeneID:3757 | Uniprot_SwissProt_Accession:Q12809]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_IC_rCaBTZCHL": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_IC_rCaBTZCHL assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Diltiazem] are indicative of a change in receptor function and kinetics for the Norway rat calcium channel, voltage-dependent, P/Q type, alpha 1A subunit [GeneSymbol:Cacna1a | GeneID:25398 | Uniprot_SwissProt_Accession:P54282]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_IC_rCaDHPRCh_L": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_IC_rCaDHPRCh_L assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Nitrendipine] are indicative of a change in receptor function and kinetics for the Norway rat calcium channel, voltage-dependent, P/Q type, alpha 1A subunit [GeneSymbol:Cacna1a | GeneID:25398 | Uniprot_SwissProt_Accession:P54282]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_IC_rNaCh_site2": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_IC_rNaCh_site2 assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Batrachotoxin] are indicative of a change in receptor function and kinetics for the Norway rat sodium channel, voltage-gated, type I, alpha subunit [GeneSymbol:Scn1a | GeneID:81574 | Uniprot_SwissProt_Accession:P04774]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_LGIC_bGABARa1": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_LGIC_bGABARa1 assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Flunitrazepam] are indicative of a change in receptor function and kinetics for the cattle gamma-aminobutyric acid (GABA) A receptor, alpha 1 [GeneSymbol:GABRA1 | GeneID:780973 | Uniprot_SwissProt_Accession:P08219]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_LGIC_h5HT3": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_LGIC_h5HT3 assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-GR 65630] are indicative of a change in receptor function and kinetics for the human 5-hydroxytryptamine (serotonin) receptor 3A, ionotropic [GeneSymbol:HTR3A | GeneID:3359 | Uniprot_SwissProt_Accession:P46098]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_LGIC_hNNR_NBungSens": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_LGIC_hNNR_NBungSens assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Epibatidine] are indicative of a change in receptor function and kinetics for the human cholinergic receptor, nicotinic, alpha 2 (neuronal) [GeneSymbol:CHRNA2 | GeneID:1135 | Uniprot_SwissProt_Accession:Q15822]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_LGIC_rGABAR_NonSelective": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_LGIC_rGABAR_NonSelective assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-GABA] are indicative of a change in receptor function and kinetics for the Norway rat gamma-aminobutyric acid (GABA) A receptor, alpha 1 [GeneSymbol:Gabra1 | GeneID:29705 | Uniprot_SwissProt_Accession:P62813]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_LGIC_rNNR_BungSens": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_LGIC_rNNR_BungSens assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[125I]-a-bungarotoxin] are indicative of a change in receptor function and kinetics for the Norway rat cholinergic receptor, nicotinic, alpha 7 (neuronal) [GeneSymbol:Chrna7 | GeneID:25302 | Uniprot_SwissProt_Accession:Q05941]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_MP_hPBR": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_MP_hPBR assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-PK11195] are indicative of a change in transporter function and kinetics for the human translocator protein (18kDa) [GeneSymbol:TSPO | GeneID:706 | Uniprot_SwissProt_Accession:P30536]. The biological focus is loss of receptor binding and the technological target is transporter.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_MP_rPBR": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_MP_rPBR assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-PK11195] are indicative of a change in transporter function and kinetics for the Norway rat translocator protein [GeneSymbol:Tspo | GeneID:24230 | Uniprot_SwissProt_Accession:P16257]. The biological focus is loss of receptor binding and the technological target is transporter.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_NR_bER": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_NR_bER assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-estradiol] are indicative of a change in receptor function and kinetics for the cattle estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:407238 | Uniprot_SwissProt_Accession:P49884]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_NR_bPR": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_NR_bPR assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Promegestone] are indicative of a change in receptor function and kinetics for the cattle progesterone receptor-like [GeneSymbol:PGR | GeneID:100848466 | Uniprot_SwissProt_Accession:NA]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_NR_cAR": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_NR_cAR assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-methyltrienolone] are indicative of a change in receptor function and kinetics for the chimpanzee androgen receptor [GeneSymbol:AR | GeneID:747460 | Uniprot_SwissProt_Accession:O97775]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_NR_hAR": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_NR_hAR assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-methyltrienolone] are indicative of a change in receptor function and kinetics for the human androgen receptor [GeneSymbol:AR | GeneID:367 | Uniprot_SwissProt_Accession:P10275]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_NR_hCAR_Antagonist": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_NR_hCAR_Antagonist assay is as follows: Changes to fluorescent resonance energy transfer signals produced from the binding between the key ligand and antibody reagents [Fluorescein-labeled coactivator peptide and Terbium-labeled anti-GST antibody] are indicative of a change in the receptor antagonist activity for the human nuclear receptor subfamily 1, group I, member 3 [GeneSymbol:NR1I3 | GeneID:9970 | Uniprot_SwissProt_Accession:Q14994]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_NR_hER": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_NR_hER assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-estradiol] are indicative of a change in receptor function and kinetics for the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_NR_hFXR_Agonist": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_NR_hFXR_Agonist assay is as follows: Changes to fluorescent resonance energy transfer signals produced from the binding between the key ligand and antibody reagents [Fluorescein-labeled coactivator peptide and Terbium-labeled anti-GST antibody] are indicative of a change in the receptor agonist activity for the human nuclear receptor subfamily 1, group H, member 4 [GeneSymbol:NR1H4 | GeneID:9971 | Uniprot_SwissProt_Accession:Q96RI1]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_NR_hFXR_Antagonist": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_NR_hFXR_Antagonist assay is as follows: Changes to fluorescent resonance energy transfer signals produced from the binding between the key ligand and antibody reagents [Fluorescein-labeled coactivator peptide and Terbium-labeled anti-GST antibody] are indicative of a change in the receptor antagonist activity for the human nuclear receptor subfamily 1, group H, member 4 [GeneSymbol:NR1H4 | GeneID:9971 | Uniprot_SwissProt_Accession:Q96RI1]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_NR_hGR": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_NR_hGR assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-dexamethasone] are indicative of a change in receptor function and kinetics for the human nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) [GeneSymbol:NR3C1 | GeneID:2908 | Uniprot_SwissProt_Accession:P04150]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_NR_hPPARa": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_NR_hPPARa assay is as follows: Changes to fluorescent resonance energy transfer signals produced from the receptor-ligand binding of the key ligand [Fluoromone PPAR green] are indicative of a change in receptor function and kinetics for the human peroxisome proliferator-activated receptor alpha [GeneSymbol:PPARA | GeneID:5465 | Uniprot_SwissProt_Accession:Q07869]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_NR_hPPARg": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_NR_hPPARg assay is as follows: Changes to fluorescence polarization signals produced from the receptor-ligand binding of the key ligand [Fluorescent Ligand] are indicative of a change in receptor function and kinetics for the human peroxisome proliferator-activated receptor gamma [GeneSymbol:PPARG | GeneID:5468 | Uniprot_SwissProt_Accession:P37231]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_NR_hPR": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_NR_hPR assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Promegestone] are indicative of a change in receptor function and kinetics for the human progesterone receptor [GeneSymbol:PGR | GeneID:5241 | Uniprot_SwissProt_Accession:P06401]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_NR_hPXR": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_NR_hPXR assay is as follows: Changes to fluorescent resonance energy transfer signals produced from the receptor-ligand binding of the key ligand [Fluormone PXR (SXR) green] are indicative of a change in receptor function and kinetics for the human nuclear receptor subfamily 1, group I, member 2 [GeneSymbol:NR1I2 | GeneID:8856 | Uniprot_SwissProt_Accession:O75469]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_NR_hRAR_Antagonist": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_NR_hRAR_Antagonist assay is as follows: Changes to fluorescent resonance energy transfer signals produced from the binding between the key ligand and antibody reagents [Fluorescein-labeled coactivator peptide and Terbium-labeled anti-GST antibody] are indicative of a change in the receptor antagonist activity for the human retinoic acid receptor, alpha [GeneSymbol:RARA | GeneID:5914 | Uniprot_SwissProt_Accession:P10276]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_NR_hRARa_Agonist": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_NR_hRARa_Agonist assay is as follows: Changes to fluorescent resonance energy transfer signals produced from the binding between the key ligand and antibody reagents [Fluorescein-labeled coactivator peptide and Terbium-labeled anti-GST antibody] are indicative of a change in the receptor agonist activity for the human retinoic acid receptor, alpha [GeneSymbol:RARA | GeneID:5914 | Uniprot_SwissProt_Accession:P10276]. The biological focus is gain of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_NR_hTRa_Antagonist": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_NR_hTRa_Antagonist assay is as follows: Changes to chemiluminescence signals produced from the receptor-ligand binding of the key ligand [3,3\",5-triiodo-L-thyronine] are indicative of a change in receptor antagonist activity for the human thyroid hormone receptor, alpha [GeneSymbol:THRA | GeneID:7067 | Uniprot_SwissProt_Accession:P10827]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_NR_mERa": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_NR_mERa assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-estradiol] are indicative of a change in receptor function and kinetics for the house mouse estrogen receptor 1 (alpha) [GeneSymbol:Esr1 | GeneID:13982 | Uniprot_SwissProt_Accession:P19785]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_NR_rAR": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_NR_rAR assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-methyltrienolone] are indicative of a change in receptor function and kinetics for the Norway rat androgen receptor [GeneSymbol:Ar | GeneID:24208 | Uniprot_SwissProt_Accession:P15207]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_NR_rMR": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_NR_rMR assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Aldosterone] are indicative of a change in receptor function and kinetics for the Norway rat nuclear receptor subfamily 3, group C, member 2 [GeneSymbol:Nr3c2 | GeneID:25672 | Uniprot_SwissProt_Accession:P22199]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_OR_gSIGMA_NonSelective": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_OR_gSIGMA_NonSelective assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[5-3H]-(1,3-di-O-2-tolylguanidine-DI-[p-Ring-3H]] are indicative of a change in receptor function and kinetics for the domestic guinea pig sigma non-opioid intracellular receptor 1 [GeneSymbol:Sigmar1 | GeneID:100135589 | Uniprot_SwissProt_Accession:Q60492]. The biological focus is loss of receptor binding and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_TR_gDAT": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_TR_gDAT assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-WIN,35,428] are indicative of a change in transporter function and kinetics for the domestic guinea pig solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 [GeneSymbol:Slc6a3 | GeneID:100714898 | Uniprot_SwissProt_Accession:NA]. The biological focus is loss of receptor binding and the technological target is transporter.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_TR_hAdoT": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_TR_hAdoT assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Nitrobenzylthioinosine] are indicative of a change in transporter function and kinetics for the human solute carrier family 29 (equilibrative nucleoside transporter), member 1 [GeneSymbol:SLC29A1 | GeneID:2030 | Uniprot_SwissProt_Accession:Q99808]. The biological focus is loss of receptor binding and the technological target is transporter.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_TR_hDAT": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_TR_hDAT assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-WIN,35,428] are indicative of a change in transporter function and kinetics for the human solute carrier family 6 (neurotransmitter transporter), member 3 [GeneSymbol:SLC6A3 | GeneID:6531 | Uniprot_SwissProt_Accession:Q01959]. The biological focus is loss of receptor binding and the technological target is transporter.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_TR_hNET": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_TR_hNET assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Nisoxetine] are indicative of a change in transporter function and kinetics for the human solute carrier family 6 (neurotransmitter transporter), member 2 [GeneSymbol:SLC6A2 | GeneID:6530 | Uniprot_SwissProt_Accession:P23975]. The biological focus is loss of receptor binding and the technological target is transporter.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_TR_hSERT": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_TR_hSERT assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-N-methyl-citalopram] are indicative of a change in transporter function and kinetics for the human solute carrier family 6 (neurotransmitter transporter), member 4 [GeneSymbol:SLC6A4 | GeneID:6532 | Uniprot_SwissProt_Accession:P31645]. The biological focus is loss of receptor binding and the technological target is transporter.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_TR_rNET": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_TR_rNET assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-Nisoxetine] are indicative of a change in transporter function and kinetics for the Norway rat solute carrier family 6 (neurotransmitter transporter), member 2 [GeneSymbol:Slc6a2 | GeneID:83511 | Uniprot_SwissProt_Accession:NA]. The biological focus is loss of receptor binding and the technological target is transporter.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_TR_rSERT": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_TR_rSERT assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-N-methyl-citalopram] are indicative of a change in transporter function and kinetics for the Norway rat solute carrier family 6 (neurotransmitter transporter), member 4 [GeneSymbol:Slc6a4 | GeneID:25553 | Uniprot_SwissProt_Accession:P31652]. The biological focus is loss of receptor binding and the technological target is transporter.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_NVS_TR_rVMAT2": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the NVS_TR_rVMAT2 assay is as follows: Changes to scintillation counting signals produced from the receptor-ligand binding of the key ligand [[3H]-dihydrotetrabenazine] are indicative of a change in transporter function and kinetics for the Norway rat solute carrier family 18 (vesicular monoamine transporter), member 2 [GeneSymbol:Slc18a2 | GeneID:25549 | Uniprot_SwissProt_Accession:Q01827]. The biological focus is loss of receptor binding and the technological target is transporter.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_OT_AR_ARELUC_AG_1440": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the OT_AR_ARELUC_AG_1440 assay is as follows: Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [D-luciferin] are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human androgen receptor [GeneSymbol:AR | GeneID:367 | Uniprot_SwissProt_Accession:P10275]. The biological focus is gain of regulation of gene expression and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_OT_AR_ARSRC1_0480": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the OT_AR_ARSRC1_0480 assay is as follows: Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human androgen receptor and SRC proto-oncogene, non-receptor tyrosine kinase [GeneSymbol:AR & SRC | GeneID:367 & 6714 | Uniprot_SwissProt_Accession:P10275 & P12931]. The biological focus is gain of protein stabilization and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_OT_AR_ARSRC1_0960": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the OT_AR_ARSRC1_0960 assay is as follows: Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human androgen receptor and SRC proto-oncogene, non-receptor tyrosine kinase [GeneSymbol:AR & SRC | GeneID:367 & 6714 | Uniprot_SwissProt_Accession:P10275 & P12931]. The biological focus is gain of protein stabilization and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_OT_ER_ERaERa_0480": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the OT_ER_ERaERa_0480 assay is as follows: Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372]. The biological focus is gain of protein stabilization and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_OT_ER_ERaERa_1440": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the OT_ER_ERaERa_1440 assay is as follows: Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372]. The biological focus is gain of protein stabilization and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_OT_ER_ERaERb_0480": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the OT_ER_ERaERb_0480 assay is as follows: Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human estrogen receptor 1 and estrogen receptor 2 (ER beta) [GeneSymbol:ESR1 & ESR2 | GeneID:2099 & 2100 | Uniprot_SwissProt_Accession:P03372 & Q92731]. The biological focus is gain of protein stabilization and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_OT_ER_ERaERb_1440": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the OT_ER_ERaERb_1440 assay is as follows: Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human estrogen receptor 1 and estrogen receptor 2 (ER beta) [GeneSymbol:ESR1 & ESR2 | GeneID:2099 & 2100 | Uniprot_SwissProt_Accession:P03372 & Q92731]. The biological focus is gain of protein stabilization and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_OT_ER_ERbERb_0480": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the OT_ER_ERbERb_0480 assay is as follows: Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human estrogen receptor 2 (ER beta) [GeneSymbol:ESR2 | GeneID:2100 | Uniprot_SwissProt_Accession:Q92731]. The biological focus is gain of protein stabilization and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_OT_ER_ERbERb_1440": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the OT_ER_ERbERb_1440 assay is as follows: Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human estrogen receptor 2 (ER beta) [GeneSymbol:ESR2 | GeneID:2100 | Uniprot_SwissProt_Accession:Q92731]. The biological focus is gain of protein stabilization and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_OT_ERa_EREGFP_0120": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the OT_ERa_EREGFP_0120 assay is as follows: Changes to optical microscopy: fluorescence microscopy signals produced from the fluorescent protein induction are indicative of a change in the receptor function and kinetics for the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372]. The biological focus is gain of regulation of gene expression and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_OT_ERa_EREGFP_0480": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the OT_ERa_EREGFP_0480 assay is as follows: Changes to optical microscopy: fluorescence microscopy signals produced from the fluorescent protein induction are indicative of a change in the receptor function and kinetics for the human estrogen receptor 1 [GeneSymbol:ESR1 | GeneID:2099 | Uniprot_SwissProt_Accession:P03372]. The biological focus is gain of regulation of gene expression and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_OT_FXR_FXRSRC1_0480": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the OT_FXR_FXRSRC1_0480 assay is as follows: Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human SRC proto-oncogene, non-receptor tyrosine kinase and nuclear receptor subfamily 1, group H, member 4 [GeneSymbol:SRC & NR1H4 | GeneID:6714 & 9971 | Uniprot_SwissProt_Accession:P12931 & Q96RI1]. The biological focus is gain of protein stabilization and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_OT_FXR_FXRSRC1_1440": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the OT_FXR_FXRSRC1_1440 assay is as follows: Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human SRC proto-oncogene, non-receptor tyrosine kinase and nuclear receptor subfamily 1, group H, member 4 [GeneSymbol:SRC & NR1H4 | GeneID:6714 & 9971 | Uniprot_SwissProt_Accession:P12931 & Q96RI1]. The biological focus is gain of protein stabilization and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_OT_NURR1_NURR1RXRa_0480": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the OT_NURR1_NURR1RXRa_0480 assay is as follows: Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human nuclear receptor subfamily 4, group A, member 2 and retinoid X receptor, alpha [GeneSymbol:NR4A2 & RXRA | GeneID:4929 & 6256 | Uniprot_SwissProt_Accession:P43354 & P19793]. The biological focus is gain of protein stabilization and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_OT_NURR1_NURR1RXRa_1440": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the OT_NURR1_NURR1RXRa_1440 assay is as follows: Changes to fluorescence intensity signals produced from the protein fragment complementation are indicative of a change in the receptor function and kinetics for the human nuclear receptor subfamily 4, group A, member 2 and retinoid X receptor, alpha [GeneSymbol:NR4A2 & RXRA | GeneID:4929 & 6256 | Uniprot_SwissProt_Accession:P43354 & P19793]. The biological focus is gain of protein stabilization and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_ARE_BLA_Agonist_ch1": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_ARE_BLA_Agonist_ch1 assay is as follows: TOX21_ARE_BLA_Agonist_ch1 was designed to measure uncleaved reporter gene substrate to target transcription factor activity, specifically mapping to NFE2L2 gene(s) using a positive control of Beta-Naphthoflavone The biological focus is loss of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_ARE_BLA_Agonist_ch2": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_ARE_BLA_Agonist_ch2 assay is as follows: TOX21_ARE_BLA_Agonist_ch2 was designed to measure cleaved reporter gene substrate to target transcription factor activity, specifically mapping to NFE2L2 gene(s) using a positive control of Beta-Naphthoflavone The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_ARE_BLA_agonist_ratio": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_ARE_BLA_agonist_ratio assay is as follows: TOX21_ARE_BLA_Agonist_ratio was designed to target transcription factor activity, specifically mapping to NFE2L2 gene(s) using a positive control of Beta-Naphthoflavone The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_ARE_BLA_agonist_viability": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_ARE_BLA_agonist_viability assay is as follows: Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system. The biological focus is loss of cell proliferation and the technological target is ATP.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_AR_BLA_Agonist_ch1": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_AR_BLA_Agonist_ch1 assay is as follows: TOX21_AR_BLA_Agonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to AR gene(s) using a positive control of R1881 The biological focus is loss of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_AR_BLA_Agonist_ch2": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_AR_BLA_Agonist_ch2 assay is as follows: TOX21_AR_BLA_Agonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to AR gene(s) using a positive control of R1881 The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_AR_BLA_Agonist_ratio": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_AR_BLA_Agonist_ratio assay is as follows: TOX21_AR_BLA_Agonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to AR gene(s) using a positive control of R1881 The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_AR_BLA_Antagonist_ch1": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_AR_BLA_Antagonist_ch1 assay is as follows: TOX21_AR_BLA_Antagonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to AR gene(s) using a positive control of Cyproterone acetate The biological focus is loss of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_AR_BLA_Antagonist_ch2": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_AR_BLA_Antagonist_ch2 assay is as follows: TOX21_AR_BLA_Antagonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to AR gene(s) using a positive control of Cyproterone acetate The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_AR_BLA_Antagonist_ratio": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_AR_BLA_Antagonist_ratio assay is as follows: TOX21_AR_BLA_Antagonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to AR gene(s) using a positive control of Cyproterone acetate The biological focus is loss of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_AR_BLA_Antagonist_viability": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_AR_BLA_Antagonist_viability assay is as follows: Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system. The biological focus is loss of cell proliferation and the technological target is ATP.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_AR_LUC_MDAKB2_Agonist": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_AR_LUC_MDAKB2_Agonist assay is as follows: Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human androgen receptor [GeneSymbol:AR | GeneID:367 | Uniprot_SwissProt_Accession:P10275]. The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_AR_LUC_MDAKB2_Antagonist": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_AR_LUC_MDAKB2_Antagonist assay is as follows: Measures inhibition of androgen receptor signaling.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_AR_LUC_MDAKB2_Antagonist2": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_AR_LUC_MDAKB2_Antagonist2 assay is as follows: Measures inhibition of androgen receptor signaling.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_AhR_LUC_Agonist": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_AhR_LUC_Agonist assay is as follows: Changes to bioluminescence signals produced from the luciferase induction are indicative of agonist activity regulated by the receptor function and kinetics for the human aryl hydrocarbon receptor [GeneSymbol:AHR | GeneID:196 | Uniprot_SwissProt_Accession:P35869]. The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_Aromatase_Inhibition": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_Aromatase_Inhibition assay is as follows: Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to modulation of the human cytochrome P450, family 19, subfamily A, polypeptide 1 [GeneSymbol:CYP19A1 | GeneID:1588 | Uniprot_SwissProt_Accession:P11511]. The biological focus is loss of regulation of transcription factor activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_AutoFluor_HEK293_Cell_blue": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_AutoFluor_HEK293_Cell_blue assay is as follows: Changes to fluorescence intensity signals are indicative of the test substance having some physical feature that alters or influences the background fluorescence. The biological focus is none of autofluorescence and the technological target is physical feature.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_AutoFluor_HEK293_Media_blue": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_AutoFluor_HEK293_Media_blue assay is as follows: Changes to fluorescence intensity signals are indicative of the test substance having some physical feature that alters or influences the background fluorescence. The biological focus is none of autofluorescence and the technological target is physical feature.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_AutoFluor_HEPG2_Cell_blue": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_AutoFluor_HEPG2_Cell_blue assay is as follows: Changes to fluorescence intensity signals are indicative of the test substance having some physical feature that alters or influences the background fluorescence. The biological focus is none of autofluorescence and the technological target is physical feature.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_AutoFluor_HEPG2_Cell_green": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_AutoFluor_HEPG2_Cell_green assay is as follows: Changes to fluorescence intensity signals are indicative of the test substance having some physical feature that alters or influences the background fluorescence. The biological focus is none of autofluorescence and the technological target is physical feature.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_AutoFluor_HEPG2_Media_blue": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_AutoFluor_HEPG2_Media_blue assay is as follows: Changes to fluorescence intensity signals are indicative of the test substance having some physical feature that alters or influences the background fluorescence. The biological focus is none of autofluorescence and the technological target is physical feature.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_AutoFluor_HEPG2_Media_green": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_AutoFluor_HEPG2_Media_green assay is as follows: Changes to fluorescence intensity signals are indicative of the test substance having some physical feature that alters or influences the background fluorescence. The biological focus is none of autofluorescence and the technological target is physical feature.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_ELG1_LUC_Agonist": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_ELG1_LUC_Agonist assay is as follows: Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human ATPase family, AAA domain containing 5 [GeneSymbol:ATAD5 | GeneID:79915 | Uniprot_SwissProt_Accession:Q96QE3]. The biological focus is gain of regulation of transcription factor activity and the technological target is enzyme.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_ERa_BLA_Agonist_ch1": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_ERa_BLA_Agonist_ch1 assay is as follows: TOX21_ERa_BLA_Agonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to ESR1 gene(s) using a positive control of 17b-estradiol The biological focus is loss of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_ERa_BLA_Agonist_ch2": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_ERa_BLA_Agonist_ch2 assay is as follows: TOX21_ERa_BLA_Agonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor (steroidal) activity at the protein (receptor) level, specifically mapping to ESR1 gene(s) using a positive control of 17b-estradiol The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_ERa_BLA_Agonist_ratio": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_ERa_BLA_Agonist_ratio assay is as follows: TOX21_ERa_BLA_Agonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to ESR1 gene(s) using a positive control of 17b-estradiol The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_ERa_BLA_Antagonist_ch1": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_ERa_BLA_Antagonist_ch1 assay is as follows: TOX21_ERa_BLA_Antagonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to ESR1 gene(s) using a positive control of 4-hydroxytamoxifen The biological focus is loss of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_ERa_BLA_Antagonist_ch2": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_ERa_BLA_Antagonist_ch2 assay is as follows: TOX21_ERa_BLA_Antagonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor (steroidal) activity at the protein (receptor) level, specifically mapping to ESR1 gene(s) using a positive control of 4-hydroxytamoxifen The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_ERa_BLA_Antagonist_ratio": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_ERa_BLA_Antagonist_ratio assay is as follows: TOX21_ERa_BLA_Antagonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to ESR1 gene(s) using a positive control of 4-hydroxytamoxifen The biological focus is loss of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_ERa_BLA_Antagonist_viability": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_ERa_BLA_Antagonist_viability assay is as follows: Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system. The biological focus is loss of cell proliferation and the technological target is ATP.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_ERa_LUC_BG1_Agonist": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_ERa_LUC_BG1_Agonist assay is as follows: Measures activation of estrogen receptor signaling in ovarian cells.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_ERa_LUC_BG1_Antagonist": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_ERa_LUC_BG1_Antagonist assay is as follows: Measures inhibition of estrogen receptor signaling in ovarian cells.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_ESRE_BLA_ch1": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_ESRE_BLA_ch1 assay is as follows: TOX21_ESRE_BLA_ch1 was designed to measure uncleaved reporter gene substrate to target transcription factor activity, specifically mapping to ATF6 gene(s) using a positive control of 17-AAG The biological focus is loss of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_ESRE_BLA_ch2": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_ESRE_BLA_ch2 assay is as follows: TOX21_ESRE_BLA_ch2 was designed to measure cleaved reporter gene substrate to target transcription factor activity, specifically mapping to ATF6 gene(s) using a positive control of 17-AAG The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_ESRE_BLA_ratio": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_ESRE_BLA_ratio assay is as follows: TOX21_ESRE_BLA_ratio was designed to target transcription factor activity, specifically mapping to ATF6 gene(s) using a positive control of 17-AAG The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_ESRE_BLA_viability": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_ESRE_BLA_viability assay is as follows: Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system. The biological focus is loss of cell proliferation and the technological target is ATP.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_FXR_BLA_Antagonist_ch1": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_FXR_BLA_Antagonist_ch1 assay is as follows: TOX21_FXR_BLA_Antagonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR1H4 gene(s) using a positive control of Guggulsterone The biological focus is loss of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_FXR_BLA_Antagonist_ch2": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_FXR_BLA_Antagonist_ch2 assay is as follows: TOX21_FXR_BLA_Antagonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR1H4 gene(s) using a positive control of Guggulsterone The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_FXR_BLA_agonist_ch2": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_FXR_BLA_agonist_ch2 assay is as follows: TOX21_FXR_BLA_Agonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR1H4 gene(s) using a positive control of Chenodeoxycholic acid The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_FXR_BLA_agonist_ratio": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_FXR_BLA_agonist_ratio assay is as follows: TOX21_FXR_BLA_Agonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR1H4 gene(s) using a positive control of Chenodeoxycholic acid The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_FXR_BLA_antagonist_ratio": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_FXR_BLA_antagonist_ratio assay is as follows: TOX21_FXR_BLA_Antagonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR1H4 gene(s) using a positive control of Guggulsterone The biological focus is loss of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_FXR_BLA_antagonist_viability": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_FXR_BLA_antagonist_viability assay is as follows: Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system. The biological focus is loss of cell proliferation and the technological target is ATP.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_GR_BLA_Agonist_ch1": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_GR_BLA_Agonist_ch1 assay is as follows: TOX21_GR_BLA_Agonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR3C1 gene(s) using a positive control of Dexamethasone The biological focus is loss of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_GR_BLA_Agonist_ch2": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_GR_BLA_Agonist_ch2 assay is as follows: TOX21_GR_BLA_Agonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor (non-steroidal) activity at the protein (receptor) level, specifically mapping to NR3C1 gene(s) using a positive control of Dexamethasone The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_GR_BLA_Agonist_ratio": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_GR_BLA_Agonist_ratio assay is as follows: TOX21_GR_BLA_Agonist_ratio was designed to target nuclear receptor (non-steroidal) activity at the protein (receptor) level, specifically mapping to NR3C1 gene(s) using a positive control of Dexamethasone The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_GR_BLA_Antagonist_ch2": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_GR_BLA_Antagonist_ch2 assay is as follows: TOX21_GR_BLA_Antagonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor (non-steroidal) activity at the protein (receptor) level, specifically mapping to NR3C1 gene(s) using a positive control of Mifepristone The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_GR_BLA_Antagonist_ratio": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_GR_BLA_Antagonist_ratio assay is as follows: TOX21_GR_BLA_Antagonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR3C1 gene(s) using a positive control of Mifepristone The biological focus is loss of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_GR_BLA_Antagonist_viability": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_GR_BLA_Antagonist_viability assay is as follows: Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system. The biological focus is loss of cell proliferation and the technological target is ATP.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_HSE_BLA_agonist_ch1": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_HSE_BLA_agonist_ch1 assay is as follows: TOX21_HSE_BLA_Agonist_ch1 was designed to measure uncleaved reporter gene substrate to target transcription factor activity, specifically mapping to HSF1 gene(s) using a positive control of 17-AAG The biological focus is loss of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_HSE_BLA_agonist_ch2": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_HSE_BLA_agonist_ch2 assay is as follows: TOX21_HSE_BLA_Agonist_ch2 was designed to measure cleaved reporter gene substrate to target transcription factor activity, specifically mapping to HSF1 gene(s) using a positive control of 17-AAG The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_HSE_BLA_agonist_ratio": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_HSE_BLA_agonist_ratio assay is as follows: TOX21_HSE_BLA_Agonist_ratio was designed to target transcription factor activity, specifically mapping to HSF1 gene(s) using a positive control of 17-AAG The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_HSE_BLA_agonist_viability": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_HSE_BLA_agonist_viability assay is as follows: Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system. The biological focus is loss of cell proliferation and the technological target is ATP.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_MMP_ratio_down": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_MMP_ratio_down assay is as follows: Mito-MPS is used as a stain for the membrane potential of the mitochondria. The biological focus is gain/loss of mitochondrial depolarization and the technological target is mitochondria.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_MMP_ratio_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_MMP_ratio_up assay is as follows: Mito-MPS is used as a stain for the membrane potential of the mitochondria. The biological focus is gain/loss of mitochondrial depolarization and the technological target is mitochondria.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_MMP_viability": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_MMP_viability assay is as follows: Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system. The biological focus is loss of cell proliferation and the technological target is ATP.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_NFkB_BLA_agonist_ch1": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_NFkB_BLA_agonist_ch1 assay is as follows: TOX21_NFkB_BLA_Agonist_ch1 was designed to measure uncleaved reporter gene substrate to target transcription factor activity, specifically mapping to NFKB1 gene(s) using a positive control of TNFa The biological focus is loss of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_NFkB_BLA_agonist_ch2": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_NFkB_BLA_agonist_ch2 assay is as follows: TOX21_NFkB_BLA_Agonist_ch2 was designed to measure cleaved reporter gene substrate to target transcription factor activity, specifically mapping to NFKB1 gene(s) using a positive control of TNFa The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_NFkB_BLA_agonist_ratio": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_NFkB_BLA_agonist_ratio assay is as follows: TOX21_NFkB_BLA_Agonist_ratio was designed to target transcription factor activity, specifically mapping to NFKB1 gene(s) using a positive control of TNFa The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_NFkB_BLA_agonist_viability": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_NFkB_BLA_agonist_viability assay is as follows: Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system. The biological focus is loss of cell proliferation and the technological target is ATP.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_PPARd_BLA_Agonist_viability": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_PPARd_BLA_Agonist_viability assay is as follows: Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system. The biological focus is loss of cell proliferation and the technological target is ATP.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_PPARd_BLA_Antagonist_ch1": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_PPARd_BLA_Antagonist_ch1 assay is as follows: TOX21_PPARD_BLA_Antagonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to PPARD gene(s) using a positive control of MK886 The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_PPARd_BLA_agonist_ch1": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_PPARd_BLA_agonist_ch1 assay is as follows: TOX21_PPARD_BLA_Agonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to PPARD gene(s) using a positive control of L-165,041 The biological focus is loss of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_PPARd_BLA_agonist_ch2": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_PPARd_BLA_agonist_ch2 assay is as follows: TOX21_PPARD_BLA_Agonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to PPARD gene(s) using a positive control of L-165,041 The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_PPARd_BLA_agonist_ratio": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_PPARd_BLA_agonist_ratio assay is as follows: TOX21_PPARD_BLA_Agonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to PPARD gene(s) using a positive control of L-165,041 The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_PPARd_BLA_antagonist_ratio": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_PPARd_BLA_antagonist_ratio assay is as follows: TOX21_PPARD_BLA_Antagonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to PPARD gene(s) using a positive control of MK886 The biological focus is loss of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_PPARd_BLA_antagonist_viability": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_PPARd_BLA_antagonist_viability assay is as follows: Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system. The biological focus is loss of cell proliferation and the technological target is ATP.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_PPARg_BLA_Agonist_ch1": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_PPARg_BLA_Agonist_ch1 assay is as follows: TOX21_PPARg_BLA_Agonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to PPARG gene(s) using a positive control of Rosiglitazone. The biological focus is loss of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_PPARg_BLA_Agonist_ch2": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_PPARg_BLA_Agonist_ch2 assay is as follows: TOX21_PPARg_BLA_Agonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor (non-steroidal) activity at the protein (receptor) level, specifically mapping to PPARG gene(s) using a positive control of Rosiglitazone The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_PPARg_BLA_Agonist_ratio": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_PPARg_BLA_Agonist_ratio assay is as follows: TOX21_PPARg_BLA_Agonist_ratio was designed to target nuclear receptor (non-steroidal) activity at the protein (receptor) level, specifically mapping to PPARG gene(s) using a positive control of Rosiglitazone The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_PPARg_BLA_Antagonist_ch1": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_PPARg_BLA_Antagonist_ch1 assay is as follows: TOX21_PPARg_BLA_Antagonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to PPARG gene(s) using a positive control of GW9662 The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_PPARg_BLA_antagonist_ratio": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_PPARg_BLA_antagonist_ratio assay is as follows: TOX21_PPARg_BLA_Antagonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to PPARG gene(s) using a positive control of GW9662 The biological focus is loss of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_PPARg_BLA_antagonist_viability": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_PPARg_BLA_antagonist_viability assay is as follows: Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system. The biological focus is loss of cell proliferation and the technological target is ATP.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_TR_LUC_GH3_Agonist": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_TR_LUC_GH3_Agonist assay is as follows: Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to agonist activity regulated by the human thyroid hormone receptor, alpha and thyroid hormone receptor, beta [GeneSymbol:THRA & THRB | GeneID:7067 & 7068 | Uniprot_SwissProt_Accession:P10827 & P10828]. Thyroid receptor (TR), a nuclear hormone receptor, plays an important role in development, proliferation, differentiation, metabolism, brain function, and cardiovascular system. TR-interacting compounds have been shown to disrupt thyroid homeostasis. The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_TR_LUC_GH3_Antagonist": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_TR_LUC_GH3_Antagonist assay is as follows: Changes to bioluminescence signals produced from an enzymatic reaction involving the key substrate [One-Glo] are indicative of changes in transcriptional gene expression due to antagonist activity regulated by the human thyroid hormone receptor, alpha and thyroid hormone receptor, beta [GeneSymbol:THRA & THRB | GeneID:7067 & 7068 | Uniprot_SwissProt_Accession:P10827 & P10828]. Thyroid receptor (TR), a nuclear hormone receptor, plays an important role in development, proliferation, differentiation, metabolism, brain function, and cardiovascular system. TR-interacting compounds have been shown to disrupt thyroid homeostasis. The biological focus is loss of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_VDR_BLA_Agonist_viability": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_VDR_BLA_Agonist_viability assay is as follows: Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system. The biological focus is loss of cell proliferation and the technological target is ATP.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_VDR_BLA_Antagonist_ch1": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_VDR_BLA_Antagonist_ch1 assay is as follows: TOX21_VDR_BLA_Antagonist_ch1 was designed to measure uncleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR1I1 gene(s) using a positive control of Tetraoctyl ammonium bromide The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_VDR_BLA_agonist_ch2": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_VDR_BLA_agonist_ch2 assay is as follows: TOX21_VDR_BLA_Agonist_ch2 was designed to measure cleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR1I1 gene(s) using a positive control of Calcitriol The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_VDR_BLA_agonist_ratio": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_VDR_BLA_agonist_ratio assay is as follows: TOX21_VDR_BLA_Agonist_ratio was designed to measure cleaved reporter gene substrate to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR1I1 gene(s) using a positive control of Calcitriol The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_VDR_BLA_antagonist_ratio": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_VDR_BLA_antagonist_ratio assay is as follows: TOX21_VDR_BLA_Antagonist_ratio was designed to target nuclear receptor activity at the protein (receptor) level, specifically mapping to NR1I1 gene(s) using a positive control of Tetraoctyl ammonium bromide The biological focus is loss of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_VDR_BLA_antagonist_viability": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_VDR_BLA_antagonist_viability assay is as follows: Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system. The biological focus is loss of cell proliferation and the technological target is ATP.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_p53_BLA_p1_ch1": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_p53_BLA_p1_ch1 assay is as follows: TOX21_p53_BLA_p1_ch1 was designed to measure uncleaved reporter gene substrate to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C The biological focus is loss of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_p53_BLA_p1_ch2": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_p53_BLA_p1_ch2 assay is as follows: TOX21_p53_BLA_p1_ch2 was designed to measure cleaved reporter gene substrate to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_p53_BLA_p1_ratio": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_p53_BLA_p1_ratio assay is as follows: TOX21_p53_BLA_p1_ratio was designed to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_p53_BLA_p1_viability": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_p53_BLA_p1_viability assay is as follows: Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system. The biological focus is loss of cell proliferation and the technological target is ATP.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_p53_BLA_p2_ch1": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_p53_BLA_p2_ch1 assay is as follows: TOX21_p53_BLA_p2_ch1 was designed to measure uncleaved reporter gene substrate to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C The biological focus is loss of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_p53_BLA_p2_ch2": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_p53_BLA_p2_ch2 assay is as follows: TOX21_p53_BLA_p2_ch2 was designed to measure cleaved reporter gene substrate to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_p53_BLA_p2_ratio": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_p53_BLA_p2_ratio assay is as follows: TOX21_p53_BLA_p2_ratio was designed to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_p53_BLA_p2_viability": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_p53_BLA_p2_viability assay is as follows: Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system. The biological focus is loss of cell proliferation and the technological target is ATP.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_p53_BLA_p3_ch1": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_p53_BLA_p3_ch1 assay is as follows: TOX21_p53_BLA_p3_ch1 was designed to measure uncleaved reporter gene substrate to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C The biological focus is loss of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_p53_BLA_p3_ch2": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_p53_BLA_p3_ch2 assay is as follows: TOX21_p53_BLA_p3_ch2 was designed to measure cleaved reporter gene substrate to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_p53_BLA_p3_ratio": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_p53_BLA_p3_ratio assay is as follows: TOX21_p53_BLA_p3_ratio was designed to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_p53_BLA_p3_viability": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_p53_BLA_p3_viability assay is as follows: Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system. The biological focus is loss of cell proliferation and the technological target is ATP.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_p53_BLA_p4_ch1": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_p53_BLA_p4_ch1 assay is as follows: TOX21_p53_BLA_p4_ch1 was designed to measure uncleaved reporter gene substrate to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C The biological focus is loss of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_p53_BLA_p4_ch2": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_p53_BLA_p4_ch2 assay is as follows: TOX21_p53_BLA_p4_ch2 was designed to measure cleaved reporter gene substrate to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_p53_BLA_p4_ratio": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_p53_BLA_p4_ratio assay is as follows: TOX21_p53_BLA_p4_ratio was designed to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_p53_BLA_p4_viability": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_p53_BLA_p4_viability assay is as follows: Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system. The biological focus is loss of cell proliferation and the technological target is ATP.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_p53_BLA_p5_ch1": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_p53_BLA_p5_ch1 assay is as follows: TOX21_p53_BLA_p5_ch1 was designed measure uncleaved reporter gene substrate to to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C The biological focus is loss of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_p53_BLA_p5_ch2": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_p53_BLA_p5_ch2 assay is as follows: TOX21_p53_BLA_p5_ch2 was designed measure cleaved reporter gene substrate to to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_p53_BLA_p5_ratio": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_p53_BLA_p5_ratio assay is as follows: TOX21_p53_BLA_p5_ratio was designed to target transcription factor activity, specifically mapping to TP53 gene(s) using a positive control of Mitomycin C The biological focus is gain of regulation of transcription factor activity and the technological target is receptor.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_TOX21_p53_BLA_p5_viability": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the TOX21_p53_BLA_p5_viability assay is as follows: Changes to bioluminescence signals produced from an enzymatic reaction catalyzed by luciferase between the key substrate [CellTiter-Glo] and the target cofactor [ATP] are correlated to the viability of the system. The biological focus is loss of cell proliferation and the technological target is ATP.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_Tanguay_ZF_120hpf_AXIS_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the Tanguay_ZF_120hpf_AXIS_up assay is as follows: Morphology is measured by light microscopic examination of developing zebrafish embryos. The biological focus is gain of regulation of morphogenesis and the technological target is body axis morphogenesis.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_Tanguay_ZF_120hpf_ActivityScore": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the Tanguay_ZF_120hpf_ActivityScore assay is as follows: An algorithm was used to combine results from 18 Tanquay_AF_120hpr assay components The biological focus is nan of regulation of morphogenesis and the technological target is nan.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_Tanguay_ZF_120hpf_BRAI_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the Tanguay_ZF_120hpf_BRAI_up assay is as follows: Morphology is measured by light microscopic examination of developing zebrafish embryos. The biological focus is gain of regulation of morphogenesis and the technological target is brain morphogenesis.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_Tanguay_ZF_120hpf_CFIN_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the Tanguay_ZF_120hpf_CFIN_up assay is as follows: Morphology is measured by light microscopic examination of developing zebrafish embryos. The biological focus is gain of regulation of morphogenesis and the technological target is caudal fin morphogenesis.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_Tanguay_ZF_120hpf_CIRC_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the Tanguay_ZF_120hpf_CIRC_up assay is as follows: Morphology is measured by light microscopic examination of developing zebrafish embryos. The biological focus is gain of regulation of morphogenesis and the technological target is angiogenesis.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_Tanguay_ZF_120hpf_EYE_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the Tanguay_ZF_120hpf_EYE_up assay is as follows: Morphology is measured by light microscopic examination of developing zebrafish embryos. The biological focus is gain of regulation of morphogenesis and the technological target is embryonic eye development.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_Tanguay_ZF_120hpf_JAW_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the Tanguay_ZF_120hpf_JAW_up assay is as follows: Morphology is measured by light microscopic examination of developing zebrafish embryos. The biological focus is gain of regulation of morphogenesis and the technological target is embryonic jaw development.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_Tanguay_ZF_120hpf_MORT_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the Tanguay_ZF_120hpf_MORT_up assay is as follows: Mortality is measured by light microscopic examination of developing zebrafish embryos. The biological focus is gain of regulation of morphogenesis and the technological target is embryonic mortality.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_Tanguay_ZF_120hpf_OTIC_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the Tanguay_ZF_120hpf_OTIC_up assay is as follows: Morphology is measured by light microscopic examination of developing zebrafish embryos. The biological focus is gain of regulation of morphogenesis and the technological target is otic vesicle morphogenesis.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_Tanguay_ZF_120hpf_PE_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the Tanguay_ZF_120hpf_PE_up assay is as follows: Morphology is measured by light microscopic examination of developing zebrafish embryos. The biological focus is gain of regulation of morphogenesis and the technological target is embryonic morphogenesis.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_Tanguay_ZF_120hpf_PFIN_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the Tanguay_ZF_120hpf_PFIN_up assay is as follows: Morphology is measured by light microscopic examination of developing zebrafish embryos. The biological focus is gain of regulation of morphogenesis and the technological target is pectoral fin morphogenesis.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_Tanguay_ZF_120hpf_PIG_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the Tanguay_ZF_120hpf_PIG_up assay is as follows: Morphology is measured by light microscopic examination of developing zebrafish embryos. The biological focus is gain of regulation of morphogenesis and the technological target is embryonic pigmentation.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_Tanguay_ZF_120hpf_SNOU_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the Tanguay_ZF_120hpf_SNOU_up assay is as follows: Morphology is measured by light microscopic examination of developing zebrafish embryos. The biological focus is gain of regulation of morphogenesis and the technological target is embryonic snout morphogenesis.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_Tanguay_ZF_120hpf_SOMI_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the Tanguay_ZF_120hpf_SOMI_up assay is as follows: Morphology is measured by light microscopic examination of developing zebrafish embryos. The biological focus is gain of regulation of morphogenesis and the technological target is somitogenesis.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_Tanguay_ZF_120hpf_SWIM_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the Tanguay_ZF_120hpf_SWIM_up assay is as follows: Morphology is measured by light microscopic examination of developing zebrafish embryos. The biological focus is gain of regulation of morphogenesis and the technological target is swim bladder morphogenesis.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_Tanguay_ZF_120hpf_TRUN_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the Tanguay_ZF_120hpf_TRUN_up assay is as follows: Morphology is measured by light microscopic examination of developing zebrafish embryos. The biological focus is gain of regulation of morphogenesis and the technological target is embryonic morphogenesis.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_Tanguay_ZF_120hpf_TR_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the Tanguay_ZF_120hpf_TR_up assay is as follows: Morphology is measured by light microscopic examination of developing zebrafish embryos. The biological focus is gain of regulation of morphogenesis and the technological target is embryonic functional response.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "ToxCast_Tanguay_ZF_120hpf_YSE_up": "Instructions: Answer the following question about drug properties.\nContext: Humans are exposed to a variety of chemicals through food, household products,and medicines, some of which can be toxic, leading to over 30% of promising pharmaceuticals failing in human trials due to toxicity. Toxicity can be due to many factors, and there are many in vitro and in vivo assays that can be performed to measure the effect of drug candidates on various aspects of bodily function. The context of the Tanguay_ZF_120hpf_YSE_up assay is as follows: Morphology is measured by light microscopic examination of developing zebrafish embryos. The biological focus is gain of regulation of morphogenesis and the technological target is extraembryonic membrane development.\nQuestion: Given a drug SMILES string, predict whether it\n(A) is not toxic in the described assay (B) is toxic in the described assay\nDrug SMILES: {Drug SMILES}\nAnswer:", "Caco2_Wang": "Instructions: Answer the following question about drug properties.\nContext: The human colon epithelial cancer cell line, Caco-2, is used as an in vitro model to simulate the human intestinal tissue. The experimental result on the rate of drug passing through the Caco-2 cells can approximate the rate at which the drug permeates through the human intestinal tissue.\nQuestion: Given a drug SMILES string, predict its normalized Caco-2 cell effective permeability from 000 to 1000, where 000 is minimum permeability and 1000 is maximum permeability.\nDrug SMILES: {Drug SMILES}\nAnswer:", "VDss_Lombardo": "Instructions: Answer the following question about drug properties.\nContext: The volume of distribution at steady state (VDss) measures the degree of a drug's concentration in body tissue compared to concentration in blood. Higher VD indicates a higher distribution in the tissue and usually indicates the drug with high lipid solubility, low plasma protein binding rate.\nQuestion: Given a drug SMILES string, predict its normalized volume of distribution from 000 to 1000, where 000 is minimum volume of distribution and 1000 is maximum volume of distribution.\nDrug SMILES: {Drug SMILES}\nAnswer:", "Half_Life_Obach": "Instructions: Answer the following question about drug properties.\nContext: Half life of a drug is the duration for the concentration of the drug in the body to be reduced by half. It measures the duration of actions of a drug. \nQuestion: Given a drug SMILES string, predict its normalized half life from 000 to 1000, where 000 is minimum half life and 1000 is maximum half life.\nDrug SMILES: {Drug SMILES}\nAnswer:", "Clearance_Hepatocyte_AZ": "Instructions: Answer the following question about drug properties.\nContext: Drug clearance is defined as the volume of plasma cleared of a drug over a specified time period and it measures the rate at which the active drug is removed from the body.\nQuestion: Given a drug SMILES string, predict its normalized hepatocyte clearance from 000 to 1000, where 000 is minimum hepatocyte clearance and 1000 is maximum hepatocyte clearance.\nDrug SMILES: {Drug SMILES}\nAnswer:", "Clearance_Microsome_AZ": "Instructions: Answer the following question about drug properties.\nContext: Drug clearance is defined as the volume of plasma cleared of a drug over a specified time period and it measures the rate at which the active drug is removed from the body.\nQuestion: Given a drug SMILES string, predict its normalized microsome clearance activity from 000 to 1000, where 000 is minimum microsome clearance and 1000 is maximum microsome clearance.\nDrug SMILES: {Drug SMILES}\nAnswer:", "LD50_Zhu": "Instructions: Answer the following question about drug properties.\nContext: Acute toxicity LD50 measures the most conservative dose that can lead to lethal adverse effects. The lower the dose, the more lethal of a drug. \nQuestion: Given a drug SMILES string, predict its normalized LD50 from 000 to 1000, where 000 is minimum LD50 and 1000 is maximum LD50.\nDrug SMILES: {Drug SMILES}\nAnswer:", "PPBR_AZ": "Instructions: Answer the following question about drug properties.\nContext: The human plasma protein binding rate (PPBR) is expressed as the percentage of a drug bound to plasma proteins in the blood. This rate strongly affect a drug's efficiency of delivery. The less bound a drug is, the more efficiently it can traverse and diffuse to the site of actions.\nQuestion: Given a drug SMILES string, predict its normalized rate of PPBR from 000 to 1000, where 000 is minimum PPBR rate and 1000 is maximum PPBR rate.\nDrug SMILES: {Drug SMILES}\nAnswer:", "BindingDB_kd": "Instructions: Answer the following question about drug target interactions.\nContext: Drug-target binding is the physical interaction between a drug and a specific biological molecule, such as a protein or enzyme. This interaction is essential for the drug to exert its pharmacological effect. The strength of the drug-target binding is determined by the binding affinity, which is a measure of how tightly the drug binds to the target. Kd is the dissociation constant of a drug-target complex. It is the concentration of drug at which half of the drug-target complexes have dissociated. A lower Kd value indicates a stronger binding affinity.\nQuestion: Given the target amino acid sequence and compound SMILES string, predict their normalized binding affinity Kd from 000 to 1000, where 000 is minimum Kd and 1000 is maximum Kd.\nDrug SMILES: {Drug SMILES}\nTarget amino acid sequence: {Target amino acid sequence}\nAnswer:", "BindingDB_ic50": "Instructions: Answer the following question about drug target interactions.\nContext: Drug-target binding is the physical interaction between a drug and a specific biological molecule, such as a protein or enzyme. This interaction is essential for the drug to exert its pharmacological effect. The strength of the drug-target binding is determined by the binding affinity, which is a measure of how tightly the drug binds to the target. IC50 is the concentration of a drug that inhibits a biological activity by 50%. It is a measure of the drug's potency, but it is not a direct measure of binding affinity. \nQuestion: Given the target amino acid sequence and compound SMILES string, predict their normalized binding affinity Kd from 000 to 1000, where 000 is minimum IC50 and 1000 is maximum IC50.\nDrug SMILES: {Drug SMILES}\nTarget amino acid sequence: {Target amino acid sequence}\nAnswer:", "BindingDB_ki": "Instructions: Answer the following question about drug target interactions.\nContext: Drug-target binding is the physical interaction between a drug and a specific biological molecule, such as a protein or enzyme. This interaction is essential for the drug to exert its pharmacological effect. The strength of the drug-target binding is determined by the binding affinity, which is a measure of how tightly the drug binds to the target. Ki is the equilibrium dissociation constant of an inhibitor. It is the concentration of inhibitor at which half of the target binding sites are occupied. A lower Ki value indicates a stronger binding affinity.\nQuestion: Given the target amino acid sequence and compound SMILES string, predict their normalized binding affinity Kd from 000 to 1000, where 000 is minimum Ki and 1000 is maximum Ki.\nDrug SMILES: {Drug SMILES}\nTarget amino acid sequence: {Target amino acid sequence}\nAnswer:", "DAVIS": "Instructions: Answer the following question about drug target interactions.\nContext: Studying the interaction between kinase inhibitors and kinases is crucial for understanding complex cellular processes, advancing drug development, enabling targeted cancer therapies, and addressing drug resistance. This research also aids in biomarker identification for personalized medicine, offers potential treatments for neurological and other diseases, and contributes significantly to the broader understanding of kinase biology and enzymology. The strength of the drug-target binding is determined by the binding affinity, which is a measure of how tightly the drug binds to the target. Kd is the dissociation constant of a drug-target complex. It is the concentration of drug at which half of the drug-target complexes have dissociated. A lower Kd value indicates a stronger binding affinity. \nQuestion: Given the target kinase amino acid sequence and kinase inhibitor SMILES string, predict their normalized binding affinity Kd from 000 to 1000, where 000 is minimum Kd and 1000 is maximum Kd.\nDrug SMILES: {Drug SMILES}\nTarget amino acid sequence: {Target amino acid sequence}\nAnswer:", "USPTO_Yields": "Instructions: Answer the following question about reaction yields.\nContext: Vast majority of small-molecule drugs are synthesized through chemical reactions. Many factors during reactions could lead to suboptimal reactants-products conversion rate, i.e. yields. Formally, it is defined as the percentage of the reactants successfully converted to the target product. Yields were measured for various patented reactions.\nQuestion: Given a catalyst SMILES string, reactant SMILES string, and product SMILES string, predict the normalized yield from 000 to 1000, where 000 is minimum yield and 1000 is maximum yield.\nCatalyst SMILES: {Catalyst SMILES}\nReactant SMILES: {Reactant SMILES}\nProduct SMILES: {Product SMILES}\nAnswer:", "Buchwald_Hartwig": "Instructions: Answer the following question about reaction yields.\nContext: Vast majority of small-molecule drugs are synthesized through chemical reactions. Many factors during reactions could lead to suboptimal reactants-products conversion rate, i.e. yields. Formally, it is defined as the percentage of the reactants successfully converted to the target product. Yields were measured for various Pd-catalysed Buchwald\u2013Hartwig C-N cross coupling reactions.\nQuestion: Given a product SMILES string, catalyst SMILES string, and reactant SMILES string, predict the normalized yield from 000 to 1000, where 000 is minimum yield and 1000 is maximum yield.\nProduct SMILES: {Product SMILES}\nCatalyst SMILES: {Catalyst SMILES}\nReactant SMILES: {Reactant SMILES}\nAnswer:", "OncoPolyPharmacology": "Instructions: Answer the following question about drug synergy.\nContext: Drug combination therapy offers enormous potential for expanding the use of existing drugs and in improving their efficacy. Synergy is a dimensionless measure of deviation of an observed drug combination response from the expected effect of non-interaction. Drug combinations were tested against cancer cell lines.\nQuestion: Given two drug SMILES strings and a cell line description, predict the normalized drug synergy from 000 to 1000, where 000 is minimum drug synergy and 1000 is maximum drug synergy.\nCell line description: {Cell line description}\nDrug1 SMILES: {Drug1 SMILES}\nDrug2 SMILES: {Drug2 SMILES}\nAnswer:", "DrugComb_CSS": "Instructions: Answer the following question about drug synergy.\nContext: Drug combination therapy offers enormous potential for expanding the use of existing drugs and in improving their efficacy. Synergy is a dimensionless measure of deviation of an observed drug combination response from the expected effect of non-interaction. Drug combinations were tested against cancer cell lines. CSS measures the drug combination sensitivity and is derived using relative IC50 values of compounds and the area under their dose-response curves. \nQuestion: Given two drug SMILES strings and a cell line description, predict the normalized drug synergy from 000 to 1000, where 000 is minimum drug synergy and 1000 is maximum drug synergy.\nDrug1 SMILES: {Drug1 SMILES}\nDrug2 SMILES: {Drug2 SMILES}\nCell line description: {Cell line description}\nAnswer:", "DrugComb_HSA": "Instructions: Answer the following question about drug synergy.\nContext: Drug combination therapy offers enormous potential for expanding the use of existing drugs and in improving their efficacy. Synergy is a dimensionless measure of deviation of an observed drug combination response from the expected effect of non-interaction. Drug combinations were tested against cancer cell lines. Synergy is calculated using Highest Single Agent (HSA).\nQuestion: Given two drug SMILES strings and a cell line description, predict the normalized drug synergy from 000 to 1000, where 000 is minimum drug synergy and 1000 is maximum drug synergy.\nDrug1 SMILES: {Drug1 SMILES}\nDrug2 SMILES: {Drug2 SMILES}\nCell line description: {Cell line description}\nAnswer:", "DrugComb_Loewe": "Instructions: Answer the following question about drug synergy.\nContext: Drug combination therapy offers enormous potential for expanding the use of existing drugs and in improving their efficacy. Synergy is a dimensionless measure of deviation of an observed drug combination response from the expected effect of non-interaction. Drug combinations were tested against cancer cell lines. Synergy is calculated using the Loewe additivity model.\nQuestion: Given two drug SMILES strings and a cell line description, predict the normalized drug synergy from 000 to 1000, where 000 is minimum drug synergy and 1000 is maximum drug synergy.\nDrug1 SMILES: {Drug1 SMILES}\nDrug2 SMILES: {Drug2 SMILES}\nCell line description: {Cell line description}\nAnswer:", "DrugComb_Bliss": "Instructions: Answer the following question about drug synergy.\nContext: Drug combination therapy offers enormous potential for expanding the use of existing drugs and in improving their efficacy. Synergy is a dimensionless measure of deviation of an observed drug combination response from the expected effect of non-interaction. Drug combinations were tested against cancer cell lines. Synergy is calculated using the Bliss model.\nQuestion: Given two drug SMILES strings and a cell line description, predict the normalized drug synergy from 000 to 1000, where 000 is minimum drug synergy and 1000 is maximum drug synergy.\nDrug1 SMILES: {Drug1 SMILES}\nDrug2 SMILES: {Drug2 SMILES}\nCell line description: {Cell line description}\nAnswer:", "DrugComb_ZIP": "Instructions: Answer the following question about drug synergy.\nContext: Drug combination therapy offers enormous potential for expanding the use of existing drugs and in improving their efficacy. Synergy is a dimensionless measure of deviation of an observed drug combination response from the expected effect of non-interaction. Drug combinations were tested against cancer cell lines. Synergy is calculated using Zero Interaction Potency (ZIP).\nQuestion: Given two drug SMILES strings and a cell line description, predict the normalized drug synergy from 000 to 1000, where 000 is minimum drug synergy and 1000 is maximum drug synergy.\nDrug1 SMILES: {Drug1 SMILES}\nDrug2 SMILES: {Drug2 SMILES}\nCell line description: {Cell line description}\nAnswer:", "Protein_SAbDab": "Instructions: Answer the following question about antibody antigen interactions.\nContext: Antibodies recognize pathogen antigens and destroy them. The activity is measured by their binding affinities.\nQuestion: Given the amino acid sequence of the antibody and antigen, predict the normalized binding affinity from 000 to 1000, where 000 is minimum binding affinity and 1000 is maximum binding affinity.\nAntigen sequence: {Antigen sequence}\nAntibody heavy chain sequence: {Antibody heavy chain sequence}\nAntibody light chain sequence: {Antibody light chain sequence}\nAnswer:", "Lipophilicity_AstraZeneca": "Instructions: Answer the following question about drug properties.\nContext: Lipophilicity measures the ability of a drug to dissolve in a lipid (e.g. fats, oils) environment. High lipophilicity often leads to high rate of metabolism, poor solubility, high turn-over, and low absorption.\nQuestion: Given a drug SMILES string, predict its normalized lipophilicity from 000 to 1000, where 000 is minimum lipophilicity and 1000 is maximum lipophilicity.\nDrug SMILES: {Drug SMILES}\nAnswer:", "Solubility_AqSolDB": "Instructions: Answer the following question about drug properties.\nContext: Aqeuous solubility measures a drug's ability to dissolve in water. Poor water solubility could lead to slow drug absorptions, inadequate bioavailablity and even induce toxicity. More than 40% of new chemical entities are not soluble.\nQuestion: Given a drug SMILES string, predict its normalized solubility from 000 to 1000, where 000 is minimum solubility and 1000 is maximum solubility.\nDrug SMILES: {Drug SMILES}\nAnswer:", "TAP_CDR_Length": "Instructions: Answer the following question about antibody developability.\nContext: Immunogenicity, instability, self-association, high viscosity, polyspecificity, or poor expression can all preclude an antibody from becoming a therapeutic. Early identification of these negative characteristics is essential. Akin to the Lipinski guidelines, which measure druglikeness in small molecules, Therapeutic Antibody Profiler (TAP) highlights antibodies that possess characteristics that are rare/unseen in clinical-stage mAb therapeutics. One key criteria is the total length of the complementarity-determining regions (CDRs). Loop length has a major impact on the nature of antigen binding. For example, if an antibody has a long CDRH3 loop, it tends to form most of the interactions with an antigen, while shorter CDRH3 loops contribute to concave binding sites where other CDRs more often assist in binding. \nQuestion: Given an antibody heavy chain and light chain sequence, predict its normalized CDR length from 000 to 1000, where 000 is minimum CDR length and 1000 is maximum CDR length.\nAntibody heavy chain sequence: {Antibody heavy chain sequence}\nAntibody light chain sequence: {Antibody light chain sequence}\nAnswer:", "TAP_PSH": "Instructions: Answer the following question about antibody developability.\nContext: Immunogenicity, instability, self-association, high viscosity, polyspecificity, or poor expression can all preclude an antibody from becoming a therapeutic. Early identification of these negative characteristics is essential. Akin to the Lipinski guidelines, which measure druglikeness in small molecules, Therapeutic Antibody Profiler (TAP) highlights antibodies that possess characteristics that are rare/unseen in clinical-stage mAb therapeutics. One key criteria the extent and magnitude of surface hydrophobicity. Hydrophobicity in the CDR regions has been repeatedly linked to aggregation propensity in mAbs. Hydrophobicity can be measured by a PSH metric that yields higher scores if hydrophobic residues tend to neighbor one another in a region, rather than being evenly separated.\nQuestion: Given an antibody heavy chain and light chain sequence, predict its normalized PSH from 000 to 1000, where 000 is minimum PSH and 1000 is maximum PSH.\nAntibody heavy chain sequence: {Antibody heavy chain sequence}\nAntibody light chain sequence: {Antibody light chain sequence}\nAnswer:", "TAP_PPC": "Instructions: Answer the following question about antibody developability.\nContext: Immunogenicity, instability, self-association, high viscosity, polyspecificity, or poor expression can all preclude an antibody from becoming a therapeutic. Early identification of these negative characteristics is essential. Akin to the Lipinski guidelines, which measure druglikeness in small molecules, Therapeutic Antibody Profiler (TAP) highlights antibodies that possess characteristics that are rare/unseen in clinical-stage mAb therapeutics. One key criteria is positive charge and negative charge in the CDRs. Surface patches of positive or negative charge in the CDRs are linked to high rates of clearance and poor expression levels. PPC is a score highlighting regions of dense positive charge.\nQuestion: Given an antibody heavy chain and light chain sequence, predict its normalized PPC score from 000 to 1000, where 000 is minimum PPC and 1000 is maximum PPC.\nAntibody heavy chain sequence: {Antibody heavy chain sequence}\nAntibody light chain sequence: {Antibody light chain sequence}\nAnswer:", "TAP_PNC": "Instructions: Answer the following question about antibody developability.\nContext: Immunogenicity, instability, self-association, high viscosity, polyspecificity, or poor expression can all preclude an antibody from becoming a therapeutic. Early identification of these negative characteristics is essential. Akin to the Lipinski guidelines, which measure druglikeness in small molecules, Therapeutic Antibody Profiler (TAP) highlights antibodies that possess characteristics that are rare/unseen in clinical-stage mAb therapeutics. One key criteria is positive charge and negative charge in the CDRs. Surface patches of positive or negative charge in the CDRs are linked to high rates of clearance and poor expression levels. PNC is a score highlighting regions of dense negative charge.\nQuestion: Given an antibody heavy chain and light chain sequence, predict its normalized PNC from 000 to 1000, where 000 is minimum PNC and 1000 is maximum PNC.\nAntibody heavy chain sequence: {Antibody heavy chain sequence}\nAntibody light chain sequence: {Antibody light chain sequence}\nAnswer:", "TAP_SFvCSP": "Instructions: Answer the following question about antibody developability.\nContext: Immunogenicity, instability, self-association, high viscosity, polyspecificity, or poor expression can all preclude an antibody from becoming a therapeutic. Early identification of these negative characteristics is essential. Akin to the Lipinski guidelines, which measure druglikeness in small molecules, Therapeutic Antibody Profiler (TAP) highlights antibodies that possess characteristics that are rare/unseen in clinical-stage mAb therapeutics. One key criteria is asymmetry in the net heavy- and light-chain surface charges. Asymmetry in the net charge of the heavy- and light-chain variable domains is also correlated with self-association and viscosity at high concentrations. The structural Fv charge symmetry parameter, SFvCSP, only includes residues that are surface-exposed, and not locked in salt bridges, in the evaluation of net charge.\nQuestion: Given an antibody heavy chain and light chain sequence, predict its normalized SFvCSP from 000 to 1000, where 000 is minimum SFvCSP and 1000 is maximum SFvCSP.\nAntibody heavy chain sequence: {Antibody heavy chain sequence}\nAntibody light chain sequence: {Antibody light chain sequence}\nAnswer:", "Leenay_Fraction_Insertions": "Instructions: Answer the following question about CRISPR repair outcomes.\nContext: CRISPR-Cas9 is a gene editing technology that allows targeted deletion or modification of specific regions of the DNA within an organism. This is achieved through designing a guide RNA sequence that binds upstream of the target site which is then cleaved through a Cas9-mediated double stranded DNA break. The cell responds by employing DNA repair mechanisms (such as non-homologous end joining) that result in heterogeneous outcomes including gene insertion or deletion mutations (indels) of varying lengths and frequencies. Primary T cells are a promising cell type for therapeutic genome editing, as they can be engineered efficiently ex vivo and transferred to patients. An experiment is carried out to quantify the DNA repair outcomes of CRISPR-CAS9 knockout experiments on primary CD4+ T cells drawn from donors. For a genomic location, a GuideSeq sequence is provided, which is a 20-nucleotide guide sequence along with the 3-nucletoide PAM sequence. The PAM (protospacer adjacent motif) is a short DNA sequence that follows the DNA region targeted for cleavage by the CRISPR-Cas9 system. One particular measure of interest for repair outcome quantification is the fraction of indel reads with an insertion.\nQuestion: Given a GuideSeq sequence, predict its normalized fraction of indel reads with an insertion from 000 to 1000, where 000 is minimum fraction of indel reads with an insertion and 1000 is maximum fraction of indel reads with an insertion.\nGuideSeq: {GuideSeq}\nAnswer:", "Leenay_Avg_Insertion_Length": "Instructions: Answer the following question about CRISPR repair outcomes.\nContext: CRISPR-Cas9 is a gene editing technology that allows targeted deletion or modification of specific regions of the DNA within an organism. This is achieved through designing a guide RNA sequence that binds upstream of the target site which is then cleaved through a Cas9-mediated double stranded DNA break. The cell responds by employing DNA repair mechanisms (such as non-homologous end joining) that result in heterogeneous outcomes including gene insertion or deletion mutations (indels) of varying lengths and frequencies. Primary T cells are a promising cell type for therapeutic genome editing, as they can be engineered efficiently ex vivo and transferred to patients. An experiment is carried out to quantify the DNA repair outcomes of CRISPR-CAS9 knockout experiments on primary CD4+ T cells drawn from donors. For a genomic location, a GuideSeq sequence is provided, which is a 20-nucleotide guide sequence along with the 3-nucletoide PAM sequence. The PAM (protospacer adjacent motif) is a short DNA sequence that follows the DNA region targeted for cleavage by the CRISPR-Cas9 system. One particular measure of interest for repair outcome quantification is the average insertion length.\nQuestion: Given a GuideSeq sequence, predict its normalized average insertion length from 000 to 1000, where 000 is minimum average insertion length and 1000 is maximum average insertion length.\nGuideSeq: {GuideSeq}\nAnswer:", "Leenay_Avg_Deletion_Length": "Instructions: Answer the following question about CRISPR repair outcomes.\nContext: CRISPR-Cas9 is a gene editing technology that allows targeted deletion or modification of specific regions of the DNA within an organism. This is achieved through designing a guide RNA sequence that binds upstream of the target site which is then cleaved through a Cas9-mediated double stranded DNA break. The cell responds by employing DNA repair mechanisms (such as non-homologous end joining) that result in heterogeneous outcomes including gene insertion or deletion mutations (indels) of varying lengths and frequencies. Primary T cells are a promising cell type for therapeutic genome editing, as they can be engineered efficiently ex vivo and transferred to patients. An experiment is carried out to quantify the DNA repair outcomes of CRISPR-CAS9 knockout experiments on primary CD4+ T cells drawn from donors. For a genomic location, a GuideSeq sequence is provided, which is a 20-nucleotide guide sequence along with the 3-nucletoide PAM sequence. The PAM (protospacer adjacent motif) is a short DNA sequence that follows the DNA region targeted for cleavage by the CRISPR-Cas9 system. One particular measure of interest for repair outcome quantification is the average deletion length.\nQuestion: Given a GuideSeq sequence, predict its normalized average deletion length from 000 to 1000, where 000 is minimum average deletion length and 1000 is maximum average deletion length.\nGuideSeq: {GuideSeq}\nAnswer:", "Leenay_Indel_Diversity": "Instructions: Answer the following question about CRISPR repair outcomes.\nContext: CRISPR-Cas9 is a gene editing technology that allows targeted deletion or modification of specific regions of the DNA within an organism. This is achieved through designing a guide RNA sequence that binds upstream of the target site which is then cleaved through a Cas9-mediated double stranded DNA break. The cell responds by employing DNA repair mechanisms (such as non-homologous end joining) that result in heterogeneous outcomes including gene insertion or deletion mutations (indels) of varying lengths and frequencies. Primary T cells are a promising cell type for therapeutic genome editing, as they can be engineered efficiently ex vivo and transferred to patients. An experiment is carried out to quantify the DNA repair outcomes of CRISPR-CAS9 knockout experiments on primary CD4+ T cells drawn from donors. For a genomic location, a GuideSeq sequence is provided, which is a 20-nucleotide guide sequence along with the 3-nucletoide PAM sequence. The PAM (protospacer adjacent motif) is a short DNA sequence that follows the DNA region targeted for cleavage by the CRISPR-Cas9 system. One particular measure of interest for repair outcome quantification is the indel diveristy.\nQuestion: Given a GuideSeq sequence, predict its normalized indel diversity from 000 to 1000, where 000 is minimum indel diversity and 1000 is maximum indel diversity.\nGuideSeq: {GuideSeq}\nAnswer:", "Leenay_Fraction_Frameshifts": "Instructions: Answer the following question about CRISPR repair outcomes.\nContext: CRISPR-Cas9 is a gene editing technology that allows targeted deletion or modification of specific regions of the DNA within an organism. This is achieved through designing a guide RNA sequence that binds upstream of the target site which is then cleaved through a Cas9-mediated double stranded DNA break. The cell responds by employing DNA repair mechanisms (such as non-homologous end joining) that result in heterogeneous outcomes including gene insertion or deletion mutations (indels) of varying lengths and frequencies. Primary T cells are a promising cell type for therapeutic genome editing, as they can be engineered efficiently ex vivo and transferred to patients. An experiment is carried out to quantify the DNA repair outcomes of CRISPR-CAS9 knockout experiments on primary CD4+ T cells drawn from donors. For a genomic location, a GuideSeq sequence is provided, which is a 20-nucleotide guide sequence along with the 3-nucletoide PAM sequence. The PAM (protospacer adjacent motif) is a short DNA sequence that follows the DNA region targeted for cleavage by the CRISPR-Cas9 system. One particular measure of interest for repair outcome quantification is the fraction of repair outcomes with a frameshift.\nQuestion: Given a GuideSeq sequence, predict its normalized fraction of repair outcomes with a frameshift from 000 to 1000, where 000 is minimum fraction of repair outcomes with a frameshift and 1000 is maximum fraction of repair outcomes with a frameshift.\nGuideSeq: {GuideSeq}\nAnswer:", "KIBA": "Instructions: Answer the following question about drug target interactions.\nContext: Drug-target interaction prediction task aims to predict the interaction activity score in silico given only the accessible compound structural information and protein amino acid sequence.\nQuestion: Given the drug SMILES string and target amino acid sequence predict the normalized binding affinity from 000 to 1000, where 000 is minimum binding affinity and 1000 is maximum binding affinity.\nDrug SMILES: {Drug SMILES}\nTarget amino acid sequence: {Target amino acid sequence}\nAnswer:", "BindingDB_Patent": "Instructions: Answer the following question about drug target interactions.\nContext: Drug-target interaction prediction task aims to predict the interaction activity score in silico given only the accessible compound structural information and protein amino acid sequence.\nQuestion: Given the drug SMILES string and target amino acid sequence predict the normalized binding affinity from 000 to 1000, where 000 is minimum binding affinity and 1000 is maximum binding affinity.\nDrug SMILES: {Drug SMILES}\nTarget amino acid sequence: {Target amino acid sequence}\nAnswer:", "USPTO": "Instructions: Answer the following question about reactions.\nContext: Retrosynthesis is the process of finding a set of reactants that can synthesize a target molecule, i.e., product, which is a fundamental task in drug manufacturing. The target is recursively transformed into simpler precursor molecules until commercially available \"starting\" molecules are identified. In a data sample, there is only one product molecule, reactants can be one or multiple molecules.\nQuestion: Given a product SMILES string, predict the reactant SMILES string.\n\nProduct SMILES: {Product SMILES}\nAnswer:"} \ No newline at end of file diff --git a/tokenizer.json b/tokenizer.json new file mode 100644 index 0000000..af0eac5 --- /dev/null +++ b/tokenizer.json @@ -0,0 +1,3 @@ +version https://git-lfs.github.com/spec/v1 +oid sha256:3f289bc05132635a8bc7aca7aa21255efd5e18f3710f43e3cdb96bcd41be4922 +size 17525357 diff --git a/tokenizer.model b/tokenizer.model new file mode 100644 index 0000000..796efe9 --- /dev/null +++ b/tokenizer.model @@ -0,0 +1,3 @@ +version https://git-lfs.github.com/spec/v1 +oid sha256:61a7b147390c64585d6c3543dd6fc636906c9af3865a5548f27f31aee1d4c8e2 +size 4241003 diff --git a/tokenizer_config.json b/tokenizer_config.json new file mode 100644 index 0000000..2357fc1 --- /dev/null +++ b/tokenizer_config.json @@ -0,0 +1,2012 @@ +{ + "add_bos_token": true, + "add_eos_token": false, + "added_tokens_decoder": { + "0": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": true + }, + "1": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": true + }, + "2": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": true + }, + "3": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": true + }, + "4": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "5": { + "content": "<2mass>", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "6": { + "content": "[@BOS@]", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "7": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "8": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "9": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "10": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "11": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "12": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "13": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "14": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "15": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "16": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "17": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "18": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "19": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "20": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "21": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "22": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "23": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "24": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "25": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "26": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "27": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "28": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "29": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "30": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "31": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "32": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "33": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "34": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "35": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "36": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "37": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "38": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "39": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "40": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "41": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "42": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "43": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "44": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "45": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "46": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "47": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "48": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "49": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "50": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "51": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "52": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "53": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "54": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "55": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "56": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "57": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "58": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "59": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "60": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "61": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "62": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "63": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "64": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "65": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "66": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "67": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "68": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "69": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "70": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "71": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "72": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "73": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "74": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "75": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "76": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "77": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "78": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "79": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "80": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "81": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "82": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "83": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "84": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "85": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "86": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "87": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "88": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "89": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "90": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "91": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "92": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "93": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "94": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "95": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "96": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "97": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "98": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "99": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "100": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "101": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "102": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "103": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "104": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "105": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "106": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": true + }, + "107": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": true + }, + "108": { + "content": "\n", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "109": { + "content": "\n\n", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "110": { + "content": "\n\n\n", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "111": { + "content": "\n\n\n\n", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "112": { + "content": "\n\n\n\n\n", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "113": { + "content": "\n\n\n\n\n\n", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "114": { + "content": "\n\n\n\n\n\n\n", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "115": { + "content": "\n\n\n\n\n\n\n\n", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "116": { + "content": "\n\n\n\n\n\n\n\n\n", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "117": { + "content": "\n\n\n\n\n\n\n\n\n\n", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "118": { + "content": "\n\n\n\n\n\n\n\n\n\n\n", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "119": { + "content": "\n\n\n\n\n\n\n\n\n\n\n\n", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "120": { + "content": "\n\n\n\n\n\n\n\n\n\n\n\n\n", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "121": { + "content": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "122": { + "content": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "123": { + "content": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "124": { + "content": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "125": { + "content": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "126": { + "content": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "127": { + "content": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "128": { + "content": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "129": { + "content": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "130": { + "content": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "131": { + "content": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "132": { + "content": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "133": { + "content": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "134": { + "content": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "135": { + "content": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "136": { + "content": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "137": { + "content": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "138": { + "content": "\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "139": { + "content": "▁▁", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "140": { + "content": "▁▁▁", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "141": { + "content": "▁▁▁▁", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "142": { + "content": "▁▁▁▁▁", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "143": { + "content": "▁▁▁▁▁▁", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "144": { + "content": "▁▁▁▁▁▁▁", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "145": { + "content": "▁▁▁▁▁▁▁▁", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "146": { + "content": "▁▁▁▁▁▁▁▁▁", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "147": { + "content": "▁▁▁▁▁▁▁▁▁▁", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "148": { + "content": "▁▁▁▁▁▁▁▁▁▁▁", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "149": { + "content": "▁▁▁▁▁▁▁▁▁▁▁▁", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "150": { + "content": "▁▁▁▁▁▁▁▁▁▁▁▁▁", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "151": { + "content": "▁▁▁▁▁▁▁▁▁▁▁▁▁▁", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "152": { + "content": "▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "153": { + "content": "▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "154": { + "content": "▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "155": { + "content": "▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "156": { + "content": "▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "157": { + "content": "▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "158": { + "content": "▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "159": { + "content": "▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "160": { + "content": "▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "161": { + "content": "▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "162": { + "content": "▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "163": { + "content": "▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "164": { + "content": "▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "165": { + "content": "▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "166": { + "content": "▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "167": { + "content": "▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "168": { + "content": "▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁▁", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "169": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "170": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "172": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "173": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "174": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "175": { + "content": "
", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "171": { + "content": "
", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "176": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "177": { + "content": "
", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "178": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "179": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "180": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "181": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "182": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "183": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "184": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "185": { + "content": "

", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "186": { + "content": "

", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "187": { + "content": "

", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "188": { + "content": "

", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "189": { + "content": "

", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "190": { + "content": "
", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "191": { + "content": "
", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "192": { + "content": "
", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "193": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "194": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "195": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "196": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "197": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "198": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "199": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "200": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "201": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "202": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "203": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "204": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "205": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "206": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "207": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "208": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "209": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "210": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "211": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "212": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "213": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "214": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "215": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "216": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "255968": { + "content": "[toxicity=0]", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "255969": { + "content": "\t\t", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "255970": { + "content": "\t\t\t", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "255971": { + "content": "\t\t\t\t", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "255972": { + "content": "\t\t\t\t\t", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "255973": { + "content": "\t\t\t\t\t\t", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "255974": { + "content": "\t\t\t\t\t\t\t", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "255975": { + "content": "\t\t\t\t\t\t\t\t", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "255976": { + "content": "\t\t\t\t\t\t\t\t\t", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "255977": { + "content": "\t\t\t\t\t\t\t\t\t\t", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "255978": { + "content": "\t\t\t\t\t\t\t\t\t\t\t", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "255979": { + "content": "\t\t\t\t\t\t\t\t\t\t\t\t", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "255980": { + "content": "\t\t\t\t\t\t\t\t\t\t\t\t\t", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "255981": { + "content": "\t\t\t\t\t\t\t\t\t\t\t\t\t\t", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "255982": { + "content": "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "255983": { + "content": "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "255984": { + "content": "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "255985": { + "content": "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "255986": { + "content": "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "255987": { + "content": "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "255988": { + "content": "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "255989": { + "content": "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "255990": { + "content": "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "255991": { + "content": "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "255992": { + "content": "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "255993": { + "content": "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "255994": { + "content": "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "255995": { + "content": "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "255996": { + "content": "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "255997": { + "content": "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "255998": { + "content": "\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + }, + "255999": { + "content": "", + "lstrip": false, + "normalized": false, + "rstrip": false, + "single_word": false, + "special": false + } + }, + "additional_special_tokens": [ + "", + "" + ], + "bos_token": "", + "clean_up_tokenization_spaces": false, + "eos_token": "", + "model_max_length": 1000000000000000019884624838656, + "pad_token": "", + "sp_model_kwargs": {}, + "spaces_between_special_tokens": false, + "tokenizer_class": "GemmaTokenizer", + "unk_token": "", + "use_default_system_prompt": false +}